VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 28 (1-10 diciembre / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas Covid.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

La OMS declaró variante de interés a la cepa BA.2.86 de COVID y seguirá de cerca su evolución

1 dic. Si bien no la consideró "variante preocupante", la designación más alta, el organismo avisó que la falta de datos y la velocidad con que se propaga la última mutación surgida del SARS-CoV-2 es para tener en cuenta. ¿Qué alarma a los expertos?



La OMS cree que el alto nivel de inmunidad de la población hace que sea "poco probable" que la aparición de la variante agregue una mayor carga a los sistemas nacionales de salud pública (Getty)

La Organización Mundial de la Salud (OMS) declaró variante de interés a la cepa BA.2.86 del SARS-CoV-2 surgida en agosto pasado en los EEUU e instalada como la tercera más común y responsable de uno de cada 11 nuevos casos de COVID-19, según la última actualización del rastreador de variantes de los Centros para el Control y la Prevención de Enfermedades (CDC).

Es que a casi cuatro años de descubierto el SARS-CoV-2 en China, y pese a que se cree que lo peor de la pandemia ya pasó, la COVID-19 sigue siendo noticia. Ahora, debido a la escasez de datos de la última variante del virus y la velocidad a la que se propaga.

Anteriormente, la OMS había catalogado a este nuevo linaje como una "variante bajo seguimiento", y si bien aún no alcanza la designación más alta de "variante preocupante", sí escaló un nivel más y desde el organismo avisaron que amerita seguirla de cerca.

La prevalencia parece haberse triplicado en las últimas dos semanas, aunque a menudo se sobreestima el crecimiento de una variante en las primeras semanas después de que aparece en el seguimiento de los CDC.

Según publicó la doctora Maria Van Kerkhove, líder técnica de la OMS en COVID-19, en un video en las redes sociales, desde el organismo vieron "un aumento lento y constante en su detección en todo el mundo". "Caracterizarla como una variante de interés realmente ayuda a promover la vigilancia de este tipo de variantes en todo el mundo, así como a estimular la investigación" para comprender si causan enfermedades más graves o son más evasivas para el sistema inmunológico, agregó.

La experta consideró que la cepa parece tener una ventaja de crecimiento sobre otras, pero no parece causar una enfermedad más grave.

"Cuando analizamos la gravedad, observamos cualquier cambio en las hospitalizaciones, así como en la presentación de la enfermedad, y no vemos eso para esta variante de interés particular y sus sublinajes", reconoció Van Kerkhove.

La OMS publicó este mes una evaluación de riesgo de la cepa y encontró que "el riesgo para la salud pública que plantea BA.2.86 se considera actualmente bajo a nivel mundial".

Debido al alto nivel de inmunidad de la población a través de infecciones y vacunas previas, es "poco probable" que la aparición de la variante agregue una mayor carga a los sistemas nacionales de salud pública, según analizaron desde el organismo.

Desde la OMS instaron a seguir de cerca a la nueva variante (Europa Press)

Por qué la siguen de cerca

Meses después de su hallazgo, la BA.2.86, a la que algunos observadores de virus apodaron "Pirola", está empezando a afianzarse.

La variante llamó la atención del mundo durante el verano del hemisferio norte porque compartía muchas de las características que causaron que BA.1 -la cepa Ómicron original del coronavirus- se propagara a gran velocidad en noviembre de 2021 y provocara un aumento exponencial en las hospitalizaciones y muertes a nivel mundial.

Con más de 30 mutaciones en sus proteínas de pico, BA.2.86 era tan genéticamente distinta de las versiones anteriores del virus que los científicos temían que pudiera escapar por completo de la inmunidad de las vacunas y las infecciones y causara otra ola de contagios.

Sin embargo, BA.2.86 nunca despegó de la misma manera que lo hizo el primer Ómicron, y algunos estudios sugirieron que lo que sucedió fue que a medida que desarrolló todas sus nuevas mutaciones, esta variante perdió parte de su capacidad de infectar las células, lo cual frenó su crecimiento.

La OMS declaró variante de interés a la cepa BA.2.86 del SARS-CoV-2 surgida en agosto pasado en los EEUU (Reuters)

Otros estudios encontraron que no evadía por completo la inmunidad del cuerpo y que la actual vacuna contra la COVID, que fue modificada para combatir la subvariante XBB.1.5, ofrecía cierta protección contra ella, lo cual fue recibido como una buena noticia.

Pese a todo esto, los expertos en variantes prefieren "moderar ese optimismo" y advirtieron que si BA.2.86 todavía está evolucionando, uno de sus descendientes podría recuperar suficiente aptitud para convertirse en una fuerza a tener en cuenta.

Fuente: infobae. Disponible en https://acortar.link/SZdiRV

Finlay Vaccines Institute, more than three decades making history

Dec 3. The Finlay Vaccines Institute (IFV) is celebrating its anniversary and that of its Plant III on Sunday, with dreams fulfilled and others yet to come true in pursuit of improving the people's quality of life.

“I have great confidence in the productive capacity and quality of that plant since it is already the third one,” Commander-in-Chief Fidel Castro said at the inauguration ceremony of that facility on December 3, 1993.

The IFV, a center for research, development, and production of vaccines, was founded in 1991, after a group of Cuban scientists presented a vaccine against meningitis (Neisseria meningitidis), whose trade name is VA-MENGOC-BC®.

The vaccine’s introduction had a notable impact by eliminating the epidemic that affected children and adolescents mainly.

The institution was named, as a tribute, after the prominent Cuban scientist Dr. Carlos J. Finlay, who was born in Camagüey province. He proved that a biological agent that transmits yellow fever spreads the disease from a sick person to a healthy one. The production of the Soberana 02 and Soberana Plus vaccines and the vaccine candidate Soberana 01 to fight the COVID-19 pandemic stand out among the IFV’s leading contributions over the last two years. Other vaccines have been developed to support the Institute’s scientific value throughout its history.

IFV Deputy Director for Industrial Operations Roselyn Martínez told Prensa Latina that the scientific institution already has six production plants that can obtain polysaccharides through chemical synthesis and whole-cell components.

Fuente: Prensa Latina. Disponible en https://acortar.link/kYJjbw

IFV INSTITUTO FINLAY DE VACUNAS

CUBA

La ONG sevillana África Arco Iris administra 8.500 vacunas contra la meningitis a niños de Costa de Marfil

3 dic. La ONG sevillana África Arco Iris administrará unas 8.500 vacunas contra la meningitis y la fiebre tifoidea a niños de hasta doce años de edad de Costa de Marfil. Con este propósito saldrá una expedición este domingo desde la capital andaluza dirección al citado país. Una iniciativa que comenzó en 2005 de la mano del Instituto Hispalense de Pediatría, con el doctor Alfonso Carmona, actual presidente del Colegio de Médicos, como uno de sus precursores.

El presidente de la ONG, Jesús Mejías, en declaraciones a Europa Press, remarca que en estas casi dos décadas han suministrado ya unas 960.000 dosis y que el objetivo es llegar al millón de vacunas.

El equipo de África Arco Iris, conformado por un reducido número de personas que viajan dos veces cada año desde España para esta labor solidaria, lleva a cabo esta campaña en colaboración estrecha con las autoridades de Costa Marfil, "siguiendo en todo momento las peticiones de las autoridades sanitarias del país".

Los menores, previa cumplimentación de su cartilla de vacunación, suelen ir saliendo "clase a clase" para recibir las dosis. En este sentido, las vacunas son vendidas y proporcionadas por el Ministerio de Costa de Marfil y los profesionales sanitarios que conforman este dispositivo son los encargados de ponerlas.

A pesar de la dilatada trayectoria de esta ONG en esta parte del continente africano, "no son pocas las dificultades que nos encontramos, ya que es un país con muchos inconvenientes", asegura el presidente de la entidad social, quien reconoce que, "en años difíciles de guerras, cuando nos hemos desplazado de punta a punta y de Norte a Sur, unos 600 kilómetros aproximadamente, han intentado robarnos. Por suerte, viajamos con policías que nos proporciona el Gobierno costamarfileño".

Mejías ha agradecido el apoyo prestado para la expedición por las Diputaciones de Córdoba y Sevilla, la Fundación Cajasol, los ayuntamientos de Dos hermanas, Alcalá de Guadaíra, Los Palacios y Lora del Río, así como el Parlamento de Andalucía y el citado Instituto Hispalense de Pediatría.

La ONG también impulsó la creación de un colegio en ese país africano con la ayuda de la Fundación Cajasol y la Diputación de Sevilla.

Un sanitario pone una vacuna a un menor de Costa de Marfil.- ÁFRICA ARCO IRIS

Fuente: epSevilla. Disponible en https://acortar.link/Dmlkwh

Vacunación por ultrasonidos, la solución al miedo a los pinchazos

4 dic. Investigadores de Oxford trabajan en este nuevo método, que además promete una mejor respuesta inmunitaria.

El miedo a las agujas (llamado técnicamente tripanofobia) no es tan residual como pensamos. La estimaciones más recientes apuntan a que afecta a entre el 20 y el 25% de los adultos. En el caso de los niños, este temor es más frecuente: afecta a 2 de cada 3. Esta limitación se puso especialmente de manifiesto con las recientes campañas de vacunación mundial frente a la covid, en las que se calculó que 1 de cada 10 personas no se habría inmunizado por esta causa.

Pero parece que la solución a este problema podría estar cerca, ya que investigadores de la Universidad de Oxford (Reino Unido) trabajan en un nuevo método de vacunación por ultrasonidos, aún en estudio, que podría sustituir a las agujas, consiguiendo además una mejor respuesta inmunitaria, según publican en la revista Frontiers in Conservation Science.

Darcy Dunn-Lawless, estudiante de doctorado del Instituto de Ingeniería Biomédica de la Universidad de Oxford, está investigando el potencial de esta administración de vacunas indolora y sin agujas mediante ultrasonidos, que también ha presentado en la conferencia dedicada a la ciencia y la ingeniería del sonido Acoustics 2023 Sydney. "Nuestro método se basa en un efecto acústico llamado cavitación, que consiste en la formación y estallido de burbujas en respuesta a una onda sonora", explica, según recoge Ep. Se trata de un procedimiento que lleva décadas usándose en medicina estética para eliminar la grasa localizada mediante el uso de ultrasonidos de baja frecuencia, que se aplican sobre la zona donde se concentra la grasa para disolver las células adiposas desde su interior.

Dunn-Lawless detalla el proceso en el artículo. "Nuestro objetivo es aprovechar las explosiones concentradas de energía mecánica producidas por el colapso de estas burbujas de tres formas principales. En primer lugar, para despejar los pasajes a través de la capa externa de células muertas de la piel y permitir el paso de las moléculas de la vacuna. En segundo lugar, para actuar como una bomba que impulsa las moléculas del fármaco hacia estos pasajes. Por último, para abrir las membranas que rodean a las propias células, ya que algunos tipos de vacuna deben introducirse en el interior de una célula para funcionar".

La piel mejor que los músculos

Aunque las pruebas iniciales in vivo revelaron que se administraban 700 veces menos moléculas de vacuna

con el método de cavitación que con la inyección convencional, este último produjo una mayor respuesta inmunitaria. Según la teoría de los investigadores, esto podría deberse a la piel, rica en inmunidad, a la que se dirige la administración ultrasónica, en contraste con los músculos que reciben la inyección. El resultado es una vacuna más eficiente que podría ayudar a reducir costes y aumentar la eficacia con poco riesgo de efectos secundarios.

Su método de cavitación puede ser especialmente útil para las vacunas de ADN, que actualmente son difíciles de administrar. Si la cavitación ayuda a abrir las membranas que bloquean el acceso terapéutico al núcleo celular, podrán aprovecharse mejor las demás ventajas de las vacunas de ADN, como la respuesta inmunitaria selectiva, el bajo riesgo de infección y la estabilidad en almacenamiento.

"En mi opinión, el principal efecto secundario potencial es universal a todas las técnicas físicas en medicina: si se aplica demasiada energía al cuerpo, se pueden dañar los tejidos -afirma Dunn-Lawless-. La exposición a una cavitación excesiva puede causar daños mecánicos en células y estructuras. Sin embargo, hay pruebas fehacientes de que estos daños pueden evitarse limitando la exposición, por lo que una parte clave de mi investigación es tratar de identificar plenamente dónde se encuentra este umbral de seguridad para la administración de vacunas".

Fuente: La Razón. Disponible en https://acortar.link/xxBoAp

Best-in-Class 24-Valent Pneumococcal Conjugate Vaccine Candidate Identified

Dec 5. Vaxcyte, Inc. today announced the publication of the results from the VAX-24 vaccine candidate's pneumococcal disease (PD) proof-of-concept study in the journal The Lancet Infectious Diseases.

This phase 1/2 clinical trial evaluated the safety, tolerability, and immunogenicity of Vaxcyte's investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) compared to the current standard-of-care, Prevnar 20® (PCV20, APEXXNAR), for the prevention of invasive pneumococcal disease (IPD) in healthy adults.

The study results showed that VAX-24 demonstrated a safety and tolerability profile comparable to PCV20 at all doses studied and an immunogenicity profile that met or exceeded established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose.

"The results from the proof-of-concept study provided the first look at the safety and immunogenicity profile of VAX-24 in adults, giving us confidence in the 2.2 mcg dose we plan to advance into Phase 3," said Dr. Jakub Simon, Chief Medical Officer of Vaxcyte, in a press release on December 4, 2023.

"We look forward to initiating our Phase 3 pivotal, non-inferiority study, designed to further establish the clinical potential of VAX-24, and announcing topline data, which we expect in 2025."

PD is an infection caused by Streptococcus pneumoniae bacteria, says the U.S. CDC.

It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media, and sinusitis.

People can get pneumococcal disease more than once. A previous pneumococcal infection will not protect you from future infection.

Therefore, CDC recommends pneumococcal vaccination even if someone has had pneumococcal disease in the past.

In the United States, approximately 320,000 people get pneumococcal pneumonia each year, which is estimated to result in about 150,000 hospitalizations and 5,000 deaths.

Pneumococci also cause over 50% of all cases of bacterial meningitis in the U.S.

As of December 2023, several approved pneumococcal vaccines are available at clinics and pharmacies in the U.S.

Fuente: Precisión Vaccinations. Disponible en https://acortar.link/pMJAIP

Moderna y Pfizer entregan a la Cofepris la información faltante para el permiso de comercialización de sus vacunas contra la COVID-19

5 dic. La Comisión Federal para la Protección Contra Riesgos Sanitarios (Cofepris) informó este martes que ya recibió la información faltante de Moderna y Pfizer para el permiso de comercialización de sus respectivas vacunas contra la COVID-19.

Foto: Cuartoscuro

Pfizer ingresó la información de su vacuna Comirnaty, mientras que Moderna, a través de Asofarma, lo hizo con la de la monovalente Spikevax.

La dependencia sanitaria señaló que estima emitir una resolución en los próximos días.

El pasado 22 de noviembre, la Cofepris señaló que el 29 de noviembre se daría conocer una resolución definitiva sobre las empresas que podrán comercializar vacunas para la COVID-19; sin embargo, al llegar el día de la presentación de la resolución, el órgano indicó que las empresas requerían más tiempo para solventar la información técnica faltante.

“Las empresas solicitantes Pfizer, para la vacuna Comirnaty, y ModernaTx. Inc., para la vacuna Spikevax monovalente, requirieron mayor tiempo para solventar los elementos e información técnica faltante en el expediente que ingresaron para obtener el registro sanitario”, precisó la Cofepris en un comunicado.

En octubre, la dependiencia informó que ya había recibido las solicitudes de empresas farmacéuticas para obtener le registro de cuatro vacunas contra la Covid, entre ellas Comirnaty, Vaxzevria y Spikevax.

La convocatoria para la comercialización de dichas vacunas se lanzó el pasado 22 de septiembre.

La comisión también había señalado que Comirnaty de Pfizer iba a ser la primera vacuna en ser evaluada por el Comité de Moléculas Nuevas (CMN).

Fuente: LATINUS. Disponible en https://acortar.link/yo6g0h

Repeated mRNA vaccines supercharge immune response against COVID-19, study finds

Dec 7. In a recent study published in the journal Nature Immunology, researchers investigated how repeated mRNA vaccinations improve COVID-19 immunity in SARS-CoV-2-naïve and priorly infected individuals. Focusing on the latter cohort, the study evaluated the diversity and concertation in tandem with multiple sequencing analyses of immune cells isolated from the patient's peripheral blood mononuclear cells. Study findings reveal that sequential vaccination promotes heterogeneous immune cell clonal expansions, with the third mRNA vaccination resulting in almost two times the number of clones as the first vaccination dose. Parallelly, populations of CD8+ T cells substantially increase, thereby better preparing an individual's immune system to cope with multiple COVID-19 strains. Surprisingly, the presence and severity of COVID-19 infection were directly associated with post-vaccination immunity.



Study: Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19.
Image Credit: CI Photos / Shutterstock

Does infection prevent infection?

First, a disclaimer – under no circumstances are the authors of the publication or the author of this article recommending that you allow yourself to become infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a means of improving your future immunity against the Coronavirus disease 2019 (COVID-19) pandemic. However, a number of previous studies have established the improved anti-COVID-19 capabilities of 'hybrid immunity.' Hybrid immunity arises from the combined effects of both a previous COVID-19 infection and vaccination, which have been consistently found to confer better protection than either alone.

Two main mechanisms for this improved observed immunity have been proposed – an increase in the abundance and diversity of virus-specific memory T (Tm) cells and an increased diversity of spike (S) proteins in the Tm cell pool. Hitherto, however, these hypotheses have never been scientifically tested. Understanding the mechanisms underpinning observed immune responses to COVID-19 in hybrid individuals may allow for improved and personalized vaccination regimes, thereby improving global resistance against the pandemic, which has hitherto infected more than 770 million individuals and cost humanity almost 7 million lives.

About the study

In the present study, researchers used peripheral blood mononuclear cells (PBMCs) to identify and quantify the variations in T and B cell populations across individuals exposed to multiple vaccination doses in tandem with COVID-19 infections of varying severity. They then focused their efforts on evaluating the kinetics and diversity of T spike (Ts) cells, thereby verifying both proposed hypothesized mechanisms underpinning previously observed immunity improvements.

The study cohort comprised 54 (28 female) self-reported COVID-19 survivors recruited from Seattle, USA,

between April and August 2020. All participants had their demographic and medical data recorded and were subjected to convalescent plasma donation for PBMC isolation. The cohort consisted of 35 individuals with mild to moderate COVID-19, 19 with severe illness (hospital and oxygen support required), and eight with critical COVID-19 (intensive care unit [ICU] admission required).

Participants ranged from 31 to 74 years of age, with 60.3 presenting the median value. Participants presented a diverse array of comorbidities, including cancer (n = 8), renal disease (n = 4), heart ailments (n = 9), hypertension (n = 9), and diabetes (n = 9).

From preserved PCMBs, selective staining was used to identify and isolate live CD3+ single cells, single positive CD4−CD8+, and CD4+CD8−, excluding all double positive and negative CD cells from further experiments. Gating and Boolean analyses with PBMC stimulation were used to identify and study AIM assay combinations of antigen-specific (in this case, SARS-CoV-2 Wu-1 strain) T-cell frequency.

Intracellular cytokine staining (ICS) was used to identify and quantify the production of cytokines following SARS-CoV-2 stimulation. Genomic DNA isolated from PBMCs was used for T-cell Receptor Sequencing (TCR-Seq), a method used to identify and track specific T cells and their clones. TCR-Seq was carried out independently for bulk repertoire analyses (bulk TCR-Seq) and antibody feature barcode library generation (single-cell TCR-Seq).

The library generated above was used for CD4+ and CD8+ assignments using unique molecular identifier (UMI) counts. SARS-CoV-2 Wu-1 strain-transfected Cos-7 cells were used to evaluate the specificity of assigned CD8+ T cells.

Finally, next-generation Human Leukocyte Antigen (HLA) Typing was carried out to identify class 1 and class 2 allotypes.

Study findings

Results from the above tests revealed divergent vaccine response kinetics, both between CD4+ and CD8+ TS cells and between individuals with differing COVID-19 disease severity. “In persons with previous SARS-CoV-2 infection, mRNA vaccines induced profound, albeit variable, expansion of preexisting circulating TM cell clones.” These results were amplified based on the number of mRNA vaccines received following COVID-19 disease, with the first two vaccine doses observed to augment S-reactive clonotypic diversity in the blood, resulting in substantial expansion in CD8+ TS clonotypes.

A similar expansion in CD8+ TS clonotypes has been reported in COVID-19-naïve individuals following their first vaccination dose, albeit to a much lower extent. This study further revealed that while not as substantial as CD8+ TS clonotype expansion, CD4+ clonotypes also expanded following the second vaccination dose.

Fuente: News Medical Life Sciences. Disponible en https://acortar.link/UYY3qD

Vaccine Manufacturing in Africa Receives Up to $1B in Support

Dec 8. The board of Gavi, the Vaccine Alliance approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA), a financing mechanism that will make up to $1 billion available to support a sustainable vaccine manufacturing industry in Africa. The goal for that industry is to make it capable of addressing future pandemics, outbreaks, and other health emergencies as well as the health of global vaccine markets.

The Gavi decision was made after months of collaboration with the African Union and the Africa Centers for Disease Control and Prevention (Africa CDC).

A lab worker at Atlantic Lifesciences in Ghana. [Gavi/Svetlomir Slavchev]

Targeting clear and unmet needs

Gavi is one of the largest purchasers of vaccines in the world. AVMA aims to make up to $1 billion available to manufacturers at critical moments in the development process as a way of helping offset high start-up costs and provide assurance of demand. By focusing on "priority" antigens, product profiles, and vaccine platforms, as well as constructing clear incentives for both "fill and finish" and drug substance production, AVMA says it will support global vaccine markets by targeting clear unmet needs and help establish a thriving, sustainable, end-to-end African vaccine manufacturing ecosystem.

Two years ago, the African Union Heads of States and Governments established The Partnerships for African Vaccine Manufacturing (PAVM) under the Africa CDC to deliver the goal of enabling the African vaccine manufacturing industry to develop, produce, and supply over 60% of the total vaccine doses required on the continent by 2040, up from less than one percent today (with interim goals of 10% by 2025 and 30% by 2030).

Since then, several vaccine manufacturing projects have been taking shape with others coming up, all of which with the objective of guaranteeing self-reliance of Africa should any health emergency or outbreak hit the continent, according to Jean Kaseya, MD, director of Africa CDC.

"[This] is a significant moment for Africa by establishing the African Vaccine Manufacturing Accelerator. The targeted $1 billion from GAVI to African manufacturers is a game changer for the continent and advances our efforts towards vaccine self-reliance. Africa CDC remains determined that Africa should produce its own vaccine and protect the lives of all Africans," he said. "GAVI has been an incredible partner in this, we will continue to advance together on this journey of self-reliance. Together, we are united with a mission for vaccine equity."

Africa CDC recently launched the Trusted Health Initiative to revolutionize digital health in Africa. [Africa CDC]

"We are grateful for the incredible close collaboration with the African Union and Africa CDC in support of our shared vision of a thriving, sustainable African vaccine ecosystem" added David Marlow, Interim CEO, Gavi, the Vaccine Alliance. "AVMA is an important step forward, sending a powerful signal that GAVI is serious about its efforts to support this vital initiative."

Fuente: GEN Genetic Engineering & Biotechnology News . Disponible en https://acortar.link/B2aIh5

El Gobierno de México aprueba la venta de las vacunas de Moderna y de Pfizer contra COVID-19

8 dic. El Gobierno de México aprobó la venta de vacunas contra la COVID-19 fabricadas por las empresas Moderna y Pfizer, un hecho que marca un giro respecto de la política seguida por el país hasta ahora.

Desde que las primeras vacunas contra el covid-19 llegaron a México en diciembre de 2020, las sustancias para prevenir la enfermedad han estado resguardadas y controladas por las autoridades gubernamentales y su comercialización estaba prohibida.

Ahora, la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) informó este jueves en un comunicado que otorgó la autorización para la venta de las vacunas Spikevax, elaborada por Moderna, y Comirnaty, de Pfizer.

“La dictaminación simultánea para expedir registro sanitario a vacunas contra COVID-19, permitiendo su comercialización en México, sienta precedente hacia una regulación enfocada en garantizar el acceso sin beneficiar a ningún usuario en particular, y eliminando cualquier necesidad de intermediario o gestor”, dijo la Cofepris.

El organismo también señaló que el suministro de las vacunas “debe ser bajo vigilancia médica y no se deberá aplicar de manera indiscriminada, ya que pueden representar riesgos para la salud”.

Las autoridades mexicanas no dijeron cuál será el precio aproximado de las vacunas.

En Estados Unidos, el precio de la vacuna de Moderna en el sector privado es de US$ 128; el de la vacuna de Pfizer es de US$ 115, de acuerdo con los registros de los Centros para la Prevención y el Control de Enfermedades (CDC, por sus siglas en inglés).

La autorización a la venta de estas vacunas se da a casi siete meses de que el Gobierno de México declaró el fin de la emergencia sanitaria por COVID-19, que se extendió de marzo de 2020 a mayo de 2023.

Durante ese periodo, COVID-19 causó 7,6 millones de contagios en México y 334.336 fallecimientos, de acuerdo con las cifras oficiales.

Fuente: CNN en español. Disponible en https://acortar.link/BhDpmA

New COVID vaccines targeting Omicron subvariant XBB 1.5 are now available in Australia

Dec 10. New COVID booster shots are now available in Australia. And as cases rise ahead of the holiday period yet again, experts say the latest vaccine will help protect against the subvariants currently spreading around the country.

What is the latest COVID-19 vaccine?

The new generation of boosters are called "monovalent Omicron XBB 1.5 vaccines".

"Monovalent" means they contain just one strain of COVID-19, making them a bit different to the "bivalent" vaccines we already had on the market.

They are designed to target the Omicron subvariant XBB 1.5, which you might remember by its unofficial nickname, the "Kraken".

Three versions are available in Australia:

- One for people over the age of 12 from Pfizer.
- One for children aged between five and 12 from Pfizer.
- One for people over the age of 12 from Moderna.

Novavax has also developed an XBB.1.5 vaccine, but it is not approved for use in Australia.

All adults can get the new vaccine if it's been more than six months since their last booster shot or COVID illness.

The new vaccine was modelled on the "Kraken" strain, but still provides protection against other variants.

(Pexels: Maksim Goncharenok)

However, Australia's leading vaccine advisory group, ATAGI, only recommends it for certain groups.

If you're over 65 or have underlying health conditions and haven't had a 2023 booster yet, it's strongly recommended that you get one.

If you're 75 or above, ATAGI says you should get the new vaccine even if you have already had a booster shot this year.

The new vaccine could also be beneficial as a second 2023 booster if you live in residential aged care, have never had COVID before, or have complex medical conditions, ATAGI says.

For everyone else between the ages of 18 and 65, ATAGI says you can "consider" a 2023 booster shot.

Clinical epidemiologist Nancy Baxter says if you're in this age group and haven't gotten a COVID-19 jab in the past 12 months, it's worth looking at the latest monovalent vaccines.

"What we want to make sure is that when we face COVID, we're as protected as we can be," she said.

ATAGI does not recommend that anyone aged 17 or under get booster shots unless they have a medical condition which increases the risk of severe COVID-19.

For babies, toddlers and the youngest children, only one COVID-19 vaccine is available: the original jab from Pfizer, designed for those aged between six months and five years.

Extra booster shots are not recommended for this young age group, so speak to a doctor if you have any concerns.

Is the new Omicron vaccine better than the others?

COVID-19 vaccines are always a little bit behind the curve: in the time it takes companies to develop new shots, the virus mutates into something different.

Older vaccines still greatly reduce your risk of getting gravely ill or dying from a COVID-19 infection, but are not as effective at reducing transmission.

And while the XBB 1.5 "Kraken" variant isn't dominating cases in Australia anymore, experts like Dr McMullen say the vaccines it inspired will help protect against other Omicron strains.

"The new XBB vaccines recently approved by ATAGI are better targeted to the strains currently circulating in

Australia and provide a modest improvement in immunity compared to previous vaccines," Dr McMullen said.

ATAGI says available data suggests "monovalent XBB vaccines provide modestly enhanced protection from severe disease compared to older vaccines".

A recent American study found the monovalent vaccine boosted protective antibodies against not only XBB.1.5 and the currently dominant EG.5.1 (known as "Eris"), but also other new sub-variants like HV.1, HK.3, JD.1.1, and JN.1.

The research, which assessed antibody levels in blood samples from 60 patients, has not been peer-reviewed yet — but overall, it means the new vaccines are promising.

Fuente: ABC News. Disponible en https://acortar.link/GGVZHQ

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/12/01 to 2023/12/10. "Covid-19 vaccine" (Title/Abstract) 458 records.

Rational development of multicomponent mRNA **vaccine** candidates against mpox.
Zhang RR, Wang ZJ, Zhu YL, Tang W, Zhou C, Zhao SQ, Wu M, Ming T, Deng YQ, Chen Q, Jin NY, Ye Q, Li X, Qin CF. Emerg Microbes Infect. 2023 Dec;12(1):2192815. doi: 10.1080/22221751.2023.2192815. PMID: 36947428

Vaccine envy during the **COVID-19** pandemic.
Erz E, Rentzsch K. Int J Psychol. 2023 Dec;58(6):545-553. doi: 10.1002/ijop.12929. Epub 2023 Jul 10. PMID: 37427842

SARS-CoV-2 spike S2-specific neutralizing antibodies.
Li CJ, Chang SC. Emerg Microbes Infect. 2023 Dec;12(2):2220582. doi: 10.1080/22221751.2023.2220582. PMID: 37254830

COVID-19 vaccination and myasthenia gravis.
Arbel A, Bishara H, Barnett-Griness O, Cohen S, Najjar-Debbiny R, Gronich N, Auriel E, Saliba W. Eur J Neurol. 2023 Dec;30(12):3989-3990. doi: 10.1111/ene.16087. Epub 2023 Oct 5. PMID: 37797299

COVID-19 vaccination and myasthenia gravis.
Kleebayoon A, Wiwanitkit V. Eur J Neurol. 2023 Dec;30(12):3988. doi: 10.1111/ene.16086. Epub 2023 Oct 5. PMID: 37797298

COVID-19 and SLE: Infection and autoimmunity at its best.
Mahroum N, Elsalti A, Ozkan MF, Shoenfeld Y. Lupus. 2023 Dec;32(14):1591-1597. doi: 10.1177/09612033231213914. Epub 2023 Nov 5. PMID: 37927085

Understanding **COVID-19 Vaccine** Hesitancy Among K-12 Staff, Parents, and Students: District of Columbia, February to April, 2022.
Mark-Carew M, van Zyl A, Tatti KM, Chong M, Rose C, Sifre K, Jarris D, Still W, Aynalem G, Welton M, Thomas ES, Hall L, Samson ME. J Sch Health. 2023 Dec;93(12):1079-1090. doi: 10.1111/josh.13382. Epub 2023 Aug 21. PMID: 37602945

COVID-19 in Brazil: a 3-year update.
Martins JP, Siqueira BA, Sansone NMS, Marson FAL. Diagn Microbiol Infect Dis. 2023 Dec;107(4):116074. doi: 10.1016/j.diagmicrobio.2023.116074. Epub 2023 Aug 27. PMID: 37729718

Unpacking adverse events and associations post **COVID-19** vaccination: a deep dive into **vaccine** adverse event reporting system data.
Li Y, Lundin SK, Li J, Tao W, Dang Y, Chen Y, Tao C. Expert Rev Vaccines. 2023 Dec 8. doi: 10.1080/14760584.2023.2292203. Online ahead of print. PMID: 38063069

New-onset aplastic anemia after SARS-CoV-2 vaccination.
Chatzikalil E, Kattamis A, Diamantopoulos P, Solomou EE. Int J Hematol. 2023 Dec;118(6):667-681. doi: 10.1007/s12185-023-03666-z. Epub 2023 Sep 28. PMID: 37768509

COVID-19 Vaccine Accessibility, Perceptions, and Attitudes in the LGBTQ+ Community.
Traister T. West J Nurs Res. 2023 Dec;45(12):1130-1138. doi: 10.1177/01939459231211473. Epub 2023 Nov 1. PMID: 37909671

The **COVID-19** experience in Africa and the Middle East.
Bizri AR, Al Akoury N, Mhlanga T, Morales GDC, Haridy H, Hussey GD, Srivastava A. Ann Med. 2023 Dec;55(1):2222641. doi: 10.1080/07853890.2023.2222641. PMID: 37345635

COVID-19 vaccine uptake and hesitancy in Chinese patients with asthma.
Chang C, Zhang X, Feng Y, Jin R, Sun L, Liang Y, Liu X, Ma Y, Song J, Xiang P, Zhang E, Chen L, Jiang Y, Huang K, Wang W, Chen Y, Sun Y. J Asthma. 2023 Dec;60(12):2111-2120. doi: 10.1080/02770903.2023.2220790. Epub 2023 Jun 9. PMID: 37272671

Global **COVID-19** Vaccination in Infants and Children: Effectiveness, Safety, and Challenges.
Jantarabenjakul W, Chantasrisawad N, Nantanee R, Ganguli S, Puthanakit T. Asian Pac J Allergy Immunol. 2023 Dec;41(4):292-303. doi: 10.12932/AP-300423-1596. PMID: 37874316

Novel **COVID-19 vaccine** hesitancy and acceptance, and associated factors, amongst medical students: a scoping review.
Pandher R, Bilszta JLC. Med Educ Online. 2023 Dec;28(1):2175620. doi: 10.1080/10872981.2023.2175620. PMID: 36788502

COVID-19 and Pregnancy: Interrelationships With Asthma and Allergy.
Mustafa SS, Huang J, Perrotta K, Chambers C, Namazy J. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3597-3604. doi: 10.1016/j.jaip.2023.08.022. Epub 2023 Aug 19. PMID: 37604428

Trends in influenza **vaccine** uptake before and during the **COVID-19** pandemic in the USA.
Lin J, Li C, He W. Public Health. 2023 Dec;225:291-298. doi: 10.1016/j.puhe.2023.10.028. Epub 2023 Nov 11. PMID: 37956641

Tuberculosis in Spain: An opinion paper.
Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Santiago B, Caminero JA, Barros C, García de Viedma D, Martín C, Bouza E. Rev Esp Quimioter. 2023 Dec;36(6):562-583. doi: 10.37201/req/115.2023. Epub 2023 Nov 2. PMID: 37922367

Viruses and amyloids - a vicious liaison.
Hammarström P, Nyström S. Prion. 2023 Dec;17(1):82-104. doi: 10.1080/19336896.2023.2194212. PMID: 36998202

COVID-19 Vaccine Uptake and Hesitancy in a Latino Agricultural Community.
Rosado JI, Costero JM, Wang Y. Health Educ Behav. 2023 Dec;50(6):815-821. doi: 10.1177/10901981231167893. Epub 2023 Apr 28. PMID: 37118930

COVID-19 vaccination and autoimmunity: Causality, precipitation or chance association?
Mv P, Ahmed S. Int J Rheum Dis. 2023 Dec;26(12):2371-2372. doi: 10.1111/1756-185X.14893. PMID: 38041647

COVID-19 vaccine hesitancy between family decision-makers and non-decision-makers among college teachers.
Xu R, Shi G, Zheng S, Tung TH, Zhang M. Ann Med. 2023 Dec;55(1):292-304. doi: 10.1080/07853890.2022.2162114. PMID: 36594480

Children, **vaccines**, and financial incentives.
Erdem O, Erdem S, Monson K. Int J Health Econ Manag. 2023 Dec;23(4):537-552. doi: 10.1007/s10754-023-09343-2. Epub 2023 Feb 28. PMID: 36853572

COVID-19 vaccine decision-making in remote Alaska between November 2020 and November 2021.
Eichelberger L, Hansen A, Cochran P, Hahn M, Fried R. Int J Circumpolar Health. 2023 Dec;82(1):2242582. doi: 10.1080/22423982.2023.2242582. PMID: 37535846

Breakthrough infections and acceptance of **COVID-19 vaccine** boosters: A survey analysis.
Stevens CW, Neely SR, Scacco JM. PEC Innov. 2023 Dec;2:100167. doi: 10.1016/j.pecinn.2023.100167. Epub 2023 May 16. PMID: 37214503

Long **COVID** and possible preventive options.
Sebők S, Gyires K. Inflammopharmacology. 2023 Dec;31(6):2807-2817. doi: 10.1007/s10787-023-01204-1. Epub 2023 Jun 21. PMID: 37344737

Newer **COVID-19 vaccines**: Still lights and shadows?
Angeli F, Zappa M, Verdecchia P. Eur J Intern Med. 2023 Dec;118:32-35. doi: 10.1016/j.ejim.2023.10.025. Epub 2023 Oct 25. PMID: 37891024

Alleviation of shoulder injury related to **vaccine** administration (SIRVA) pain and disability following **COVID-19 vaccine** with chiropractic biophysics® (CBP®) methods: a case report and long-term follow-up with global implications.
Haas JW, Oakley PA, Harrison DE. J Phys Ther Sci. 2023 Dec;35(12):831-837. doi: 10.1589/jpts.35.831. Epub 2023 Dec 1. PMID: 38075507

Global burden of **vaccine**-associated anaphylaxis and their related **vaccines**, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.
Lee K, Lee H, Kwon R, Shin YH, Yeo SG, Lee YJ, Kim MS, Choi YS, Papadopoulos NG, Rahmati M, Jung J, Lee J, Yon DK. Allergy. 2023 Dec 10. doi: 10.1111/all.15968. Online ahead of print. PMID: 38071735

COVID-19 vaccine or booster hesitancy among children aged 6 month-5 years, 5-11 years, and 12-17 years in the United States: An analytic cross-sectional study.

Park C, Vagoyan Zabala P, Irene Trisnadi A. Prev Med Rep. 2023 Sep 22;36:102436. doi: 10.1016/j.pmedr.2023.102436. eCollection 2023 Dec. PMID: 37822978

Platelet dropping, bleeding and new treatment requirements in ITP patients after inactivated **COVID-19** vaccination.
Zhan XY, Chen H, Kong H, Meng T, Ye J, Liu Y, Ng MHL, Li L, Zhang Y, Huang J, Peng Q, Chen C, He Y, Yang M. Immunol Lett. 2023 Dec;264:56-63. doi: 10.1016/j.imlet.2023.11.007. Epub 2023 Nov 24. PMID: 38006954

COVID-19 Vaccine Acceptance Among Latino/a Immigrants: The Role of Collective Responsibility and Confidence.
Kirchoff C, Penn A, Wang W, Babino R, De La Rosa M, Cano MA, Sanchez M. J Immigr Minor Health. 2023 Dec;25(6):1246-1253. doi: 10.1007/s10903-023-01513-1. Epub 2023 Jul 4. PMID: 37402075

CDC **COVID-19 Vaccine** Pregnancy Registry: Design, data collection, response rates, and cohort description.
Madni SA, Sharma AJ, Zauche LH, Waters AV, Nahabedian JF 3rd, Johnson T, Olson CK; CDC COVID-19 Vaccine Pregnancy Registry Work Group. Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.11.061. Online ahead of print. PMID: 38057207

COVID and **COVID vaccine**-related corneal morbidity: A review.
Sidhu N, Vanathi M, Gupta N, Tandon R. Indian J Ophthalmol. 2023 Dec 1;71(12):3595-3599. doi: 10.4103/IJO.IJO_765_23. Epub 2023 Nov 20. PMID: 37991289

Safety, immunogenicity and efficacy of an mRNA-based **COVID-19 vaccine**, GLB-COV2-043, in preclinical animal models.
Lelis F, Byk LA, Pustylnikov S, Nguyen V, Nguyen B, Nitz M, Tarte P, Tungare K, Li J, Manna S, Maiti S, Mehta DH, Sekar N, Posadas DM, Dhamankar H, Hughes JA, Aulisa L, Khan A, Melo MB, Dey AK. Sci Rep. 2023 Dec 1;13(1):21172. doi: 10.1038/s41598-023-46233-6. PMID: 38040905

Passive antibody therapy in emerging infectious diseases.
Yang X. Front Med. 2023 Dec 2. doi: 10.1007/s11684-023-1021-y. Online ahead of print. PMID: 38040914

Distinctions between survivors and non-survivors with SARS-CoV-2 **vaccine**-induced thrombotic thrombocytopenia: A systematic review and meta-analysis.
Castro-Varela A, Garza Salas AK, Barrios-Ruiz A, Ambriz Morales E, Abascal-Lanzagorta P, Reyes-Chavez MF, Cárdenas-Rodríguez IT, Solorzano-Lopez EJ, Sánchez-Pizarro C, Fernando de Los Ríos Arce L, Vazquez-Garza E, Jerjes-Sanchez C. Vaccine X. 2023 Nov 18;15:100407. doi: 10.1016/j.jvacx.2023.100407. eCollection 2023 Dec. PMID: 38075434

Previous Infection and Effectiveness of **COVID-19** Vaccination in Middle- and High-School Students.
Almendares OM, Ruffin JD, Collingwood AH, Nolen LD, Lanier WA, Dash SR, Ciesla AA, Wiegand R, Tate JE, Kirking HL. Pediatrics. 2023 Dec 1;152(6):e2023062422. doi: 10.1542/peds.2023-062422. PMID: 37960897

Evaluation of a Community **COVID-19 Vaccine** Ambassador Train-the-Trainer Program.
Corley AMS, Gomes SM, Martin KJ, Watkins S, Lindsey K, Frenck RW Jr, Mitchell MJ, Rule ARL, Crosby LE. J Immigr Minor Health. 2023 Dec;25(6):1302-1306. doi: 10.1007/s10903-023-01502-4. Epub 2023 Jun 5. PMID: 37273119

Perceptions of the **COVID-19 Vaccine** and Other Adult Vaccinations in Malawi: A Qualitative Assessment.
Tibbels N, Kaseghe R, Chisambi AB, Ndovi V, Mang'ando A, Figueroa ME. Glob Health Sci Pract. 2023 Dec 1. doi: 10.9745/GHSP-D-23-00146. Online ahead of print. PMID: 38050087

Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
Sadhu S, Dandotiya J, Dalal R, Khatri R, Mykytyn AZ, Batra A, Kaur M, Chandwaskar R, Singh V, Kamboj A, Srivastava M, Mani S, Asthana S, Samal S, Rizvi ZA, Salunke DB, Haagmans BL, Awasthi A. Antiviral Res. 2023 Dec;220:105743. doi: 10.1016/j.antiviral.2023.105743. Epub 2023 Nov 8. PMID: 37949319

Understanding Stakeholders' Perspectives to Increase **COVID-19 Vaccine** and Booster Uptake Among Black Individuals With Rheumatic Conditions.
Ezeh N, Sirek G, Ulysse SN, Williams JN, Chandler MT, Ojikutu BO, York M, Crespo-Bosque M, Jean-Jacques M, Roberson T, Mancera-Cuevas K, Milaeger H, Losina E, Dhand A, Son MB, Ramsey-Goldman R, Feldman CH. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2508-2518. doi: 10.1002/acr.25172. Epub 2023 Jul 30. PMID: 37309724

Fibrinogenolysis and fibrinolysis in **vaccine**-induced immune thrombocytopenia and thrombosis.
Simpson M, Narwal A, West E, Martin J, Bagot CN, Page AR, Watson HG, Whyte CS, Mutch NJ. J Thromb Haemost. 2023 Dec;21(12):3589-3596. doi: 10.1016/j.jtha.2023.09.007. Epub 2023 Sep 19. PMID: 37734715

Belief in **vaccine** myths and **vaccine** uptake in Utah during the **COVID-19** pandemic.
Omisakin OA, Ulrich-Schad JD, Hunt A, Givens JE, Beacham M. Prev Med Rep. 2023 Sep 1;36:102390. doi: 10.1016/j.pmedr.2023.102390. eCollection 2023 Dec. PMID: 37719795

Female reproductive health during the **COVID-19** pandemic: latest evidence and understanding.
Li S, Liu H, Li D, Chen F. Arch Gynecol Obstet. 2023 Dec;308(6):1691-1696. doi: 10.1007/s00404-023-06976-z. Epub 2023 Mar 1. PMID: 36856820

Modeling vaccination strategies with limited early **COVID-19 vaccine** access in low- and middle-income countries: A case study of Thailand.
Anupong S, Chantanasaro T, Wilasang C, Jitsuk NC, Sararat C, Sornbundit K, Pattanasiri B, Wannigama DL, Amarasiri M, Chadsuthi S, Modchang C. Infect Dis Model. 2023 Nov 15;8(4):1177-1189. doi: 10.1016/j.idm.2023.11.003. eCollection 2023 Dec. PMID: 38074078

Respiratory viral infections including **COVID-19** in solid organ transplantation.
Lo CKL, Kumar D. Curr Opin Organ Transplant. 2023 Dec 1;28(6):471-482. doi: 10.1097/MOT.0000000000001106. Epub 2023 Sep 26. PMID: 37909926

Effects of **COVID-19** or **vaccines** for SARS-COV-2 on sperm parameters: A systematic review and meta-analysis.

Edele Santos D, Colonetti T, Rodrigues Uggioni ML, Rech P, Marcelino Baptista M, Medeiros LR, Grande AJ, Rosa MI. J Reprod Immunol. 2023 Dec;160:104140. doi: 10.1016/j.jri.2023.104140. Epub 2023 Sep 1. PMID: 37696225

Test negative design for **vaccine** effectiveness estimation in the context of the **COVID-19** pandemic: A systematic methodology review.
Mésidor M, Liu Y, Talbot D, Skowronski DM, De Serres G, Merckx J, Koushik A, Tadrous M, Carazo S, Jiang C, Schnitzer ME. Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.12.013. Online ahead of print. PMID: 38072756

Safety and immunogenicity of the **COVID-19** mRNA **vaccine** CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Jin Z, Wu J, Wang Y, Huang T, Zhao K, Liu J, Wang H, Zhu T, Gou J, Huang H, Wu X, Yin H, Song J, Li R, Zhang J, Li L, Chen J, Li X, Zhang M, Li J, Hou M, Song Y, Wang B, Gao Q, Wu L, Kong Y, Dong R. J Infect. 2023 Dec;87(6):556-570. doi: 10.1016/j.jinf.2023.10.012. Epub 2023 Oct 28. PMID: 37898410

Nephrotic syndrome following **COVID-19** vaccination: a systematic review.
Parikh C, Upadhyay H, Patel S, Sundararajan R, Shah D, Anand A, Baraskar B, Bhatt T, Verma D, Agrawal S, Mittal A, Gupta S. J Nephrol. 2023 Dec;36(9):2431-2440. doi: 10.1007/s40620-023-01710-z. Epub 2023 Jul 28. PMID: 37505405

Willingness to Receive the **COVID-19 Vaccine** in California: Disparities by Race and Citizenship Status.
Bacong AM, Haro-Ramos AY. J Racial Ethn Health Disparities. 2023 Dec;10(6):2911-2920. doi: 10.1007/s40615-022-01468-3. Epub 2022 Nov 30. PMID: 36449129

Migraine worsening after **COVID-19** and **COVID-19** vaccination: Are we facing a nocebo effect?
Melgarejo L, Caronna E, Rosell-Mirmi J, Elosua-Bayés I, Alpuente A, Torres-Ferrus M, Gallardo VJ, Pozo-Rosich P. Eur J Neurol. 2023 Dec;30(12):3877-3885. doi: 10.1111/ene.16058. Epub 2023 Oct 4. PMID: 37791410

Adhesive capsulitis after **COVID-19 vaccine** injection: a peculiar case treated with combined bursa distention and glenohumeral capsular hydrodilatation.
Biglia A, Morandi V, Zanframundo G, Donati D, Maggiore F, Vita F, Sammarchi L, Pagani C, Cavagna L, Galletti S, Montecucco C. J Ultrasound. 2023 Dec;26(4):909-911. doi: 10.1007/s40477-022-00739-3. Epub 2023 Jan 3. PMID: 36595199

SARS-CoV-2 Epidemiology and **COVID-19** mRNA **Vaccine** Effectiveness Among Infants and Children Aged 6 Months-4 Years - New **Vaccine** Surveillance Network, United States, July 2022-September 2023.
Tannis A, Englund JA, Perez A, Harker EJ, Staat MA, Schlaudecker EP, Halasa NB, Stewart LS, Williams JV, Michaels MG, Selvarangan R, Schuster JE, Sahni LC, Boom JA, Weinberg GA, Szilagyi PG, Clopper BR, Zhou Y, McMorrow ML, Klein EJ, Moline HL. MMWR Morb Mortal Wkly Rep. 2023 Dec 1;72(48):1300-1306. doi: 10.15585/mmwr.mm7248a2. PMID: 38032834

Effects of SARS-CoV-2 **Vaccines** on Sperm Quality: Systematic Review.
Li G, Zhang R, Song B, Wang C, Shen Q, He X, Cao Y. JMIR Public Health Surveill. 2023 Dec 6;9:e48511. doi: 10.2196/48511. PMID: 37976132

Characterization of **COVID-19 vaccine** clinical trial discussions on the social question-and-answer site Quora.
Xu Q, McMann TJ, Li J, Wenzel C, Mackey TK. Trials. 2023 Dec 5;24(1):790. doi: 10.1186/s13063-023-07837-5. PMID: 38053216

Test negative case-control study of **COVID-19 vaccine** effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
Mweso O, Simwanza J, Malambo W, Banda D, Fwoloshi S, Sinyange N, Yoo YM, Feldstein LR, Kapina M, Mulenga LB, Liwewe MM, Musonda K, Kapata N, Mwansa FD, Agolory S, Bobo P, Hines J, Chilengi R. BMJ Open. 2023 Dec 10;13(12):e072144. doi: 10.1136/bmjopen-2023-072144. PMID: 38072491

Newborn and Early Infant Outcomes Following Maternal **COVID-19** Vaccination During Pregnancy.
Jorgensen SCJ, Drover SSM, Fell DB, Austin PC, D'Souza R, Guttmann A, Buchan SA, Wilson SE, Nasreen S, Schwartz KL, Tadrous M, Wilson K, Kwong JC. JAMA Pediatr. 2023 Dec 1;177(12):1314-1323. doi: 10.1001/jamapediatrics.2023.4499. PMID: 37870875

Online health information seeking and **Covid-19 vaccine** hesitancy: Evidence from 50+ Europeans.
Principe F, Weber G. Health Policy. 2023 Dec;138:104942. doi: 10.1016/j.healthpol.2023.104942. Epub 2023 Nov 8. PMID: 37984096

Sociodemographic predictors of **COVID-19 vaccine** hesitancy: correspondence.
Mungmunpuntipantip R, Wiwanitkit V. J Matern Fetal Neonatal Med. 2023 Dec;36(2):2229475. doi: 10.1080/14767058.2023.2229475. PMID: 37424048

Rational design of an influenza-**COVID-19** chimeric protective **vaccine** with HA-stalk and S-RBD.
Li Y, Liu P, Hao T, Liu S, Wang X, Xie Y, Xu K, Lei W, Zhang C, Han P, Li Y, Jin X, Huan Y, Lu Y, Zhang R, Li X, Zhao X, Xu K, Liao P, Lu X, Bi Y, Song H, Wu G, Zhu B, Gao GF. Emerg Microbes Infect. 2023 Dec;12(2):2231573. doi: 10.1080/22221751.2023.2231573. PMID: 37394992

Exclusive and dual influenza and **COVID-19** vaccination among U.S. adults and adolescents in 2021.
Nguyen KH, Zhao R, Chen S, Bednarczyk RA. Ann Med. 2023 Dec;55(1):2196436. doi: 10.1080/07853890.2023.2196436. PMID: 37052255

Assessing **COVID-19 Vaccine** Hesitancy and Trust in Home Health Workers in New York City: A Pilot Study.
McCabe CA, Venkatram C, Yarakala S, Korin M, Boulos A, Oliver K. J Occup Environ Med. 2023 Dec 1. doi: 10.1097/JOM.0000000000003019. Online ahead of print. PMID: 38037263

Vaccine Hesitancy in India: Facilitators and Inhibitors.
Parveen H, Nasir S, Shahnawaz MG, Husain F, Baig J, Shankar A. Health Educ Behav. 2023 Dec;50(6):822-834. doi: 10.1177/10901981231179503. Epub 2023 Jul 4. PMID: 37401790

A comparison of anxiety levels before and during the **COVID-19** pandemic.
Voss C, Shorter P, Weatrowski G, Mueller-Coyne J, Turner K. Psychol Rep. 2023 Dec;126(6):2669-2689. doi: 10.1177/00332941221093250. Epub 2022 May 3. PMID: 35503814

Vaccination, immunity, and the changing impact of **COVID-19** on infant health.
Torche F, Nobles J. Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2311573120. doi: 10.1073/pnas.2311573120. Epub 2023 Nov 27. PMID: 38011548

The **COVID-19** inflammation and high mortality mechanism trigger.
Stróż S, Kosiorek P, Stasiak-Barmuta A. Immunogenetics. 2023 Dec 8. doi: 10.1007/s00251-023-01326-4. Online ahead of print. PMID: 38063879

Association between **COVID-19** vaccination and myasthenia gravis: A population-based, nested case-control study.
Arbel A, Bishara H, Barnett-Griness O, Cohen S, Najjar-Debbiny R, Gronich N, Auriel E, Saliba W. Eur J Neurol. 2023 Dec;30(12):3868-3876. doi: 10.1111/ene.16025. Epub 2023 Aug 13. PMID: 37552795

Outcome findings of **COVID-19 vaccine** among 31 977 pregnant women in Indonesia.
Wiweko B, Januarto AK, Saleh N, Hadisaputra W, Hestiantoro A, Hidayat YM, Baharuddin M, Pusponegoro AD, Maidarti M, Dilmy MA, Alamsyah M, Bachnas MA, Hasanuddin H, Sahil MF, Djanas HD, Effendy Y, Sasotya RMS, Rumekti D, Respati SH, Askandar B, Winarno B, Gunawan R, Irianta T, Wantania J, Abimanyu B, Sofyan O, Kristanto H, Mahayasa PD, Sutrisno S, Demsi D, Wiradhama H, Hamid AR, Suhaimi D, Kaput JF, Sayuti M, Brizain M, Zainal Arifin Y, Muchtar BB, Paulus LD, Patai A, Abbas M, Adhie RP, Sulaiman MI, Taliak DM, Jabiy F, Dzakaria E, Siregar FA, Hayatunnufus Y, Jovito A, Khairani N, Cahya NP, Lukmana AA, Yulinda D. Int J Gynaecol Obstet. 2023 Dec;163(3):1018-1023. doi: 10.1002/ijgo.15073. Epub 2023 Sep 13. PMID: 37703057

COVID-19 vaccination in pregnancy: ambiguity in decision-making.
Jones E, Neely E. Health Promot Int. 2023 Dec 1;38(6):daad144. doi: 10.1093/heapro/daad144. PMID: 37935170

COVID-19 Vaccination Among Skilled Nursing Facility Staff: Challenges and Strategies Identified by Administrators.
Gadbois EA, Brazier JF, Meehan A, Madrigal C, White EM, Rafat A, Grabowski D, Shield RR. Med Care Res Rev. 2023 Dec;80(6):608-618. doi: 10.1177/10775587231168435. Epub 2023 May 12. PMID: 37170944

Impact of implemented vaccination strategies on **vaccine** uptake and attitude of final year pharmacy students toward **COVID-19 vaccines** in Gezira State, Sudan.
Wedaa A, Elmustafa M, Babiker HA, Ahmed R. Vaccine X. 2023 Nov 28;15:100416. doi: 10.1016/j.jvacx.2023.100416. eCollection 2023 Dec. PMID: 38075433

Unveiling the interplay between evidence, values and cognitive biases. The case of the failure of the AstraZeneca **COVID-19 vaccine**.
Amoretti MC, Lalumera E. J Eval Clin Pract. 2023 Dec;29(8):1294-1301. doi: 10.1111/jep.13903. Epub 2023 Jul 29. PMID: 37515407

Respiratory syncytial virus in children: epidemiology and clinical impact post-**COVID-19**.
Rice E, Oakes DB, Holland C, Moore HC, Blyth CC. Curr Opin Infect Dis. 2023 Dec 1;36(6):522-528. doi: 10.1097/QCO.0000000000000967. Epub 2023 Oct 13. PMID: 37830952

COVID-19 and obstetric outcomes: a single-center retrospective experience in a predominantly Black population.
Kuriloff M, Patel E, Mueller A, Dada T, Duncan C, Arnolds D, Rana S. J Matern Fetal Neonatal Med. 2023 Dec;36(1):2196364. doi: 10.1080/14767058.2023.2196364. PMID: 37005011

Papuloerythroderma of Ofuji following **COVID-19** vaccination.
Huang YW, Chung WH, Chen CB. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1360-e1362. doi: 10.1111/jdv.19294. Epub 2023 Jul 21. PMID: 37369630

Effects of **COVID-19** vaccination on human fertility: a post-pandemic literature review.
Wang C, Wang M, Li G, Song B, Xing Q, Cao Y. Ann Med. 2023 Dec;55(2):2261964. doi: 10.1080/07853890.2023.2261964. Epub 2023 Sep 27. PMID: 37756386

COVID-19 vaccine short-term adverse events in the real-life family practice in Krakow, Poland.
Oleszczyk M, Marciniak Z, Nessler K, Wójtowicz E, Szozda N, Kryj-Radziszewska E, Boroń M, Gajos K, Paziewski MP, Sajdak P, Windak A. Eur J Gen Pract. 2023 Dec;29(2):2147500. doi: 10.1080/13814788.2022.2147500. Epub 2022 Dec 5. PMID: 36469611

Adverse reactions to cosmetic implants after **COVID-19** vaccination: A literature review.
Cheng WJ, Cai ZX, Tang XJ. J Cosmet Dermatol. 2023 Dec;22(12):3199-3212. doi: 10.1111/jocd.15828. Epub 2023 Aug 17. PMID: 37592436

The relationship between **vaccine** acceptance and **COVID-19** mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data.
Brnic S, Buric B, Marcec R, Likic R. Vaccine X. 2023 Sep 19;15:100391. doi: 10.1016/j.jvacx.2023.100391. eCollection 2023 Dec. PMID: 37772201

Wastewater surveillance provides 10-days forecasting of **COVID-19** hospitalizations superior to cases and test positivity: A prediction study.
Hill DT, Alazawi MA, Moran EJ, Bennett LJ, Bradley I, Collins MB, Gobler CJ, Green H, Insaf TZ, Kmush B, Neigel D, Raymond S, Wang M, Ye Y, Larsen DA. Infect Dis Model. 2023 Oct 31;8(4):1138-1150. doi: 10.1016/j.idm.2023.10.004. eCollection 2023 Dec. PMID: 38023490

Analyzing an immunization resource website: User browsing trends.
Cheng DR, Reimer H, Le D, Crawford NW. Vaccine. 2023 Dec 7;41(50):7498-7502. doi: 10.1016/j.vaccine.2023.11.019. Epub 2023 Nov 15. PMID: 37977940

COVID-19 Vaccine Intention and Social Cognitive Theory: The Role of Individual Responsibility and Partisan Media Use in a Moderated Moderated Mediation Model.
Borah P, Austin EW, Lee DKL. Health Commun. 2023 Dec;38(12):2765-2773. doi: 10.1080/10410236.2022.2114766. Epub 2022 Aug 24. PMID: 36002351

COVID-19 vaccination preferences during a pause in Johnson & Johnson **vaccine** administration.
Wagner AL, Zhang F, Kerekes S, Shih SF, Zhao L. Vaccine X. 2023 Aug 18;15:100373. doi: 10.1016/j.jvacx.2023.100373. eCollection 2023 Dec. PMID: 37674932

Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored **COVID-19 Vaccine** Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial.
Jia S, Zhang J, Wang X, Zhang Z, Wang B, Zhang J, Jiang H, Guo G, Wang Y, Wan J, Wang W, Hou L, Zhu F. Infect Dis Ther. 2023 Dec 1. doi: 10.1007/s40121-023-00892-0. Online ahead of print. PMID: 38038866

Association between acceptance of routine pregnancy vaccinations and **COVID-19 vaccine** uptake in pregnant patients.
Ha L, Levian C, Greene N, Goldfarb I, Hirsch A, Naqvi M. J Infect. 2023 Dec;87(6):551-555. doi: 10.1016/j.jinf.2023.10.010. Epub 2023 Oct 19. PMID: 37865294

Awareness of and attitude toward **COVID-19** vaccination among individuals with COPD and the strategies to overcome **vaccine** hesitation: A mini review.
Liang Y, Sun Y. Hum Vaccin Immunother. 2023 Dec 15;19(3):2286686. doi: 10.1080/21645515.2023.2286686. Epub 2023 Dec 7. PMID: 38059434

Emerging mRNA therapies for cardiac fibrosis.
Jardin B, Epstein JA. Am J Physiol Cell Physiol. 2023 Dec 4. doi: 10.1152/ajpcell.00504.2023. Online ahead of print. PMID: 38047297

The **COVID-19 Vaccine** Conundrum: An Assessment of **Vaccine** Hesitancy Amongst Patients at a Federally Qualified Health Center.
Clark LR, Sawkin MT, Melton BL, Meyer EG. J Pharm Pract. 2023 Dec;36(6):1350-1355. doi: 10.1177/08971900221116193. Epub 2022 Jul 21. PMID: 35861329

College students' willingness to accept **COVID-19 vaccines**.
Brunson EK, Rohde RE, Fulton LV. J Am Coll Health. 2023 Dec;71(9):2804-2812. doi: 10.1080/07448481.2021.1996375. Epub 2021 Dec 14. PMID: 34905717

Prostate-specific antigen level association with **COVID-19** infection and vaccination.
Frumer M, Aharony SM, Shoshany O, Kedar D, Baniel J, Golan S. Clin Genitourin Cancer. 2023 Dec;21(6):e405-e411. doi: 10.1016/j.clgc.2023.05.001. Epub 2023 May 5. PMID: 37270370

COVID-19 vaccination uptake and hesitancy reasons in food production workers.
Haire G, Gleeson D, Reid A. Ir J Med Sci. 2023 Dec;192(6):3105-3108. doi: 10.1007/s11845-023-03342-5. Epub 2023 Mar 22. PMID: 36944843

The disparity in hesitancy toward **COVID-19** vaccination between older individuals in nursing homes and those in the community in Taizhou, China.
Lv L, Wu XD, Yan HJ, Zhao SY, Zhang XD, Zhu KL. BMC Geriatr. 2023 Dec 9;23(1):828. doi: 10.1186/s12877-023-04518-5. PMID: 38066433

Booster vaccination is required to elicit and maintain **COVID-19 vaccine**-induced immunity in SIV-infected macaques.
Li P, Wang Q, He Y, Yang C, Zhang Z, Liu Z, Liu B, Yin L, Cui Y, Hu P, Liu Y, Zheng P, Wang W, Qu L, Sun C, Guan S, Feng L, Chen L. Emerg Microbes Infect. 2023 Dec;12(1):e2136538. doi: 10.1080/22221751.2022.2136538. PMID: 36239345

Substantial Disparities In **COVID-19 Vaccine** Uptake And Unmet Immunization Demand In Low- And Middle-Income Countries.
Fox AM, Choi Y, Lin L. Health Aff (Millwood). 2023 Dec;42(12):1697-1705. doi: 10.1377/hlthaff.2023.00729. PMID: 38048509

Review of adverse events associated with **COVID-19 vaccines**, highlighting their frequencies and reported cases.
Yaamika H, Muralidas D, Elumalai K. J Taibah Univ Med Sci. 2023 Sep 5;18(6):1646-1661. doi: 10.1016/j.jtumed.2023.08.004. eCollection 2023 Dec. PMID: 37732332

Factors associated with **COVID-19** vaccination in Belize.
Rios-Zertuche D, Daga G, Iorillo F, Aguilar Rivera AM, Diaz-Musa M, Largaespada Beer N, López Boo F, Sabido J. Vaccine X. 2023 Sep 1;15:100380. doi: 10.1016/j.jvacx.2023.100380. eCollection 2023 Dec. PMID: 37693845

Hybrid immunity and protection against infection during the Omicron wave in Malta.
Cauchi JP, Dziugyte A, Borg ML, Melillo T, Zahra G, Barbara C, Souness J, Agius S, Calleja N, Gauci C, Vassallo P, Baruch J. Emerg Microbes Infect. 2023 Dec;12(1):e2156814. doi: 10.1080/22221751.2022.2156814. PMID: 36510837

COVID-19 vaccine confidence in the post-vaccination era: Perceptions among adults with immune-mediated inflammatory diseases.
Santana FM, Rezende RPV, Paschoal NOS, Rocha LF, Lopes JB, Perez MO, Bunjes BG, Dório M, Furquim MAD, Cobra JF, Sales LP, Figueiredo CP. Public Health Pract (Oxf). 2023 Aug 9;6:100419. doi: 10.1016/j.puhip.2023.100419. eCollection 2023 Dec. PMID: 37608848

Clinical impact and cost-effectiveness of the updated **COVID-19** mRNA autumn 2023 **vaccines** in Germany.
Joshi K, Scholz S, Maschio M, Kohli M, Lee A, Fust K, Ultsch B, vandeVelde N, Beck E. J Med Econ. 2023 Dec 5:1-18. doi: 10.1080/13696998.2023.2290388. Online ahead of print. PMID: 38050685

Adverse events following the first, second and third doses of a **COVID-19 vaccine** in hemodialysis patients.
Pai MF, Tung KT, Hsu SP, Peng YS, Lin WY, Yang JY, Wu HY, Chiu YL, Shu KH, Tsai WC. Ren Fail. 2023 Dec;45(1):2172432. doi: 10.1080/0886022X.2023.2172432. PMID: 36715434

Pregnant women's acceptance and views on **COVID-19 vaccine** in Northern Italy.
Lubrano C, Vilca LM, Coco C, Schirripa I, Zuliani PL, Corneo R, Pavone G, Pellegrino A, Vignali M, Savasi V, Di Simone N, Cetin I. J Obstet Gynaecol. 2023 Dec;43(1):2139596. doi: 10.1080/01443615.2022.2139596. Epub 2022 Nov 2. PMID: 36322410

Disparities in child and adolescent **COVID-19** vaccination coverage and parental intent toward vaccinations for their children and adolescents.
Nguyen KH, Levisohn A, McChesney C, Vasudevan L, Bednarczyk RA, Corlin L. Ann Med. 2023 Dec;55(1):2232818. doi: 10.1080/07853890.2023.2232818. PMID: 37449878

COVID-19 and Pediatric Rheumatology: A Comprehensive Study from a Leading Tertiary Center in Saudi Arabia.
Alqanatish J, Almojali A, Alfadhel A, Albelali A, Ahmed A, Alqahtani A, Alrasheed A, Alsewairi W, Alghnam S. J Epidemiol Glob Health. 2023 Dec;13(4):676-684. doi: 10.1007/s44197-023-00142-z. Epub 2023 Aug 18. PMID: 37594620

Evaluating the Role of Pharmacy Technician-Administered **Vaccines**.
Fuschetto KS, Amin KA, Gothard MD, Merico EM. J Pharm Pract. 2023 Dec;36(6):1383-1391. doi: 10.1177/08971900221117893. Epub 2022 Aug 6. PMID: 35938480

Strategic and scientific contributions of human challenge trials for **vaccine** development: facts versus fantasy.
Abo YN, Jamrozik E, McCarthy JS, Roestenberg M, Steer AC, Osowicki J. Lancet Infect Dis. 2023 Dec;23(12):e533-e546. doi: 10.1016/S1473-3099(23)00294-3. Epub 2023 Aug 10. PMID: 37573871

Preparation for the next pandemic: challenges in strengthening surveillance.
Chiu KH, Sridhar S, Yuen KY. Emerg Microbes Infect. 2023 Dec;12(2):2240441. doi: 10.1080/22221751.2023.2240441. PMID: 37474466

Characteristics of sudden hearing loss after different **COVID-19** vaccinations: a systematic review and meta-analysis.
Albakri K, Abdelwahab OA, Gabra MD, Nafady MH, Alabdallat YJ, Soliman A, Cadri S, Hanaqtah B, Albazee E. Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5167-5176. doi: 10.1007/s00405-023-08172-w. Epub 2023 Aug 18. PMID: 37594544

Obstacles to routine immunization in Madagascar: Structural, relational and cultural constraints.
Ramaroson HJV, Mattern C, Huysmans E, Razafiarimanana H, Brazy-Nancy E, Haritiana Ranaivoharimina M, Pourette D. Vaccine X. 2023 Jul 13;15:100348. doi: 10.1016/j.jvacx.2023.100348. eCollection 2023 Dec. PMID: 37533680

A prospective cohort study of preconception **COVID-19** vaccination and miscarriage.
Yland JJ, Wesselink AK, Regan AK, Hatch EE, Rothman KJ, Savitz DA, Wang TR, Huybrechts KF, Hernández-Díaz S, Eisenberg ML, Wise LA. Hum Reprod. 2023 Dec 4;38(12):2362-2372. doi: 10.1093/humrep/dead211. PMID: 37864485

Factors Associated with **COVID-19 Vaccine** Uptake Among High School Students in a Large, Diverse Metropolitan Area.
Qi JZ, Weller SC. J Sch Health. 2023 Dec;93(12):1070-1078. doi: 10.1111/josh.13379. Epub 2023 Aug 1. PMID: 37528550

Assessing the risk of **COVID-19** reinfection and severe outcomes among individuals with substance use disorders: a retrospective study using real-world electronic health records.
Tuan WJ, Kindt HM, Lennon RP. BMJ Open. 2023 Dec 10;13(12):e074993. doi: 10.1136/bmjopen-2023-074993. PMID: 38072495

Safety of **COVID-19** vaccination in pregnant women and their neonatal outcome: a narrative Review.

Askary E, Moradi Alamdarloo S, Keshtvarz Hesam Abadi A. J Matern Fetal Neonatal Med. 2023 Dec;36(1):2183750. doi: 10.1080/14767058.2023.2183750. PMID: 36906793

New-Onset Acute Interstitial Nephritis Post-SARS-CoV-2 Infection and **COVID-19** Vaccination: A Panoramic Review.
Wang Y, Yang L, Xu G. J Epidemiol Glob Health. 2023 Dec;13(4):615-636. doi: 10.1007/s44197-023-00159-4. Epub 2023 Oct 23. PMID: 37870719

Autoimmune inflammatory reactions triggered by the **COVID-19** genetic **vaccines** in terminally differentiated tissues.
Polykretis P, Donzelli A, Lindsay JC, Wiseman D, Kyriakopoulos AM, Mörz M, Bellavite P, Fukushima M, Seneff S, McCullough PA. Autoimmunity. 2023 Dec;56(1):2259123. doi: 10.1080/08916934.2023.2259123. PMID: 37710966

Waning protection after vaccination and prior infection against **COVID-19**-related mortality over 18 months.
Dietler D, Kahn F, Inghammar M, Björk J. Clin Microbiol Infect. 2023 Dec;29(12):1573-1580. doi: 10.1016/j.cmi.2023.08.007. Epub 2023 Aug 12. PMID: 37580016

COVID-19 vaccine eligibility of pregnant and lactating women in Bangladesh: Gap between policy and policy interpretation among policymakers and healthcare workers.
Limaye RJ, Fesshaye B, Singh P, Zavala E, Akter S, Siddiqua TJ, Rahman H, Ali H, Karron R. Vaccine X. 2023 Aug 9;15:100370. doi: 10.1016/j.jvacx.2023.100370. eCollection 2023 Dec. PMID: 37589020

Vaccine development: Current trends and technologies.
Poria R, Kala D, Nagraik R, Dhir Y, Dhir S, Singh B, Kaushik NK, Noorani MS, Kaushal A, Gupta S. Life Sci. 2023 Dec 7:122331. doi: 10.1016/j.lfs.2023.122331. Online ahead of print. PMID: 38070863

The prize of prizes: mRNA research paving the way for **COVID-19 vaccine** success wins the Nobel Prize in Physiology or Medicine 2023.
Buggert M, Höglund P. Scand J Immunol. 2023 Dec;98(6):e13340. doi: 10.1111/sji.13340. PMID: 37953432

Clinical characteristics and outcomes of **COVID-19** infection in Chinese patients with hematologic malignancies in the Omicron era.
Li X, Zhao A, Jiang H, Lu Y, Le J, Xie Y, Hu M, Zeng H, Zhao J, Zhou M, Zhou H, Chen L, Zhu W, Ouyang G, Qiu H, Jiang S, Guo Q, Qian W, Liang Y. Hematology. 2023 Dec;28(1):2288477. doi: 10.1080/16078454.2023.2288477. Epub 2023 Dec 1. PMID: 38038062

Comparison of Venous Thromboembolism Outcomes after **COVID-19** and Influenza Vaccinations.
Gaddh M, Scott D, Wysokinski WE, McBane RD, Casanegra AI, Baumann Kreuziger L, Houghton DE. TH Open. 2023 Dec 4;7(4):e303-e308. doi: 10.1055/a-2183-5269. eCollection 2023 Oct. PMID: 38053618

Direct Support Professionals and **COVID-19** Vaccination: A Comparison of Vaccinated Early Adopters and In-Betweeners.
Pettingell SL, Bershadsky J, Hewitt A, Anderson LL, Zhang A. Intellect Dev Disabil. 2023 Dec 1;61(6):492-505. doi: 10.1352/1934-9556-61.6.492. PMID: 38011745

Coronavac inactivated **vaccine** triggers durable, cross-reactive Fc-mediated phagocytosis activities.
Wang L, Li C, Li W, Zhao L, Zhao T, Chen L, Li M, Fan J, Li J, Wu C, Chen Y. Emerg Microbes Infect. 2023 Dec;12(2):2225640. doi: 10.1080/22221751.2023.2225640. PMID: 37309826

SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in **vaccine** recipients suggesting a role for immune regulation in preventing severe symptoms in **COVID-19**.
Franco A, Song J, Chambers C, Sette A, Grifoni A. Autoimmunity. 2023 Dec;56(1):2259133. doi: 10.1080/08916934.2023.2259133. Epub 2023 Sep 19. PMID: 37724524

State policies increase vaccination by shaping social norms.
Fayaz-Farkhad B, Jung H, Calabrese C, Albarracin D. Sci Rep. 2023 Dec 1;13(1):21227. doi: 10.1038/s41598-023-48604-5. PMID: 38040774

Global equity and timely access: **COVID-19** & beyond 23rd DCVMN Annual General Meeting 2022 report.
Suri RK, Liu C, Marini A. Vaccine X. 2023 Jul 13;15:100353. doi: 10.1016/j.jvacx.2023.100353. eCollection 2023 Dec. PMID: 37533681

Does **COVID-19** Message Fatigue Lead to Misinformation Acceptance? An Extension of the Risk Information Seeking and Processing Model.
Hwang Y, So J, Jeong SH. Health Commun. 2023 Dec;38(12):2742-2749. doi: 10.1080/10410236.2022.2111636. Epub 2022 Aug 15. PMID: 35968837

Did **COVID-19** or **COVID-19 Vaccines** Influence the Patterns of Dengue in 2021? An Exploratory Analysis of Two Observational Studies from North India.
Kaur U, Jethwani P, Mishra S, Dehade A, Yadav AK, Chakrabarti S, Chakrabarti SS. Am J Trop Med Hyg. 2023 Oct 30;109(6):1290-1297. doi: 10.4269/ajtmh.23-0418. Print 2023 Dec 6. PMID: 37903443

Unveiling **vaccine** safety: a narrative review of pharmacovigilance in India's **COVID-19** vaccination.
Hegde M, Raj S, Tikadar D, Nyamagoud SB. Monaldi Arch Chest Dis. 2023 Dec 1. doi: 10.4081/monaldi.2023.2793. Online ahead of print. PMID: 38037892

Persistence of antibody responses to **COVID-19 vaccines** among participants in the **COVID-19** Community Research Partnership.
Berry AA, Tjaden AH, Renteria J, Friedman-Klabanoff D, Hinkelman AN, Gibbs MA, Ahmed A, Runyon MS, Schieffelin J, Santos RP, Oberhelman R, Bott M, Correa A, Edelstein SL, Uschner D, Wierzba TF; COVID-19 Community Research Partnership. Vaccine X. 2023 Aug 11;15:100371. doi: 10.1016/j.jvacx.2023.100371. eCollection 2023 Dec. PMID: 37649617

Oral delivery of a chitosan adjuvanted **COVID-19 vaccine** provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
Wang S, Cui H, Zhang C, Li W, Wang W, He W, Feng N, Zhao Y, Wang T, Tang X, Yan F, Xia X. Antiviral Res. 2023 Dec;220:105765. doi: 10.1016/j.antiviral.2023.105765. Epub 2023 Nov 28. PMID: 38036065

Impact of a hypothetical **COVID-19 vaccine** mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.

Sarafian JT, Eucker SA, Gillman M, DeLaroche AM, Rodriguez RM, Rayburn D, Nadeau NL, Drago LA, Cullen D, Kugler EM, Meskill SD, Bialeck S, Baumann BM. Vaccine. 2023 Dec 7;41(50):7493-7497. doi: 10.1016/j.vaccine.2023.11.022. Epub 2023 Nov 14. PMID: 37973509

Recent advances in nano- and micro-scale carrier systems for controlled delivery of **vaccines**.
Wang EY, Sarmadi M, Ying B, Jaklenec A, Langer R. Biomaterials. 2023 Dec;303:122345. doi: 10.1016/j.biomaterials.2023.122345. Epub 2023 Oct 16. PMID: 37918182

Attitudes Toward **COVID-19** Vaccination Among Behavioral Health Service Clients.
Grove LR, Emerson KR, Merola LS, Andries S, Cohen DA. Psychiatr Serv. 2023 Dec 1;74(12):1281-1284. doi: 10.1176/appi.ps.20230019. Epub 2023 Jul 18. PMID: 37461817

Geographical and practical challenges in the implementation of digital health passports for cross-border **COVID-19** pandemic management: a narrative review and framework for solutions.
Towett G, Snead RS, Grigoryan K, Marczika J. Global Health. 2023 Dec 8;19(1):98. doi: 10.1186/s12992-023-00998-7. PMID: 38066568

Examining the Relationship Between Rurality, Risk Perception, and **COVID-19 Vaccine** Willingness Among Rural Latinos in Arizona and California.
Straus A, Sharma N, Mattie H, Pine KH, Lopez G. J Community Health. 2023 Dec;48(6):945-950. doi: 10.1007/s10900-023-01217-5. Epub 2023 Jun 15. PMID: 37316613

Optic Neuritis After **COVID-19** Vaccination: An Analysis of the **Vaccine** Adverse Event Reporting System.
Jaffry M, Aftab OM, Mostafa FB, Faiz I, Jaffry K, Mandava K, Rosario S, Jedidi K, Khan H, Souayah N. J Neuroophthalmol. 2023 Dec 1;43(4):499-503. doi: 10.1097/WNO.0000000000001900. Epub 2023 Jun 14. PMID: 37314860

Black in the pandemic: Comparing experiences of mistrust, anxiety, and the **COVID-19 vaccine** among Black adults in the U.S.
Goodwill JR, Fike KJ. Soc Sci Med. 2023 Dec;338:116302. doi: 10.1016/j.socscimed.2023.116302. Epub 2023 Oct 11. PMID: 37871396

Assessing parental intention to vaccinate against **COVID-19**, influenza, and RSV in the United States in late 2023.
Haeder SF. Vaccine. 2023 Dec 7;41(50):7503-7514. doi: 10.1016/j.vaccine.2023.11.004. Epub 2023 Nov 17. PMID: 37977941

Real-life effectiveness of **COVID-19 vaccine** during the Omicron variant-dominant pandemic: how many booster doses do we need?
Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, Nanthapisal S, Tanprasertkul C, Sritipsukho N, Mingmalairak C, Apisarnthanarak A, Tantiyavarong P. Emerg Microbes Infect. 2023 Dec;12(1):2174779. doi: 10.1080/22221751.2023.2174779. PMID: 36715323

Lichen planus after **COVID-19** infection and vaccination.
Saleh W, Alharbi H, Yue S, Fernandes RP. Oral Dis. 2023 Dec 8. doi: 10.1111/odi.14834. Online ahead of print. PMID: 38069546

Membranous nephropathy following SARS-CoV-2 mRNA-1273 vaccination.
Vongchaiudomchoke T, Cheunsuchon B, Noppakun K. Med Clin (Barc). 2023 Dec 7;161(11):504-505. doi: 10.1016/j.medcli.2023.06.044. Epub 2023 Aug 10. PMID: 37573168

Residential Segregation and County-Level **COVID-19** Booster Coverage in the Deep South: Surveillance Report and Ecological Study.
Zeng C, Zhang J, Li Z, Sun X, Ning H, Yang X, Weissman S, Olatosi B, Li X. JMIR Public Health Surveill. 2023 Dec 5;9:e44257. doi: 10.2196/44257. PMID: 38051568

Influenza **vaccine** hesitancy and influencing factors among university students in China: a multicenter cross-sectional survey.
Zou H, Huang Y, Chen T, Zhang L. Ann Med. 2023 Dec;55(1):2195206. doi: 10.1080/07853890.2023.2195206. PMID: 37102623

Vaccine Conspiracy Beliefs Scale: Validation and Measurement Invariance in a Youth Sample.
Jovanović V, Lazić M, Gavrilov-Jerković V, Zotović-Kostić M, Obradović V. Eval Health Prof. 2023 Dec;46(4):362-370. doi: 10.1177/01632787231170237. Epub 2023 Apr 12. PMID: 37042299

Severe Pediatric **COVID-19** and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting.
Tulling AJ, Lugthart G, Mooij MG, Brackel CLH, Terheggen-Lagro SWJ, Oostenbrink R, Buysse CMP, Hashimoto S, Armbrust W, Bannier MAGE, Bekhof J, van Gameren-Oosterom HB, Hendriks H, van Houten MA, van der Linden JW, Lebon A, van Onzenoort-Bokken L, Tramper-Stranders GA, van Veen M, von Asmuth EGJ, Buddingh EP; COPP-study group. Pediatr Infect Dis J. 2023 Dec 1;42(12):1077-1085. doi: 10.1097/INF.0000000000004098. Epub 2023 Oct 12. PMID: 37823702

Relationship between **COVID-19 vaccine** hesitancy and willingness to pay for the booster dose of **COVID-19 vaccine** of oncology patients in Taizhou, China.
An JX, Lin XQ, Xie BJ, Tung TH, Zhu JS. Ann Med. 2023 Dec;55(1):672-679. doi: 10.1080/07853890.2023.2165705. PMID: 36840655

Binocular Horizontal Diplopia Following mRNA-1273 **Vaccine**.
Mahgerefteh JS, Oppenheimer AG, Kay MD. J Neuroophthalmol. 2023 Dec 1;43(4):e258-e259. doi: 10.1097/WNO.0000000000001545. Epub 2022 Apr 27. PMID: 35482435

SARS-CoV-2 variants, its recombinants and epigenomic exploitation of host defenses.
Saksena NK, Reddy SB, Miranda-Saksena M, Cardoso THS, Silva EMA, Ferreira JC, Rabeh WM. Biochim Biophys Acta Mol Basis Dis. 2023 Dec;1869(8):166836. doi: 10.1016/j.bbadis.2023.166836. Epub 2023 Aug 5. PMID: 37549720

Batch-dependent safety of the BNT162b2 mRNA **COVID-19 vaccine**.
Del Saz BS. Eur J Clin Invest. 2023 Dec;53(12):e14050. doi: 10.1111/eci.14050. Epub 2023 Jul 3. PMID: 37395096

Effectiveness of **Vaccines** and Antiviral Drugs in Preventing Severe and Fatal **COVID-19**, Hong Kong.
Cheung YYH, Lau EHY, Yin G, Lin Y, Cowling BJ, Lam KF. Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print. PMID: 38040664

Omicron BA.1 breakthrough infections in inactivated **COVID-19 vaccine** recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L, Zhang Q, Zhong J, Chen L, Jiang W, Huang T, Li Y, Zhang Y, Xu L, Wang X, Xiao Y, Wang Y, Dong X, Dong T, Peng Y, Zhang B, Xie Y, Gao H, Shen Z, Ren L, Cheng T, Wang J. Emerg Microbes Infect. 2023 Dec;12(1):2202263. doi: 10.1080/22221751.2023.2202263. PMID: 37037791

Effectiveness of the BNT162b2 **vaccine** in preventing morbidity and mortality associated with **COVID-19** in children aged 5 to 11 years: A systematic review and meta-analysis.
Ebrahim S, Blose N, Gloeck N, Hohlfeld A, Balakrishna Y, Muloiwa R, Gray A, Parrish A, Cohen K, Lancaster R, Kredo T. PLOS Glob Public Health. 2023 Dec 4;3(12):e0002676. doi: 10.1371/journal.pgph.0002676. eCollection 2023. PMID: 38048340

COVID-19 vaccination in urban American Indian and Alaska Native children: Parental characteristics, beliefs and attitudes associated with **vaccine** acceptance.
Collier AF, Schaefer KR, Uddin A, Noonan C, Dillard DA, Son-Stone L, Manson SM, Buchwald D, MacLehose R; CONCERTS Collaborative. Vaccine X. 2023 Nov 14;15:100406. doi: 10.1016/j.jvacx.2023.100406. eCollection 2023 Dec. PMID: 38058791

A Systematic Review Of **COVID-19** Misinformation Interventions: Lessons Learned.
Smith R, Chen K, Winner D, Friedhoff S, Wardle C. Health Aff (Millwood). 2023 Dec;42(12):1738-1746. doi: 10.1377/hlthaff.2023.00717. Epub 2023 Nov 15. PMID: 37967291

The effect of the third dose of the BNT162b2 **vaccine** on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without **COVID-19** infection.
Wolszczak-Biedrzycka B, Bieńkowska A, Cieślikiewicz B, Smolińska-Fijołek E, Biedrzycki G, Dorf J. Ann Med. 2023 Dec;55(1):722-732. doi: 10.1080/07853890.2023.2182907. PMID: 36820816

Calculation, knowledge, and identity: Dimensions of trust when making **COVID-19** vaccination choices in China.
Jiao L, Wachinger J, Dasch S, Bärnighausen T, McMahon SA, Chen S. SSM Qual Res Health. 2023 Dec;4:100288. doi: 10.1016/j.ssmqr.2023.100288. Epub 2023 Jun 1. PMID: 37334196

Review of pediatric emergency care and the **COVID-19** pandemic.
Foster AA, Walls TA, Alade KH, Brown K, Gausche-Hill M, Lin SD, Rose EA, Ruttan T, Shahid S, Sorrentino A, Stoner MJ, Waseem M, Saidinejad M; ACEP Pediatric Emergency Medicine Committee. J Am Coll Emerg Physicians Open. 2023 Dec 1;4(6):e13073. doi: 10.1002/emp2.13073. eCollection 2023 Dec. PMID: 38045015

Batch-dependent safety of the BNT162b2 mRNA **COVID-19 vaccine**.
Schmeling M, Manniche V, Hansen PR. Eur J Clin Invest. 2023 Dec;53(12):e14102. doi: 10.1111/eci.14102. Epub 2023 Oct 13. PMID: 37833825

Immunogenicity and Safety of a SARS-CoV-2 Inactivated **Vaccine** KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials.
Liu J, Huang B, Li G, Huang T, Wang D, Zhang L, Deng Y, Chang X, Liu Y, Li W, Zhang S, Huang W, Tan W, Gao L. Pediatr Infect Dis J. 2023 Dec 1;42(12):1136-1142. doi: 10.1097/INF.0000000000004085. Epub 2023 Sep 4. PMID: 37967148

Prevalence and determinants of post-acute sequelae of **COVID-19** in Liberia.
Gwaikolo C, Sackie-Wapoe Y, Badio M, Glidden DV, Lindan C, Martin J. Int J Epidemiol. 2023 Dec 2:dyad167. doi: 10.1093/ije/dyad167. Online ahead of print. PMID: 38052015

Impact of **COVID-19** and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to **vaccine**, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
Ferri C, Raimondo V, Giuggioli D, Gragnani L, Lorini S, Dagna L, Bosello SL, Foti R, Riccieri V, Guiducci S, Cuomo G, Tavoni A, De Angelis R, Cacciapaglia F, Zanatta E, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Pellegrini R, Varcasia G, De Santis M, Selmi C, Abignano G, Caminiti M, L'Andolina M, Olivo D, Lubrano E, Spinella A, Lumetti F, De Luca G, Ruscitti P, Urraro T, Visentini M, Bellando-Randone S, Visalli E, Testa D, Sciascia G, Masini F, Pellegrino G, Saccon F, Balestri E, Elia G, Ferrari SM, Tonutti A, Dall'Ara F, Pagano Mariano G, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Dal Bosco Y, Foti R, Di Cola I, Scorpiniti D, Fusaro E, Ferrari T, Gigliotti P, Campochiaro C, Francioso F, Iandoli C, Caira V, Zignego AL, D'Angelo S, Franceschini F, Matucci-Cerinic M, Giacomelli R, Doria A, Santini SA, Fallahi P, Iannone F, Antonelli A; COVID-19 & ASD Italian Study Group. J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec. PMID: 37854035

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based **COVID-19** DNA **vaccine** candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants.
Fan F, Zhang X, Zhang Z, Ding Y, Wang L, Xu X, Pan Y, Gong FY, Jiang L, Kang L, Ha Z, Lu H, Hou J, Kou Z, Zhao G, Wang B, Gao XM. Emerg Microbes Infect. 2023 Dec;12(1):2202269. doi: 10.1080/22221751.2023.2202269. PMID: 37038652

Serological assays for differentiating natural **COVID-19** infection from **vaccine** induced immunity.
Cheng SMS, Lau JJ, Tsang LCH, Leung K, Lee CK, Hachim A, Kavian N, Chaothai S, Wong RWK, Yu JKM, Chai ZYH, Mori M, Wu C, Yiu K, Hui DSC, Amarasinghe GK, Poon LLM, Wu JT, Valkenburg SA, Peiris M. J Clin Virol. 2023 Dec 1;170:105621. doi: 10.1016/j.jcv.2023.105621. Online ahead of print. PMID: 38056114

The relative effectiveness of three and four doses of **COVID-19 vaccine** in Victoria, Australia: A data linkage study.
Canevari JT, Cheng AC, Wu L, Rowe SL, Wollersheim DE, West D, Majumdar SS, Sullivan SG. Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.11.047. Online ahead of print. PMID: 38057205

Trust and distrust in low-income Michigan residents during the early **COVID-19** pandemic: A qualitative study.
Waidyaratne G, Steinbrook E, Roy S, Opoku A, Jaffe K, Goold SD. Health Expect. 2023 Dec;26(6):2245-2251. doi: 10.1111/hex.13826. Epub 2023 Jul 14. PMID: 37452517

The future of vaccination in Latin America: learning from the **COVID-19** pandemic.
Díaz FE, Arruvito L, Geffner J. Curr Opin Immunol. 2023 Dec;85:102390. doi: 10.1016/j.coi.2023.102390. Epub 2023 Oct 6. PMID: 37806096

Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus **vaccine**, the diphtheria-tetanus-acellular pertussis **vaccine**, and measles-mumps-rubella **vaccine** to healthy infants aged 18 months in China.
Xu Y, Chen H, Wang B, Zhu X, Luo L, Wang S, Xiao Y, Wang H, Ma R, Liu S, Yan L, Li X, Chen D, Su Y, Chai Y, Fu J, Mao X, Cao J, Sun P, Tang F, Sun X, Wang Z, Yang X. Int J Infect Dis. 2023 Dec;137:9-15. doi: 10.1016/j.ijid.2023.10.006. Epub 2023 Oct 11. PMID: 37832931

Age and partisan self-identification predict uptake of additional **COVID-19** booster doses: Evidence from a longitudinal study.
Wiltse D, Viskupič F. Prev Med Rep. 2023 Sep 17;36:102407. doi: 10.1016/j.pmedr.2023.102407. eCollection 2023 Dec. PMID: 37766728

Motivators and Barriers to **COVID-19** Research Participation at the Onset of the **COVID-19** Pandemic in Black Communities in the USA: an Exploratory Study.
Barre I, Cunningham-Erves J, Moss J, Parham I, Alexander LR, Davis J. J Racial Ethn Health Disparities. 2023 Dec;10(6):2890-2899. doi: 10.1007/s40615-022-01466-5. Epub 2022 Dec 13. PMID: 36512311

COVID-19 vaccination telephone outreach: an analysis of the medical student experience.
Wu JF, Abenoza N, Bosco JM, Minshew LM, Beckius A, Kastner M, Hilgeman B, Muntz MD. Med Educ Online. 2023 Dec;28(1):2207249. doi: 10.1080/10872981.2023.2207249. PMID: 37104856

Effectiveness of **COVID-19 vaccines** in Ecuador: A test-negative design.
Pérez-Tasigchana F, Valcárcel-Pérez I, Arias-Quispe M, Astudillo L, Bruno A, Herrera G M, Armas R, de Mora D, Pinos J, Olmedo A, Salas R, Jimbo-Sotomayor R, Chiluisa C, Acosta P, Sánchez X, Whittembury A. Vaccine X. 2023 Nov 8;15:100404. doi: 10.1016/j.jvacx.2023.100404. eCollection 2023 Dec. PMID: 38033879

Model-informed health and socio-economic benefits of enhancing global equity and access to **Covid-19 vaccines**.
Italia M, Della Rossa F, Dercole F. Sci Rep. 2023 Dec 7;13(1):21707. doi: 10.1038/s41598-023-48465-y. PMID: 38066204

Impact of **Covid-19** Vaccination on Spontaneous Pharmacovigilance Reporting in France.
de Germay S, Singier A, Salvo F, Pariente A; French Pharmacovigilance Network. Drug Saf. 2023 Dec;46(12):1381-1389. doi: 10.1007/s40264-023-01359-4. Epub 2023 Nov 5. PMID: 37926785

Delayed adverse events following **COVID-19** vaccination in patients with systemic sclerosis and other autoimmune diseases: a substudy of the COVAD-2 cohort.
Panchawagh S, Bohdana D, Kuwana M, Yoshida A, Yomono K, Pauling JD, Makol A, Kadam E, Day J, Chatterjee T, Katchamart W, Goo PA, Nikiphorou E, Sen P, Dey D, Cavagna L, Gutiérrez CET, Agarwal V, Milchert M, Ziade N, Distler O, Group CS, Chinoy H, Aggarwal R, Gupta L, Agarwal V. Rheumatol Int. 2023 Dec;43(12):2211-2220. doi: 10.1007/s00296-023-05441-z. Epub 2023 Sep 15. PMID: 37712977

Family Communication Patterns and Parents' Intentions to Vaccinate Their Child Against **COVID-19**.
Egbert N, Zhu Y, Choi M, Beam MA, Smith TC. Health Commun. 2023 Dec;38(12):2774-2781. doi: 10.1080/10410236.2022.2114768. Epub 2022 Aug 26. PMID: 36017868

COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.
Mayer D, Barun B, Lazibat K, Lasić S, Adamec I, Gabelić T, Krbot Skorić M, Habek M. Acta Neurol Belg. 2023 Dec;123(6):2269-2275. doi: 10.1007/s13760-023-02296-w. Epub 2023 Jun 1. PMID: 37261658

Factors associated with receiving an initial **COVID-19 vaccine** among Alaskan residents: results from an online cross-sectional survey.
Garcia G, Meyer J, Edwards A, Cameron D. Int J Circumpolar Health. 2023 Dec;82(1):2252604. doi: 10.1080/22423982.2023.2252604. PMID: 37652714

Safety profiles of homologous and heterologous regimens containing three major types of **COVID-19 vaccine** among people living with HIV.
Khawcharoenporn T, Hanvivattanakul S. Int J STD AIDS. 2023 Dec 4:9564624231220090. doi: 10.1177/09564624231220090. Online ahead of print. PMID: 38048705

The role of occupation in SARS-CoV-2 infection within a Brazilian municipality: A test-negative case-control study.
Menezes FDS, Garcia LP, Maeno M, Prearo LC, Toporcov TN, Algranti E. Am J Ind Med. 2023 Dec;66(12):1090-1100. doi: 10.1002/ajim.23542. Epub 2023 Oct 4. PMID: 37792286

Low uptake of **COVID-19 vaccines** in Wad Medani City, Gezira State, Sudan: Hesitancy and poor accessibility.
Elmustafa M, Wedaa A, Babiker H, Elmajzoup A, Ali H, Ahmed R. Vaccine X. 2023 Aug 13;15:100369. doi: 10.1016/j.jvacx.2023.100369. eCollection 2023 Dec. PMID: 37649618

Exploring missed opportunities for influenza vaccination and influenza **vaccine** co-administration patterns among Italian older adults: a retrospective cohort study.
Domnich A, Orsi A, Ogliastro M, Trombetta CS, Scarpaleggia M, Ceccaroli C, Amadio C, Raffo A, Berisso L, Yakubovich A, Zappa G, Amicizia D, Panatto D, Icardi G. Eur J Public Health. 2023 Dec 9;33(6):1183-1187. doi: 10.1093/eurpub/ckad155. PMID: 37632235

BioHabana 2022: Preventive and Immunotherapeutic Strategies Against **COVID-19** and Cancer in Cuba.
Bello-Rivero I, Crombet-Ramos T, Mesa-Pardillo C, Morera-Díaz Y, Mazorra-Herrera Z, Garcia-Rivera D, Nodarse-Cuní H, Hernández-Bernal F, Muzio-Gonzalez V, Aguilera-Barreto A, Vazquez-Blomquist D, Domínguez-Horta MDC, Guillen-Nieto G. J Interferon Cytokine Res. 2023 Dec 4. doi: 10.1089/jir.2023.0141. Online ahead of print. PMID: 38048299

Multiple **COVID** reinfections in a vaccinated psoriatic patient receiving adalimumab.
Zargari O, Azimi SZ. J Dermatolog Treat. 2023 Dec;34(1):2149237. doi: 10.1080/09546634.2022.2149237. Epub 2022 Nov 22. PMID: 36384391

COVID-19 vaccination coverage for half a million non-EU migrants and refugees in England.
Burns R, Wyke S, Eyre MT, Boukari Y, Sørensen TB, Tsang C, Campbell CNJ, Beale S, Zenner D, Hargreaves S, Campos-Matos I, Harron K, Aldridge RW. Nat Hum Behav. 2023 Dec 4. doi: 10.1038/s41562-023-01768-6. Online ahead of print. PMID: 38049560

A multi-epitope/CXCL11 prime/pull coronavirus mucosal **vaccine** boosts the frequency and the function of lung-resident memory CD4+ and CD8+ T cells and enhanced protection against **COVID-19**-like symptoms and death caused by SARS-CoV-2 infection.
Zayou L, Prakash S, Dhanushkodi NR, Quadiri A, Ibraim IC, Singer M, Salem A, Shaik AM, Suzer B, Chilukuri A, Tran J, Nguyen PC, Sun M, Hormi-Carver KK, Belmouden A, Vahed H, Gil D, Ulmer JB, BenMohamed L. J Virol. 2023 Dec 1:e0109623. doi: 10.1128/jvi.01096-23. Online ahead of print. PMID: 38038432

Who gets **COVID-19** booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
Choi Y, Park S, Lee J, Kim Y, Kim BJ, Lin L, Fox AM. Vaccine. 2023 Dec 7;41(50):7560-7572. doi: 10.1016/j.vaccine.2023.11.001. Epub 2023 Nov 15. PMID: 37977939

Concomitant administration of seasonal influenza and **COVID-19** mRNA **vaccines**.
Aydillo T, Balsera M, Rojo-Fernandez A, Escalera A, Salamanca-Rivera C, Pachón J, Mar Muñoz-García MD, Sánchez-Cordero MJ, Sánchez-Céspedes J, García-Sastre A, Cordero E. Emerg Microbes Infect. 2023 Dec 6:2292068. doi: 10.1080/22221751.2023.2292068. Online ahead of print. PMID: 38054302

Illness anxiety predicts higher mental strain and **vaccine** willingness-A nine-wave longitudinal study during the first 1.5 years of the **COVID-19** pandemic in Germany.
Bendau A, Petzold MB, Plag J, Asselmann E, Ströhle A. Stress Health. 2023 Dec;39(5):1137-1147. doi: 10.1002/smi.3255. Epub 2023 May 9. PMID: 37158010

Acquired immunity against SARS-CoV-2 infection and vaccination.
Renia L, Ng LF. EMBO Mol Med. 2023 Dec 7;15(12):e16345. doi: 10.15252/emmm.202216345. Epub 2023 Nov 15. PMID: 37966373

Post-**COVID-19** syndrome: Descriptive analysis based on a survivors' cohort in Colombia.
Romero M, Caicedo M, Díaz A, Ortega D, Llanos C, Concha A, Vallejo A, Valdés F, González C. Glob Epidemiol. 2023 Oct 27;6:100126. doi: 10.1016/j.gloepi.2023.100126. eCollection 2023 Dec. PMID: 38023981

Artificial intelligence for diagnosis of mild-moderate **COVID-19** using haematological markers.
Chadaga K, Prabhu S, Bhat V, Sampathila N, Umakanth S, Chadaga R. Ann Med. 2023 Dec;55(1):2233541. doi: 10.1080/07853890.2023.2233541. PMID: 37436038

Mouse study of combined DNA/protein **COVID-19 vaccine** to boost high levels of antibody and cell mediated immune responses.
He Q, Liu S, Liang Z, Lu S, Cun W, Mao Q. Emerg Microbes Infect. 2023 Dec;12(1):2152388. doi: 10.1080/22221751.2022.2152388. PMID: 36426608

Autoimmune hepatitis collapsed after the **COVID-19** vaccination.
Xie X, Zhong L, Gan X, Liu Y, Zhu Y, Chen B, Yu H. Clin Res Hepatol Gastroenterol. 2023 Dec;47(10):102226. doi: 10.1016/j.clinre.2023.102226. Epub 2023 Oct 14. PMID: 37844776

Understanding stakeholders' perspectives to increase **COVID-19 vaccine** and booster: comment on the article by Ezeh et al.

Kleebayoon A, Wiwanitkit V. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2537-2538. doi: 10.1002/acr.25194. Epub 2023 Aug 29. PMID: 37458092

Importance of adjuvant selection in tuberculosis **vaccine** development: Exploring basic mechanisms and clinical implications.
Gyu Choi H, Woong Kwon K, Jae Shin S. Vaccine X. 2023 Oct 29;15:100400. doi: 10.1016/j.jvacx.2023.100400. eCollection 2023 Dec. PMID: 37965276

Combined **COVID-19**, Flu **Vaccine** Candidate Headed to Phase 3 Trials.
Harris E. JAMA. 2023 Dec 5;330(21):2044. doi: 10.1001/jama.2023.22353. PMID: 37966868

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai.
Wu Q, Wang H, Cai J, Ai J, Li Y, Zhang H, Wang S, Sun F, Wu Y, Zhou J, Wang Y, Yu H, Zhang W. Emerg Microbes Infect. 2023 Dec;12(1):e2169197. doi: 10.1080/22221751.2023.2169197. PMID: 36644859

Waning effectiveness against **COVID-19**-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study.
Yan VKC, Wan EYF, Ye X, Mok AHY, Lai FTT, Chui CSL, Li X, Wong CKH, Li PH, Ma T, Qin S, Lau CS, Wong ICK, Chan EWY. Emerg Microbes Infect. 2023 Dec;12(1):2209201. doi: 10.1080/22221751.2023.2209201. PMID: 37132361

Risk of Bell's palsy following SARS-CoV-2 infection: a nationwide cohort study.
Kim HJ, Jeong S, Song J, Park SJ, Oh YH, Jung J, Choi NK, Park SM. Clin Microbiol Infect. 2023 Dec;29(12):1581-1586. doi: 10.1016/j.cmi.2023.08.014. Epub 2023 Aug 21. PMID: 37611865

Association between Gross National Income per capita and **COVID-19** vaccination coverage: a global ecological study.
Nyachoti DO, Fwelo P, Springer AE, Kelder SH. BMC Public Health. 2023 Dec 4;23(1):2415. doi: 10.1186/s12889-023-17241-y. PMID: 38049821

Modulation of immune cells with mRNA nanoformulations for cancer immunotherapy.
Han J, Park JH. Curr Opin Biotechnol. 2023 Dec;84:103014. doi: 10.1016/j.copbio.2023.103014. Epub 2023 Oct 20. PMID: 37866058

Vaccination effects on reducing **COVID-19** complications in pregnancy: A large-scale report from Iran.
Changizi N, Eshrati B, Salehi M, Beheshtian M, Hadipour Jahromy L, Emami Afshar N, Hejazi S, Hantoushzadeh S, Eslamian L, Savaie M, Raeisi A, Pooransari P. Int J Gynaecol Obstet. 2023 Dec;163(3):1012-1017. doi: 10.1002/ijgo.15077. Epub 2023 Sep 1. PMID: 37655467

An omicron-based **vaccine** booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
Li T, Luo D, Ning N, Wang X, Zhang L, Yang X, Li D, Sun Y, Yu W, Wei W, Wang H. Emerg Microbes Infect. 2023 Dec;12(1):2207670. doi: 10.1080/22221751.2023.2207670. PMID: 37272331

Plant-Derived Natural Compounds as an Emerging Antiviral in Combating **COVID-19**.
Singh M, Lo SH, Dubey R, Kumar S, Chaubey KK, Kumar S. Indian J Microbiol. 2023 Dec;63(4):429-446. doi: 10.1007/s12088-023-01121-5. Epub 2023 Oct 31. PMID: 38031604

Risk and characteristics of Bell's palsy in adults as an adverse event following **COVID-19** vaccination: a retrospective study.
Kim S, Kang M, Park JS, Seok HY. Acta Neurol Belg. 2023 Dec;123(6):2185-2193. doi: 10.1007/s13760-023-02204-2. Epub 2023 Feb 12. PMID: 36781626

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review.
Gisondi P, Simon D, Alarcon I, Pournara E, Puig L. J Dermatolog Treat. 2023 Dec;34(1):2167487. doi: 10.1080/09546634.2023.2167487. PMID: 36625506

The effectiveness of single and two-dose Pfizer-BioNTech **vaccine** against SARS-COV-2: A real-world evidence from Saudi Arabia.
Albogami Y, Alalwan A, Batais MA, Alabdulkareem K, Alalwan AA. J Infect Public Health. 2023 Dec;16(12):1898-1903. doi: 10.1016/j.jiph.2023.09.014. Epub 2023 Sep 28. PMID: 37871358

Optimizing Signal Management in a **Vaccine** Adverse Event Reporting System: A Proof-of-Concept with **COVID-19 Vaccines** Using Signs, Symptoms, and Natural Language Processing.
Dong G, Bate A, Haguinet F, Westman G, Dürlich L, Hviid A, Sessa M. Drug Saf. 2023 Dec 7. doi: 10.1007/s40264-023-01381-6. Online ahead of print. PMID: 38062261

Post **COVID-19** Symptoms Among Infected Vaccinated Individuals: A Cross-Sectional Study in Saudi Arabia.
Adly HM, Saleh SAK, Garout MA, Abdulkhaliq AA, Khafagy AA, Saati AA, AlJahdali IA, Alandiyjany MN, Al-Tawfiq JA. J Epidemiol Glob Health. 2023 Dec;13(4):740-750. doi: 10.1007/s44197-023-00146-9. Epub 2023 Sep 4. PMID: 37665505

Safety and Benefits of **COVID-19** Vaccination in Pregnancy-Implications for the Maternal Vaccination Platform.
Healy CM, Riley LE. JAMA Pediatr. 2023 Dec 1;177(12):1261-1263. doi: 10.1001/jamapediatrics.2023.4496. PMID: 37870867

Did text-based news-media coverage about the **COVID-19** pandemic increase **vaccine** uptake? A population-based study in Alaska.
Grage L, Cuellar MJ. Int J Circumpolar Health. 2023 Dec;82(1):2213913. doi: 10.1080/22423982.2023.2213913. PMID: 37216574

The Economic Burden of Bronchiectasis: A Systematic Review.
Roberts JM, Goyal V, Kularatna S, Chang AB, Kapur N, Chalmers JD, Goeminne PC, Hernandez F, Marchant JM, McPhail SM. Chest. 2023 Dec;164(6):1396-1421. doi: 10.1016/j.chest.2023.06.040. Epub 2023 Jul 8. PMID: 37423293

Effectiveness of inactivated **COVID-19 vaccines** against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China.

Xu H, Li H, You H, Zhang P, Li N, Jiang N, Cao Y, Qin L, Qin G, Qu H, Wang H, Zou B, He X, Li D, Zhao H, Huang G, Li Y, Zhang H, Zhu L, Qiao H, Li H, Liu S, Gu L, Yin G, Hu Y, Xu S, Guo W, Wang N, Liu C, Gao P, Cao J, Zheng Y, Zhang K, Wang Y, Chen H, Zhang J, Mu D, Niu J. Emerg Microbes Infect. 2023 Dec;12(1):2149935. doi: 10.1080/22221751.2022.2149935. PMID: 36398721

Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 **Vaccine** in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, Sadeghi F, Rezaei Mokarram A, Haji Moradi M, Razaz SH, Taghdiri M, Ansarifar A, Lotfi M, Khorasani A, Nofeli M, Masoumi S, Boluki Z, Erfanpoor S, Bagheri Amiri F, Esmailzadehha N, Filsoof S, Mohseni V, Ghahremanzadeh N, Safari S, Shahsavan M, Bayazidi S, Raghami Derakhshani M, Rabiee MH, Golmoradi-Zadeh R, Khodadoost B, Solaymani-Dodaran M, Banihashemi SR. J Pharm Sci. 2023 Dec;112(12):3012-3021. doi: 10.1016/j.xphs.2023.09.027. Epub 2023 Oct 11. PMID: 37832918

The use of electroporation to deliver DNA-based **vaccines**.
Belyakov IM, Kisakov DN, Kisakova LA, Yakovlev VA, Tigeeva EV, Karpenko LI. Expert Rev Vaccines. 2023 Dec 8. doi: 10.1080/14760584.2023.2292772. Online ahead of print. PMID: 38063059

Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary **COVID-19** vaccination campaign.
Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, Buret L, Coenen S, De Sutter A, Scholtes B, Verbakel JY, Cools P, Heytens S. Eur J Gen Pract. 2023 Dec;29(2):2149732. doi: 10.1080/13814788.2022.2149732. Epub 2022 Nov 28. PMID: 36440533

Effectiveness of Monovalent mRNA **Vaccines** Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years.
Wee LE, Tang N, Pang D, Chiew C, Yung CF, Chong CY, Lee V, Ong B, Lye DC, Tan KB. JAMA Pediatr. 2023 Dec 1;177(12):1324-1331. doi: 10.1001/jamapediatrics.2023.4505. PMID: 37843856

Genome-wide association studies of response and side effects to the BNT162b2 **vaccine** in Italian healthcare workers: Increased antibody levels and side effects in carriers of the HLA-A*03:01 allele.
Magri C, Marchina E, Sansone E, D'Adamo AP, Cappellani S, Bonfanti C, Terlenghi L, Biasiotto G, Zanella I, Sala E, Caruso A, Lombardo M, Gasparini P, De Palma G, Gennarelli M. HLA. 2023 Dec;102(6):707-719. doi: 10.1111/tan.15157. Epub 2023 Jul 19. PMID: 37469131

Patterns of protection, infection, and detection: Country-level effectiveness of **COVID-19** vaccination in reducing mortality worldwide.
Rughiniș C, Dima M, Vulpe SN, Rughiniș R, Vasile S. Public Health Pract (Oxf). 2023 Jul 29;6:100416. doi: 10.1016/j.puhip.2023.100416. eCollection 2023 Dec. PMID: 37547810

Quantification of Torque Teno Virus Load to Monitor Short-term Changes in Immunosuppressive Therapy in Kidney Transplant Recipients.
Benning L, Reineke M, Bundschuh C, Klein JAF, Kühn T, Zeier M, Bartenschlager R, Schnitzler P, Morath C, Speer C. Transplantation. 2023 Dec 1;107(12):e363-e369. doi: 10.1097/TP.0000000000004816. Epub 2023 Oct 6. PMID: 37798825

Kaleidoscopic integration: Advancing the integration of incommensurable knowledge in healthcare guidelines.
Lösch L, Willems W, Bongers M, Timen A, Zuiderent-Jerak T. Soc Sci Med. 2023 Dec;339:116360. doi: 10.1016/j.socscimed.2023.116360. Epub 2023 Nov 3. PMID: 37979492

Balancing Intelectual Property Protection and Legal Risk Assessment in Registration of **Covid-19 Vaccines** in Malaysia.
Ahamat H, Sa'ban H, Manap NA. Health Care Anal. 2023 Dec;31(3-4):196-207. doi: 10.1007/s10728-023-00465-9. Epub 2023 Jul 21. PMID: 37477838

A review of health worker vaccination programs in low, middle and upper middle-income countries.
Gaviola GC, McCarville M, Shendale S, Goodman T, Lomazzi M, Desai S. Public Health Pract (Oxf). 2023 Jul 26;6:100415. doi: 10.1016/j.puhip.2023.100415. eCollection 2023 Dec. PMID: 37547811

Lipid nanoparticle-based **COVID-19 vaccines**: Ensuring pharmaceutical stability, safety, and efficacy.
Driscoll DF. Am J Health Syst Pharm. 2023 Dec 5;80(24):1847-1849. doi: 10.1093/ajhp/zxad221. PMID: 37707445

Comparison of **COVID-19** Vaccination and Infection Rates in Adult Patients With Autoimmune Inflammatory Disease on b/tsDMARD Therapy.
Avlasevich V, McCarthy K. Ann Pharmacother. 2023 Dec;57(12):1455-1458. doi: 10.1177/10600280231164109. Epub 2023 Apr 5. PMID: 37021350

COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic.
Khawaja F, Angelidakis G, Feldman A, Ravi V, Woodman E, Bhatti M, Ariza-Heredia E, Elhajj P, Spallone A, Jiang Y, Chemaly RF. Cancer Med. 2023 Dec 8. doi: 10.1002/cam4.6781. Online ahead of print. PMID: 38063366

Relationship Between Fear of **COVID-19**, Conspiracy Beliefs About **Vaccines** and Intention to Vaccinate Against **COVID-19**: A Cross-National Indirect Effect Model in 13 Latin American Countries.
Caycho-Rodríguez T, Tomás JM, Yupanqui-Lorenzo DE, Valencia PD, Carbajal-León C, Vilca LW, Ventura-León J, Paredes-Angeles R, Arias Gallegos WL, Reyes-Bossio M, Delgado-Campusano M, Gallegos M, Rojas-Jara C, Polanco-Carrasco R, Cervigni M, Martino P, Lobos-Rivera ME, Moreta-Herrera R, Palacios Segura DA, Samaniego-Pinho A, Buschiazzo Figares A, Puerta-Cortés DX, Camargo A, Torales J, Monge Blanco JA, González P, Smith-Castro V, Petzold-Rodriguez O, Corrales-Reyes IE, Calderón R, Matute Rivera WY, Ferrufino-Borja D, Ceballos-Vásquez P, Muñoz-Del-Carpio-Toia A, Palacios J, Burgos-Videla C, Florez León AME, Vergara I, Vega D, Shulmeyer MK, Barria-Asenjo NA, Urrutia Rios HT, Lira Lira AE. Eval Health Prof. 2023 Dec;46(4):371-383. doi: 10.1177/01632787231186621. Epub 2023 Jul 13. PMID: 37439361

Prosocial Interventions and Health Outcomes: A Systematic Review and Meta-Analysis.
Byrne M, Tan RKJ, Wu D, Marley G, Hlatshwako TG, Tao Y, Bissram J, Nachman S, Tang W, Ramaswamy R, Tucker JD. JAMA Netw Open. 2023 Dec 1;6(12):e2346789. doi: 10.1001/jamanetworkopen.2023.46789. PMID: 38064214

Exploring First Responder Beliefs and Decisions to Vaccinate Against SARS-COV-2.
Darnell WH, Daugherty CD, Hart ZP, Lambert South A. Health Commun. 2023 Dec;38(14):3316-3325. doi: 10.1080/10410236.2022.2149065. Epub 2023 Jan 12. PMID: 36636017

Disease severity of **COVID-19** in different phases of the pandemic: Do healthcare workers have better outcomes?
Yang X, Shi F, Zhang J, Gao H, Chen S, Olatosi B, Weissman S, Li X. Vaccine X. 2023 Aug 26;15:100377. doi: 10.1016/j.jvacx.2023.100377. eCollection 2023 Dec. PMID: 37681205

Estimated health and economic impact of using high-dose influenza **vaccine** on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia.
Raina MacIntyre C, Kevin Yin J, Felter C, Menzies RI, Thommes E, Largeron N, Moa AM, Trent M, Costantino V, Choi S, Alvarez FP. Vaccine X. 2023 Aug 4;15:100365. doi: 10.1016/j.jvacx.2023.100365. eCollection 2023 Dec. PMID: 37609557

Perceptions of **COVID-19** risk during the pandemic: perspectives from people seeking medication for opioid use disorder.
Clingan SE, Cousins SJ, Lin C, Nguyen TE, Hser YI, Mooney LJ. Ann Med. 2023 Dec;55(1):480-489. doi: 10.1080/07853890.2023.2169342. PMID: 36692029

Administration of an excessive dosage of **covid-19** pfizer **vaccine** in an infant: Case report of clinical and immune responses.
E Silva JM, Guimarães JB, Abu Jamra SR, Mirante BS, Capato CF, de Melo Jorge DM, da Fonseca BAL. Vaccine X. 2023 Oct 4;15:100395. doi: 10.1016/j.jvacx.2023.100395. eCollection 2023 Dec. PMID: 37841655

Church Leaders Share and Implement Solution-Focused Health Strategies During the **COVID-19** Pandemic in Rural Alabama.
Allen RS, McIntyre AC, Oliver JS, Payne-Foster P, Cox BS, Hay-McCutcheon MJ, Wilson L, Spencer C, Lee HY. J Racial Ethn Health Disparities. 2023 Dec 4. doi: 10.1007/s40615-023-01873-2. Online ahead of print. PMID: 38048041

Development and external validation of a prediction model for the transition from mild to moderate or severe form of **COVID-19**.
Zysman M, Asselineau J, Saut O, Frison E, Oranger M, Maurac A, Charriot J, Achkir R, Regueme S, Klein E, Bommart S, Bourdin A, Dournes G, Casteigt J, Blum A, Ferretti G, Degano B, Thiébaut R, Chabot F, Berger P, Laurent F, Benlala I. Eur Radiol. 2023 Dec;33(12):9262-9274. doi: 10.1007/s00330-023-09759-x. Epub 2023 Jul 5. PMID: 37405504

Increased Incidence of Pediatric Uveitis Associated with the **COVID-19** Pandemic Occurring Before **COVID-19 Vaccine** Implementation: A Time-Series Analysis.
Lafay C, Assad Z, Ouldali N, Quoc EB, Clement A, Durand C, Fares S, Faye A, Eveillard LA, Kaguelidou F, Titah C, Valtuille Z, Vinit C, Meinzer U, Dumaine C. J Pediatr. 2023 Dec;263:113682. doi: 10.1016/j.jpeds.2023.113682. Epub 2023 Aug 21. PMID: 37611738

Assessing the risk of **COVID-19** reinfection and severe outcomes among individuals with substance use disorders: a retrospective study using real-world electronic health records.

Tuan WJ, Kindt HM, Lennon RP. BMJ Open. 2023 Dec 10;13(12):e074993. doi: 10.1136/bmjopen-2023-074993. PMID: 38072495

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles.
Elfayres G, Paswan RR, Sika L, Girard MP, Khalfi S, Letanneur C, Milette K, Singh A, Kobinger G, Berthoux L. J Virol Methods. 2023 Dec;322:114835. doi: 10.1016/j.jviromet.2023.114835. Epub 2023 Oct 21. PMID: 37871706

Vaccines for Children Provider Practices in the **COVID-19** Vaccination Program: Barriers to Participation, Intentions to Offer **COVID-19** Vaccination to Children Aged <5 Years, and Vaccination Promotion, United States, March 2022.
Kang Y, Zhang F, Chatham-Stephens K, Carter RJ, Vogt T. Clin Pediatr (Phila). 2023 Dec;62(12):1479-1488. doi: 10.1177/00099228231161335. Epub 2023 Mar 15. PMID: 36919846

Pregnant women's attitudes and behaviours towards antenatal vaccination against Influenza and **COVID-19** in the Liverpool City Region, United Kingdom: Cross-sectional survey.
Kilada S, French N, Perkins E, Hungerford D. Vaccine X. 2023 Sep 16;15:100387. doi: 10.1016/j.jvacx.2023.100387. eCollection 2023 Dec. PMID: 37753114

Exploring missed opportunities for influenza vaccination and influenza **vaccine** co-administration patterns among Italian older adults: a retrospective cohort study.
Domnich A, Orsi A, Ogliastro M, Trombetta CS, Scarpaleggia M, Ceccaroli C, Amadio C, Raffo A, Berisso L, Yakubovich A, Zappa G, Amicizia D, Panatto D, Icardi G. Eur J Public Health. 2023 Dec 9;33(6):1183-1187. doi: 10.1093/eurpub/ckad155. PMID: 37632235

Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca **COVID-19 vaccine**.
Maher DI, Hogarty D, Ben Artsi E. Orbit. 2023 Dec;42(6):630-634. doi: 10.1080/01676830.2022.2062777. Epub 2022 May 2. PMID: 35499172

Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe **COVID-19** due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Mateo-Urdiales A, Sacco C, Fotakis EA, Del Manso M, Bella A, Riccardo F, Bressi M, Rota MC, Petrone D, Siddu A, Fedele G, Stefanelli P, Palamara AT, Brusaferro S, Rezza G, Pezzotti P, Fabiani M. Lancet Infect Dis. 2023 Dec;23(12):1349-1359. doi: 10.1016/S1473-3099(23)00374-2. Epub 2023 Jul 18. PMID: 37478877

The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M, Thomas OG, Carlin G, Khademi M, Högelin KA, Malmeström C, Axelsson M, Brandt AF, Gafvelin G, Grönlund H, Kockum I, Piehl F, Lycke J, Olsson T, Hessa T. Eur J Neurol. 2023 Dec;30(12):3789-3798. doi: 10.1111/ene.16015. Epub 2023 Aug 24. PMID: 37522464

COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records.
Hsieh TYJ, Chang R, Yong SB, Liao PL, Hung YM, Wei JC. Diabetes Care. 2023 Dec 1;46(12):2193-2200. doi: 10.2337/dc23-0936. PMID: 37851392

Pharmacists' perceptions about providing **COVID-19 vaccines** in community settings.
Alotaibi MM, Aldandan EM, Alfredan BE, Almohammed SH, Almousa ZH. Explor Res Clin Soc Pharm. 2023 Sep 5;12:100326. doi: 10.1016/j.rcsop.2023.100326. eCollection 2023 Dec. PMID: 37743853

Malaria & mRNA **Vaccines**: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South.
Borkens Y. Acta Parasitol. 2023 Dec;68(4):916-928. doi: 10.1007/s11686-023-00712-y. Epub 2023 Oct 12. PMID: 37828249

Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database.
Kumar A, Miller DC, Sun Y, Arnold BF, Acharya NR. Ophthalmology. 2023 Dec;130(12):1269-1278. doi: 10.1016/j.ophtha.2023.07.017. Epub 2023 Jul 20. PMID: 37480943

COVID-19 antibody production by vaccination in chemotherapy with CD20 antibody for B-cell lymphoma.
Tsutsumi Y, Ito S, Horikita F, Moriki A, Teshima T. Mol Clin Oncol. 2023 Oct 18;19(6):96. doi: 10.3892/mco.2023.2692. eCollection 2023 Dec. PMID: 37920416

Meningococcal Disease in the Post-**COVID-19** Era: A Time to Prepare.
Bloom DE, Bonanni P, Martinón-Torres F, Richmond PC, Safadi MAP, Salisbury DM, Charos A, Schley K, Findlow J, Balmer P. Infect Dis Ther. 2023 Dec 4. doi: 10.1007/s40121-023-00888-w. Online ahead of print. PMID: 38048020

Lumpy skin disease: Insights into current status and geographical expansion of a transboundary viral disease.
Moudgil G, Chadha J, Khullar L, Chhibber S, Harjai K. Microb Pathog. 2023 Dec 3;186:106485. doi: 10.1016/j.micpath.2023.106485. Online ahead of print. PMID: 38052279

Developing magnetic barcode bead fluorescence assay for high throughput analyzing humoral responses against multiple SARS-CoV-2 variants.
Su WY, Ho TS, Tsai TC, Du PX, Tsai PS, Keskin BB, Shizen MA, Lin PC, Lin WH, Shih HC, Syu GD. Biosens Bioelectron. 2023 Dec 1;241:115709. doi: 10.1016/j.bios.2023.115709. Epub 2023 Sep 22. PMID: 37776623

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN, Qu P, Goodarzi N, Zheng YM, Carlin C, Saif LJ, Oltz EM, Xu K, Jones D, Gumina RJ, Liu SL. Emerg Microbes Infect. 2023 Dec;12(2):2270069. doi: 10.1080/22221751.2023.2270069. Epub 2023 Oct 26. PMID: 37819267

Bacterial nasopharyngeal colonisation in children in South Africa before and during the **COVID-19** pandemic: an observational study.
Olwagen CP, Downs SL, Izu A, Tharasimbi L, Van Der Merwe L, Nunes MC, Madhi SA. Lancet Microbe. 2023 Dec 1:S2666-5247(23)00260-4. doi: 10.1016/S2666-5247(23)00260-4. Online ahead of print. PMID: 38048806

Epidemiology of RSV Bronchiolitis Among Young Children in Central New York Before and After the Onset of the **COVID-19** Pandemic.

Daniels D, Wang D, Suryadevara M, Wolf Z, Nelson CB, Suh M, Movva N, Reichert H, Fryzek JP, Domachowske JB. Pediatr Infect Dis J. 2023 Dec 1;42(12):1056-1062. doi: 10.1097/INF.0000000000004101. Epub 2023 Sep 7. PMID: 37725814

Parental motivated helplessness in vaccinating children against **COVID-19**: Its association with fear, effectiveness and willingness to vaccinate.
Kretchner M, Lifshin U, Mikulincer M. J Health Psychol. 2023 Dec;28(14):1345-1358. doi: 10.1177/13591053231170055. Epub 2023 May 15. PMID: 37183794

Engaging staff to improve **COVID-19** vaccination response at long-term care facilities (ENSPIRE): A cluster randomized trial of co-designed, tailored **vaccine** promotion materials.
Hsu C, Williamson BD, Becker M, Berry B, Cook AJ, Derus A, Estrada C, Gacuiri M, Kone A, McCracken C, McDonald B, Piccorelli AV, Senturia K, Volney J, Wilson KB, Green BB. Contemp Clin Trials. 2023 Dec 3:107403. doi: 10.1016/j.cct.2023.107403. Online ahead of print. PMID: 38052297

Considerations on the design of lipid-based mRNA **vaccines** against cancer.
Meulewaeter S, Zhang Y, Wadhwa A, Fox K, Lentacker I, Harder KW, Cullis PR, De Smedt SC, H Y Cheng M, Verbeke R. J Mol Biol. 2023 Dec 6:168385. doi: 10.1016/j.jmb.2023.168385. Online ahead of print. PMID: 38065276

Original Research: Predictors of **COVID-19 Vaccine** Hesitancy Among Asian Indians in the United States: A Cross-Sectional Descriptive Study.
Albuquerque LH, Luckose AB, Joseph M, Mathews N, Devarayasamudram S, Mahon E. Am J Nurs. 2023 Dec 6;Published Ahead of Print. doi: 10.1097/01.NAJ.0000998220.62535.e4. Online ahead of print. PMID: 38055842

Barriers to **COVID-19** Prevention Measures Among People Experiencing Homelessness with Substance Use Disorder or Serious Mental Illness.
Meehan AA, Jeffers A, Barker J, Ray CM, Laws RL, Fields VL, Miedema SS, Cha S, Cassell CH, DiPietro B, Cary M, Yang M, McLendon H, Marcus R, Mosites E. J Prev (2022). 2023 Dec;44(6):663-678. doi: 10.1007/s10935-023-00739-x. Epub 2023 Sep 26. PMID: 37750981

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA **vaccine** against a range of **COVID-19** outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, Xie F, Takhar H, Ogun OA, Simmons S, Zamparo JM, Valluri SR, Jodar L, McLaughlin JM. Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25. PMID: 37898148

Social justice in medical education: a student-led approach to addressing **COVID-19 vaccine** equity in the Hispanic/Latinx community.
Adler AV, Nadone HR, Dafinone ME, Facemyer KC. Med Educ Online. 2023 Dec;28(1):2241169. doi: 10.1080/10872981.2023.2241169. PMID: 37499134

The intention to get **COVID-19** booster vaccination and its association with cognitive and emotional factors: A survey of Chinese **COVID-19** infected people in Hong Kong.
Yu Y, Zhang X, Lau MMC, Lau JTF. Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.12.015. Online ahead of print. PMID: 38065769

Association of selenium profile with neutralizing antibody response to inactivated SARS-CoV-2 vaccination.
Gao S, Ren N, Sun T, Nie Q, Liu S, Geng X, Deng Y, Lin Z, Liu Y, Zhou L. J Trace Elem Med Biol. 2023 Dec;80:127295. doi: 10.1016/j.jtemb.2023.127295. Epub 2023 Aug 25. PMID: 37660572

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles.
Fernandes S, Cassani M, Cavalieri F, Forte G, Caruso F. Adv Sci (Weinh). 2023 Dec 6:e2305769. doi: 10.1002/advs.202305769. Online ahead of print. PMID: 38054651

Stronger and durable SARS-CoV-2 immune response to mRNA **vaccines** in 5-11 years old children with prior **COVID-19**.
Di Chiara C, Cantarutti A, Raffaella Petrara M, Bonfante F, Benetti E, Boracchini R, Bosa L, Carmona F, Cosma C, Cotugno N, Le Prevost M, Martini G, Meneghel A, Pagliari M, Palma P, Ruffoni E, Zin A, De Rossi A, Giaquinto C, Donà D, Padoan A. Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.12.006. Online ahead of print. PMID: 38071105

Do **COVID-19** Vaccination Policies Backfire? The Effects of Mandates, Vaccination Passports, and Financial Incentives on **COVID-19** Vaccination.
Fayaz-Farkhad B, Jung H. Perspect Psychol Sci. 2023 Dec 4:17456916231178708. doi: 10.1177/17456916231178708. Online ahead of print. PMID: 38048051

Methodological and statistical considerations: Batch-dependent adverse effects of **COVID-19 vaccines**.
Scott DAR, Renelle A, Niederer RL. Eur J Clin Invest. 2023 Dec;53(12):e14073. doi: 10.1111/eci.14073. Epub 2023 Aug 7. PMID: 37548000

RBD-specific antibody response after two doses of different SARS-CoV-2 **vaccines** during the mass vaccination campaign in Mongolia.
Batmunkh B, Otgonbayar D, Shaarii S, Khaidav N, Shagdarsuren OE, Boldbaatar G, Danzan NE, Dashtseren M, Unurjargal T, Dashtseren I, Dagvasumberel M, Jagdagsuren D, Bayandorj O, Biziya B, Surenjid S, Togoo K, Bat-Erdene A, Narmandakh Z, Choijilsuren G, Batmunkh U, Soodoi C, Boldbaatar EA, Byambatsogt G, Byambaa O, Deleg Z, Enebish G, Chuluunbaatar B, Zulmunkh G, Tsolmon B, Gunchin B, Chimeddorj B, Dambadarjaa D, Sandag T. PLoS One. 2023 Dec 8;18(12):e0295167. doi: 10.1371/journal.pone.0295167. eCollection 2023. PMID: 38064430

Factors influencing uptake of the **COVID-19** vaccination among pregnant women in Australia: A cross-sectional survey.
Javid N, Phipps H, Homer C, de Vries B, Kaufman J, Danchin M, Hyett J. Birth. 2023 Dec;50(4):877-889. doi: 10.1111/birt.12741. Epub 2023 Jul 11. PMID: 37431957

Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the **COVID-19** pandemic with tentative recovery in 2022.
Evans B, Keiser O, Kaiser L, Jombart T. Vaccine X. 2023 Sep 6;15:100383. doi: 10.1016/j.jvacx.2023.100383. eCollection 2023 Dec. PMID: 37841654

Thyroid Inflammation and Immunity During the **COVID-19** Pandemic: A Comprehensive Review and Case Study.

Lampropoulou E, Benz C, Kahaly GJ, Führer D. Horm Metab Res. 2023 Dec 4. doi: 10.1055/a-2222-6300. Online ahead of print. PMID: 38049146

Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S **vaccine**-mediated immune response and protection against SARS-CoV-2 infection.
Gómez-Carballa A, Albericio G, Montoto-Louzao J, Pérez P, Astorgano D, Rivero-Calle I, Martinón-Torres F, Esteban M, Salas A, García-Arriaza J. Antiviral Res. 2023 Dec;220:105760. doi: 10.1016/j.antiviral.2023.105760. Epub 2023 Nov 21. PMID: 37992765

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
Jawad B, Adhikari P, Podgornik R, Ching WY. Comput Biol Med. 2023 Dec;167:107576. doi: 10.1016/j.compbiomed.2023.107576. Epub 2023 Oct 12. PMID: 37871435

Analysis of School-Day Disruption of Administering School-Located Vaccination to Children in Three Local Areas, 2012-2013 School Year.
Yarnoff B, Wagner LD, Honeycutt AA, Vogt TM. J Sch Nurs. 2023 Dec;39(6):456-462. doi: 10.1177/10598405211038598. Epub 2021 Aug 18. PMID: 34405720

Exploring the relationship between SARS-CoV-2 variants, illness severity at presentation, in-hospital mortality and **COVID-19** vaccination in a low middle-income country: A retrospective cross-sectional study.
Mushtaq MZ, Nasir N, Mahmood SF, Khan S, Kanji A, Nasir A, Syed MA, Aamir UB, Hasan Z. Health Sci Rep. 2023 Dec 1;6(12):e1703. doi: 10.1002/hsr2.1703. eCollection 2023 Dec. PMID: 38045627

Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2.
Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z. Emerg Microbes Infect. 2023 Dec;12(1):2146538. doi: 10.1080/22221751.2022.2146538. PMID: 36354024

The relationship of intent to be **COVID-19** vaccinated with depression, anxiety, insomnia, pain and smoking among Chinese patients with a pacemaker.
Cai H, Lin Y, Liu HH, Su XJ, Zhou CY, Li J, Ungvari GS, Feng Y, Xiang YT. Prev Med Rep. 2023 Sep 1;36:102394. doi: 10.1016/j.pmedr.2023.102394. eCollection 2023 Dec. PMID: 37766721

Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: update of the literature and patient characterization.
Ginanneschi F, Vinciguerra C, Volpi N, Piscosquito G, Barone P, Rossi A. Immunol Res. 2023 Dec;71(6):833-838. doi: 10.1007/s12026-023-09406-z. Epub 2023 Jul 3. PMID: 37395901

Low-sugar universal mRNA **vaccine** against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA).
Cheng CW, Wu CY, Wang SW, Chen JY, Kung CC, Liao KS, Wong CH. Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2314392120. doi: 10.1073/pnas.2314392120. Epub 2023 Nov 27. PMID: 38011546

Lack of vitamin D predicts impaired long-term immune response to **COVID-19** vaccination.
di Filippo L, Frara S, Terenzi U, Nannipieri F, Locatelli M, Ciceri F, Giustina A. Endocrine. 2023 Dec;82(3):536-541. doi: 10.1007/s12020-023-03481-w. Epub 2023 Aug 17. PMID: 37592162

Is **vaccine** hesitancy related to mental health after the adjustment of the zero-**COVID-19** strategy in the elderly? A mediation analysis in China.
Zhang E, Wang X, Dai Z, Zhang X, Shang S, Fang Q. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288726. doi: 10.1080/21645515.2023.2288726. Epub 2023 Dec 6. PMID: 38055950

Prevalence of **COVID-19** Mitigation Behaviors in US Adults (August-December 2020): Nationwide Household Probability Survey.
Sanchez T, Hall E, Siegler AJ, Prakash-Asrani R, Bradley H, Fahimi M, Lopman B, Luisi N, Nelson KN, Sailey C, Shioda K, Valentine-Graves M, Sullivan PS. JMIR Public Health Surveill. 2023 Dec 6;9:e37102. doi: 10.2196/37102. PMID: 38055314

Global **Vaccine** Access Demands Combating Both Inequity And Hesitancy.
Hotez PJ. Health Aff (Millwood). 2023 Dec;42(12):1681-1688. doi: 10.1377/hlthaff.2023.00775. PMID: 38048497

Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of **COVID-19** in patients with systemic autoimmune rheumatic diseases.
Papagoras C, Zioga N, Papadopoulos V, Gerolymatou N, Kalavri E, Bounos C, Simopoulou T, Fragoulis GE, Panopoulos S, Fragiadaki K, Evangelatos G, Bournia VK, Arida A, Karamanakos A, Pappa M, Kravvariti E, Deftereou K, Kougkas N, Zampeli E, Kataxaki E, Melissaropoulos K, Barouta G, Panagiotopoulos A, Koutsianas C, Liossis SN, Georgiou P, Dimitroulas T, Tektonidou MG, Bogdanos DP, Elezoglou A, Voulgari PV, Sfikakis PP, Vassilopoulos D. Clin Rheumatol. 2023 Dec;42(12):3375-3385. doi: 10.1007/s10067-023-06769-4. Epub 2023 Sep 21. PMID: 37731083

Influenza vaccination in children with pulmonary disease during the **COVID-19** pandemic.
Amitai N, Wertheimer R, Prais D, Wertheimer KO, Livni G. Vaccine. 2023 Dec 7;41(50):7532-7538. doi: 10.1016/j.vaccine.2023.11.026. Epub 2023 Nov 17. PMID: 37977938

Investigating mortality trends in Italy during the **COVID-19** pandemic: life expectancy changes within provinces and vaccination campaign impact up to December 2022.
Nova A, Fazia T, Bernardinelli L. Public Health. 2023 Dec;225:168-175. doi: 10.1016/j.puhe.2023.09.031. Epub 2023 Nov 4. PMID: 37925841

Cytokine-responsive T- and NK-cells portray SARS-CoV-2 **vaccine**-responders and infection in multiple myeloma patients.
Enssle JC, Campe J, Moter A, Voit I, Gessner A, Yu W, Wolf S, Steffen B, Serve H, Bremm M, Huenecke S, Lohoff M, Vehreschild M, Rabenau HF, Widera M, Ciesek S, Oellerich T, Imkeller K, Rieger MA, von Metzler I, Ullrich E. Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02070-0. Online ahead of print. PMID: 38049509

Increased risk of fetal loss after **COVID-19** vaccination.
Thorp JA, Rogers C, Deskevich MP, Tankersley S, Benavides A, Redshaw MD, McCullough PA. Hum Reprod. 2023 Dec 4;38(12):2536. doi: 10.1093/humrep/dead204. PMID: 37823793

Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination.
Heaney CD, Hempel H, DeRosa KL, Pinto LA, Mantis NJ. Clin Chem. 2023 Dec 1:hvad169. doi: 10.1093/clinchem/hvad169. Online ahead of print. PMID: 38039096

Pandemic stressors and **vaccine** hesitancy among young, pregnant Black people: A qualitative study of health disparities during a global pandemic.
De Genna NM, Hossain F, Dwarakanath M, Ms Balascio P, Ms Moore M, Hill AV. Birth Defects Res. 2023 Dec 1;115(20):1912-1922. doi: 10.1002/bdr2.2262. Epub 2023 Oct 8. PMID: 37807480

Iatrogenic encephalopathy or reversible splenial lesion syndrome (RESLES)?
Cerimagic D. Clin Neurol Neurosurg. 2023 Dec;235:108046. doi: 10.1016/j.clineuro.2023.108046. Epub 2023 Nov 4. PMID: 37949040

Immunogenicity of mucosal **COVID-19 vaccine** candidates based on the highly attenuated vesicular stomatitis virus vector (VSV_{MT}) in golden syrian hamster.
Ke Y, Zhang E, Guo J, Zhang X, Wang L, Chen D, Fang X, Zhu J, Li F, Sun T, Zhang B. Acta Pharm Sin B. 2023 Dec;13(12):4856-4874. doi: 10.1016/j.apsb.2023.08.023. Epub 2023 Aug 25. PMID: 38045049

Optic neuropathy after **COVID-19** vaccination: a report of two cases.
Elnahry AG, Asal ZB, Shaikh N, Dennett K, Abd Elmohsen MN, Elnahry GA, Shehab A, Vytopil M, Ghaffari L, Athappilly GK, Ramsey DJ. Int J Neurosci. 2023 Dec;133(8):901-907. doi: 10.1080/00207454.2021.2015348. Epub 2021 Dec 14. PMID: 34906029

Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from **COVID-19**: a longitudinal cohort study.
Guo L, Zhang Q, Gu X, Ren L, Huang T, Li Y, Zhang H, Liu Y, Zhong J, Wang X, Chen L, Zhang Y, Li D, Fang M, Xu L, Li H, Wang Z, Li H, Bai T, Liu W, Peng Y, Dong T, Cao B, Wang J. Lancet Microbe. 2023 Dec 1:S2666-5247(23)00255-0. doi: 10.1016/S2666-5247(23)00255-0. Online ahead of print. PMID: 38048805

The gift of preexisting immunity for developing an alternative **vaccine** strategy.
Tran KA, Divangahi M. J Clin Invest. 2023 Dec 1;133(23):e174952. doi: 10.1172/JCI174952. PMID: 38038132

Willingness to receive and recommend hypothetical mpox vaccination and associated factors in Chinese adults: a community-based survey in Shenzhen, China.
Ren F, Miao J, Liu J, Xia B, Chen Z, Xu Y, Zhang R, Fan J, Lin W. Public Health. 2023 Dec;225:267-276. doi: 10.1016/j.puhe.2023.10.014. Epub 2023 Nov 10. PMID: 37952343

Safety of **COVID-19** Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S, Li J, Xu R, Chen Q, Sun G, Lin Y, Cao Y, Chen Y, Geng C, Teng Y, Nie J, Li X, Xu G, Liu X, Jin F, Fan Z, Luo T, Liu H, Wang FS, Jiang Z. JMIR Public Health Surveill. 2023 Dec 7;9:e46009. doi: 10.2196/46009. PMID: 38060302

Effect of SARS-CoV-2 vaccination in a vulnerable **COVID-19** cohort: a real-life experience in an Italian Hospital.
Russo C, Tagliafico L, Labate L, Ponzano M, Mirabella M, Portunato F, Bellezza C, Mora S, Arboscello E, Monacelli F, Nencioni A, Signori A, Bruzzone B, Giacomini M, Dentone C, Bassetti M. J Chemother. 2023 Dec;35(8):730-736. doi: 10.1080/1120009X.2023.2246716. Epub 2023 Aug 23. PMID: 37608747

Modelling the potential public health impact of different **COVID-19** vaccination strategies with an adapted **vaccine** in Singapore.
Yarnoff B, Thakkar K, Spinardi J, Kyaw MH, Yang J, Mendoza CF, Ozbilgili E, Taysi B, Dodd J, Oh HM. Expert Rev Vaccines. 2023 Dec 4. doi: 10.1080/14760584.2023.2290931. Online ahead of print. PMID: 38047434

Flares in autoimmune rheumatic diseases in the post-**COVID-19** vaccination period-a cross-sequential study based on COVAD surveys.
Jagtap K, Naveen R, Day J, Sen P, Vaidya B, Nune A, Nikiphorou E, Tan AL, Agarwal V, Saha S, Shinjo SK, Ziade N, Joshi M, Velikova T, Milchert M, Parodis I, Edgar Gracia-Ramos A, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Saavedra MA, Distler O; COVAD Study Group; Chinoy H, Agarwal V, Aggarwal R, Gupta L. Rheumatology (Oxford). 2023 Dec 1;62(12):3838-3848. doi: 10.1093/rheumatology/kead144. PMID: 36961331

Letter to the Editor: Immunogenicity After the Third Dose of **COVID-19 Vaccine** in Cardiac Transplantation.
Rahman A, Golombeck D, Malhame K, Rossi D, Wallach F, Avila M, Maybaum S. Transplantation. 2023 Dec 1;107(12):e370-e372. doi: 10.1097/TP.0000000000004843. Epub 2023 Oct 30. PMID: 37899474

Regarding Oculomotor Palsy After the Administration of the Messenger RNA-1273 **Vaccine** for SARS-CoV-2: Diplopia After the **COVID-19 Vaccine**.
Mungmungpuntipantip R, Wiwanitkit V. J Neuroophthalmol. 2023 Dec 1;43(4):e360. doi: 10.1097/WNO.0000000000001558. Epub 2022 Mar 24. PMID: 35421876

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the **COVID-19** pandemic: a cross-sectional cohort study (PsoCOVID).
Kwee KV, Murk JL, Yin Q, Visch MB, Davidson L, de Jong EMGJ, van den Reek JMPA, Tjioe M. J Dermatolog Treat. 2023 Dec;34(1):2161297. doi: 10.1080/09546634.2022.2161297. PMID: 36545844

Contextual Pathways Linking Cumulative Experiences of Racial Discrimination to Black American Men's **COVID Vaccine** Hesitancy.
Curtis MG, Whalen CC, Pjesivac I, Kogan SM. J Racial Ethn Health Disparities. 2023 Dec;10(6):2944-2956. doi: 10.1007/s40615-022-01471-8. Epub 2022 Nov 29. PMID: 36445684

Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study.
Damkier P, Cleary B, Hallas J, Schmidt JH, Ladebo L, Jensen PB, Lund LC. Otolaryngol Head Neck Surg. 2023 Dec;169(6):1472-1480. doi: 10.1002/ohn.394. Epub 2023 Jun 8. PMID: 37288514

Does **COVID-19** vaccination affect post-traumatic stress symptoms via risk perception? A large cross-sectional study among the Chinese population.
Huang N, Liu X, Liu Q, Zhang J, Fu Y, Zhu Z, Guo J, Li X, Yang L. Public Health. 2023 Dec 4;226:107-113. doi: 10.1016/j.puhe.2023.11.003. Online ahead of print. PMID: 38052112

A community-based volunteer service to reduce **COVID-19** vaccination inequities in New York City.
Tay ET, Fernbach M, Chen H, Ng C, Tapia J, O'Callaghan S. J Public Health (Oxf). 2023 Dec 8:fdad208. doi: 10.1093/pubmed/fdad208. Online ahead of print. PMID: 38070144

Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2.
Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD, Liu L. Emerg Microbes Infect. 2023 Dec;12(1):2210237. doi: 10.1080/22221751.2023.2210237. PMID: 37132357

Nasally delivered SARS-CoV-2 **vaccines**: future promise and challenges.
Shaw RH. Lancet Respir Med. 2023 Dec;11(12):1038-1039. doi: 10.1016/S2213-2600(23)00383-1. Epub 2023 Nov 15. PMID: 37979589

Vaccine Effectiveness Against SARS-CoV-2 Related Hospitalizations in People who had Experienced Homelessness or Incarceration - Findings from the Minnesota EHR Consortium.
DeSilva MB, Knowlton G, Rai NK, Bodurtha P, Essien I, Riddles J, Mehari L, Muscoplat M, Lynfield R, Rowley EA, Chamberlain AM, Patel P, Hughes A, Dickerson M, Thompson MG, Griggs EP, Tenforde M, Winkelman TN, Benitez GV, Drawz PE. J Community Health. 2023 Dec 8. doi: 10.1007/s10900-023-01308-3. Online ahead of print. PMID: 38066221

Antigen-loaded flagellate bacteria for enhanced adaptive immune response by intradermal injection.
Tao F, Ye Q, Chen Y, Luo L, Xu H, Xu J, Feng Z, Wang C, Li T, Wen Y, Hu Y, Dong H, Zhao X, Wu J. J Control Release. 2023 Dec;364:562-575. doi: 10.1016/j.jconrel.2023.10.055. Epub 2023 Nov 11. PMID: 37926245

How Mortality Salience and Self-Construal Make a Difference: An Online Experiment to Test Perception of Importance of **COVID-19 Vaccines** in China.
Yang L, Huang Y. Health Commun. 2023 Dec;38(12):2698-2701. doi: 10.1080/10410236.2022.2106413. Epub 2022 Jul 27. PMID: 35898116

Prolongation of the Menstrual Cycle After Receipt of the Primary Series and Booster Doses of mRNA Coronavirus Disease 2019 (**COVID-19**) Vaccination.
Hosoya S, Piedvache A, Nakamura A, Nasu R, Hine M, Itoi S, Yokomizo R, Umezawa A, Hiraike O, Koga K, Osuga Y, Narumi S, Morisaki N. Obstet Gynecol. 2023 Dec 7. doi: 10.1097/AOG.0000000000005476. Online ahead of print. PMID: 38061045

Heterologous Omicron-adapted **vaccine** as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice.
Liu J, He Q, Gao F, Bian L, Wang Q, An C, Song L, Zhang J, Liu D, Song Z, Li L, Bai Y, Wang Z, Liang Z, Mao Q, Xu M. Emerg Microbes Infect. 2023 Dec;12(1):e2143283. doi: 10.1080/22221751.2022.2143283. PMID: 36377297

A receptor-binding domain-based nanoparticle **vaccine** elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
Lee IJ, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Wang IH, Tao MH. Emerg Microbes Infect. 2023 Dec;12(1):2149353. doi: 10.1080/22221751.2022.2149353. PMID: 36395071

Model-informed health and socio-economic benefits of enhancing global equity and access to **Covid-19 vaccines**.
Italia M, Della Rossa F, Dercole F. Sci Rep. 2023 Dec 7;13(1):21707. doi: 10.1038/s41598-023-48465-y. PMID: 38066204

Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022.
Solastie A, Nieminen T, Ekström N, Nohynek H, Lehtonen L, Palmu AA, Melin M. Emerg Microbes Infect. 2023 Dec;12(2):2222849. doi: 10.1080/22221751.2023.2222849. PMID: 37289188

Epidemiological features of SARS-CoV-2 Omicron infection under new control strategy: a cross-sectional study of the outbreak since December 2022 in Sichuan, China.
Liu R, Zhang Y, Ma J, Wang H, Lan Y, Tang X. BMC Public Health. 2023 Dec 8;23(1):2463. doi: 10.1186/s12889-023-17361-5. PMID: 38066518

Factors associated with **COVID-19** vaccination status: A cross-sectional study of California students in higher education.
Dougan MM, Buckner A. Prev Med Rep. 2023 Sep 1;36:102386. doi: 10.1016/j.pmedr.2023.102386. eCollection 2023 Dec. PMID: 37766727

An online RCT on behavioural expectations effects of **COVID-19** certification policies in England.
Mills F, Carter H, Benny L, Barnard M, Symons C. Vaccine X. 2023 Sep 20;15:100389. doi: 10.1016/j.jvacx.2023.100389. eCollection 2023 Dec. PMID: 37829554

RE: "Risk and benefit OF mRNA **COVID-19 vaccines** for the omicron variant by age, sex, and presence of comorbidity: a quality-adjusted life years analysis".
Shiraishi M, Kurita M, Fujisawa K, Okazaki M. Am J Epidemiol. 2023 Dec 5:kwad238. doi: 10.1093/aje/kwad238. Online ahead of print. PMID: 38055629

Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study.
Chinnamadhu A, Ramakrishnan J, Suresh S, Ramadurai P, Poomani K. J Biomol Struct Dyn. 2023 Dec;41(20):10396-10410. doi: 10.1080/07391102.2022.2154844. Epub 2022 Dec 12. PMID: 36510678

The Omicron wave in Mexico: **vaccine** protection against progression to severe **Covid-19** in SARS-CoV-2-infected workers.
Hernández-Ávila M, Vieyra-Romero WI, Gutiérrez-Díaz HO, Zepeda-Tello R, Alpuche-Aranda C, Hernández-Ávila JE, Barros-Sierra D, Tamayo-Ortiz M, Duque-Molina C, Barrientos-Gutiérrez T, Carnalla-Cortés M, Dyer-Leal D, López-Ridaura R, López-Gatell-Ramírez H. Salud Publica Mex. 2023 Dec 8;66(1, ene-feb):85-94. doi: 10.21149/15125. PMID: 38065107

Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2.
Dhaka P, Singh A, Choudhary S, Peddinti RK, Kumar P, Sharma GK, Tomar S. Arch Biochem Biophys. 2023 Dec;750:109820. doi: 10.1016/j.abb.2023.109820. Epub 2023 Nov 11. PMID: 37956938

Multisystem Inflammatory Syndrome in Children Among Persons Who Completed a Two-dose **COVID-19 Vaccine** Primary Series Compared With Those Reporting No **COVID-19** Vaccination, US National MIS-C Surveillance.
Yousaf AR, Miller AD, Lindsey K, Shah AB, Wu MJ, Melgar M, Zambrano LD, Campbell AP. Pediatr Infect Dis J. 2023 Dec 1;42(12):e476-e478. doi: 10.1097/INF.0000000000004103. Epub 2023 Sep 12. PMID: 37725819

Safety and immunogenicity of locally produced trivalent inactivated influenza **vaccine** (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
Prasert K, Praphasiri P, Lerdsamran H, Nakphook S, Ditsungnoen D, Chawalchitiporn S, Sornwong K, Poopipatpol K, Wirachwong P, Narakorn P, Surichan S, Suthepakul N, Thangsupanimitchai N, Pittayawonganon C, Puthavathana P, Davis WW, Mott JA, Olsen SJ, Patumanond J. Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.11.050. Online ahead of print. PMID: 38042698

Occurrence of proliferative myositis after **COVID-19** vaccination: A case report.
Ebrahimi R, Mounesi Sohi AS, Khonji MS, Ghafouri K. Radiol Case Rep. 2023 Sep 25;18(12):4309-4312. doi: 10.1016/j.radcr.2023.08.056. eCollection 2023 Dec. PMID: 37800119

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
Jin L, Tang R, Wu S, Guo X, Huang H, Hou L, Chen X, Zhu T, Gou J, Zhong J, Pan H, Cui L, Chen Y, Xia X, Feng J, Wang X, Zhao Q, Xu X, Li Z, Zhang X, Chen W, Li J, Zhu F. Emerg Microbes Infect. 2023 Dec;12(1):2155251. doi: 10.1080/22221751.2022.2155251. PMID: 36503413

'Unable to have a proper conversation over the phone about my concerns': a multimethods evaluation of the impact of **COVID-19** on routine childhood vaccination services in London, UK.
Buck E, Burt J, Karampatsas K, Hsia Y, Whyte G, Amirthalingam G, Skirrow H, Le Doare K. Public Health. 2023 Dec;225:229-236. doi: 10.1016/j.puhe.2023.09.026. Epub 2023 Nov 7. PMID: 37944278

Despite misinformation, low trust, and conflict in Somalia, high demand for **vaccines** and a negative endorsement effect of non-state authorities.
Aarslew LF, Haas N, Khadka PB. Sci Rep. 2023 Dec 7;13(1):21689. doi: 10.1038/s41598-023-48389-7. PMID: 38066052

The onset of *de novo* autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 **vaccines**: a single centre prospective follow-up study.
Sacchi MC, Pelazza C, Bertolotti M, Agatea L, De Gaspari P, Tamiazzo S, Ielo D, Stobbione P, Grappiolo M, Bolgeo T, Novel P, Ciriello MM, Maconi A. Autoimmunity. 2023 Dec;56(1):2229072. doi: 10.1080/08916934.2023.2229072. PMID: 37381619

Proteome based analysis of circulating SARS-CoV-2 variants: approach to a universal **vaccine** candidate.
Oladipo EK, Ojo TO, Olufemi SE, Irewolede BA, Adediran DA, Abiala AG, Hezekiah OS, Idowu AF, Oladeji YG, Ikuomola MO, Olayinka AT, Akanbi GO, Idowu UA, Olubodun OA, Odunlami FD, Ogunniran JA, Akinro OP, Adegoke HM, Folakanmi EO, Usman TA, Oladokun EF, Oluwasanya GJ, Awobiyi HO,

Oluwasegun JA, Akintibubo SA, Jimah EM. Genes Genomics. 2023 Dec;45(12):1489-1508. doi: 10.1007/s13258-023-01426-1. Epub 2023 Aug 7. PMID: 37548884

Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
Moradi Marjaneh M, Challenger JD, Salas A, Gómez-Carballa A, Sivananthan A, Rivero-Calle I, Barbeito-Castiñeiras G, Foo CY, Wu Y, Liew F, Jackson HR, Habgood-Coote D, D'Souza G, Nichols SJ, Wright VJ, Levin M, Kaforou M, Thwaites RS, Okell LC, Martinón-Torres F, Cunnington AJ; PERFORM Consortium; GEN-COVID Study Group (http://gencovid.eu). J Infect. 2023 Dec;87(6):538-550. doi: 10.1016/j.jinf.2023.10.009. Epub 2023 Oct 18. PMID: 37863321

EpiMed Coronabank Chemical Collection: Compound selection, ADMET analysis, and utilisation in the context of potential SARS-CoV-2 antivirals.
Pitsillou E, Beh RC, Liang JJ, Tang TS, Zhou X, Siow YY, Ma Y, Hu Z, Wu Z, Hung A, Karagiannis TC. J Mol Graph Model. 2023 Dec;125:108602. doi: 10.1016/j.jmgm.2023.108602. Epub 2023 Aug 16. PMID: 37597309

Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
Greinacher A, Warkentin TE. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):1-10. doi: 10.1182/hematology.2023000503. PMID: 38066843

Successful endodontic treatment reduces serum levels of cardiovascular disease risk biomarkers-high-sensitivity C-reactive protein, asymmetric dimethylarginine, and matrix metalloprotease-2.
Al-Abdulla N, Bakhsh A, Mannocci F, Proctor G, Moyes D, Niazi SA. Int Endod J. 2023 Dec;56(12):1499-1516. doi: 10.1111/iej.13979. Epub 2023 Oct 3. PMID: 37787168

The role of wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence from South Africa supports sentinel site surveillance to guide public health decision-making.
Iwu-Jaja C, Ndlovu NL, Rachida S, Yousif M, Taukobong S, Macheke M, Mhlanga L, van Schalkwyk C, Pulliam JRC, Moultrie T, le Roux W, Schaefer L, Pocock G, Coetzee LZ, Mans J, Bux F, Pillay L, de Villiers D, du Toit AP, Jambo D, Gomba A, Groenink S, Madgewick N, van der Walt M, Mutshembele A, Berkowitz N, Suchard M, McCarthy K; SACCESS network. Sci Total Environ. 2023 Dec 10;903:165817. doi: 10.1016/j.scitotenv.2023.165817. Epub 2023 Jul 26. PMID: 37506905

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S, Wang L, Jiao F, Yu X, Xu W, Huang Z, Li X, Wang Q, Zhu Y, Man Q, Jiang S, Lu L. Emerg Microbes Infect. 2023 Dec;12(1):2178241. doi: 10.1080/22221751.2023.2178241. PMID: 36748716

Safety and efficacy of the intranasal spray SARS-CoV-2 **vaccine** dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu F, Huang S, Liu X, Chen Q, Zhuang C, Zhao H, Han J, Jaen AM, Do TH, Peter JG, Dorado AG, Tirador LS, Zabat GMA, Villalobos REM, Gueco GP, Botha LLG, Iglesias Pertuz SP, Tan J, Zhu K, Quan J, Lin H, Huang Y, Jia J, Chu X, Chen J, Chen Y, Zhang T, Su Y, Li C, Ye X, Wu T, Zhang J, Xia N; COVID-19-PRO-003 Study Team. Lancet Respir Med. 2023 Dec;11(12):1075-1088. doi: 10.1016/S2213-2600(23)00349-1. Epub 2023 Nov 15. PMID: 37979588

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.
Nantanee R, Jaru-Ampornpan P, Chantasrisawad N, Himananto O, Papakhee S, Sophonphan J, Tawan M, Jupimai T, Anugulruengkitt S, Puthanakit T; Study Team. Vaccine X. 2023 Aug 5;15:100367. doi: 10.1016/j.jvacx.2023.100367. eCollection 2023 Dec. PMID: 37601322

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness.
John OO, Olabode ON, Lucero-Prisno Iii DE, Adebimpe OT, Singh A. J Taibah Univ Med Sci. 2023 Dec;18(6):1285-1287. doi: 10.1016/j.jtumed.2023.05.013. Epub 2023 May 23. PMID: 37250814

Mixture modelling of *Bordetella pertussis* serology samples to evaluate anti-pertussis toxin immunoglobulin G titre thresholds for positivity: England 2008-2022.
Tessier E, Litt D, Ribeiro S, Abdul Aziz N, Campbell H, Amirthalingam G, Fry NK, Andrews N. J Med Microbiol. 2023 Dec;72(12). doi: 10.1099/jmm.0.001774. PMID: 38047762

SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M, Penfold RS, Canas LDS, Sudre C, Rjoob K, Murray B, Molteni E, Kerfoot E, Cheetham N, Pujol JC, Polidori L, May A, Wolf J, Modat M, Spector T, Hammers A, Ourselin S, Steves C. J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28. PMID: 37777159

Effectiveness of influenza vaccination against coronavirus disease (**COVID**)-**19** outcomes in hospitalized individuals in Brazil: an epidemiological study.
Sansone NMS, Boschiero MN, Darrieux M, Marson FAL. Public Health. 2023 Dec;225:8-11. doi: 10.1016/j.puhe.2023.09.015. Epub 2023 Oct 30. PMID: 37913610

Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study.
Trevisan C, Haxhiaj L, Malara A, Abbatecola A, Fedele G, Palmieri A, Leone P, Schiavoni I, Stefanelli P, Maggi S, Sergi G, Volpato S, Incalzi RA, Onder G; GeroCovid Vax Working Group. Drugs Aging. 2023 Dec;40(12):1133-1141. doi: 10.1007/s40266-023-01075-9. Epub 2023 Nov 8. PMID: 37938521

"Messengers matter": Assessing the impact of racially concordant care on **vaccine** hesitation.
Anderson A. Soc Sci Med. 2023 Dec;338:116335. doi: 10.1016/j.socscimed.2023.116335. Epub 2023 Oct 19. PMID: 37913746

Up the Nose and Down the Windpipe May Be the Path to New and Improved **COVID-19 Vaccines**.
Rubin R. JAMA. 2023 Dec 6. doi: 10.1001/jama.2023.0644. Online ahead of print. PMID: 38055302

Third dose of **COVID-19 vaccine**: is there any place for it for pregnant women?
Sookaromdee P, Wiwanitkit V. J Turk Ger Gynecol Assoc. 2023 Dec 6;24(4):289-290. doi: 10.4274/jtgga.galenos.2023.2023-3-4. PMID: 38054496

VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis.
Rizvi F, Lee YR, Diaz-Aragon R, Bawa PS, So J, Florentino RM, Wu S, Sarjoo A, Truong E, Smith AR, Wang F, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A,

Shin D, Gouon-Evans V. Cell Stem Cell. 2023 Dec 7;30(12):1640-1657.e8. doi: 10.1016/j.stem.2023.10.008. Epub 2023 Nov 28. PMID: 38029740

The systemic impact of different **COVID-19 vaccines** in 2-[18F] FDG-PET/CT.
Nazerani-Zemann T, Pernthaler B, Schwantzer G, Gstettner C. Sci Rep. 2023 Dec 9;13(1):21838. doi: 10.1038/s41598-023-49376-8. PMID: 38071353

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM, Marchi S, Leonardi M, Coppola C, Benincasa L, Marotta MG, Buonvino N, Maes P, Stufano A, Pontrelli D, Vasinioti VI, Manenti A, Camero M, Montomoli E, Decaro N, Lovreglio P. Acta Trop. 2023 Dec;248:107042. doi: 10.1016/j.actatropica.2023.107042. Epub 2023 Oct 18. PMID: 37863379

Routine childhood vaccination among ethnocultural groups in Canada during the **COVID-19** pandemic: A national cross-sectional study.
Humble RM, Dubé E, Olson J, Scott SD, MacDonald SE. Prev Med Rep. 2023 Sep 25;36:102435. doi: 10.1016/j.pmedr.2023.102435. eCollection 2023 Dec. PMID: 37822977

Avoidance of Interpersonal Discussions About the **COVID-19** Vaccination: Applying the Theory of Motivated Information Management.
Link E. Health Commun. 2023 Dec;38(13):2843-2853. doi: 10.1080/10410236.2022.2124055. Epub 2022 Sep 16. PMID: 36111750

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector.
Liang Z, Wu X, Wu J, Liu S, Tong J, Li T, Yu Y, Zhang L, Zhao C, Lu Q, Qin H, Nie J, Huang W, Wang Y. Emerg Microbes Infect. 2023 Dec;12(2):e2261566. doi: 10.1080/22221751.2023.2261566. Epub 2023 Sep 28. PMID: 37727107

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.
Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Igarashi K, Ariyasu M. Vaccine X. 2023 Sep 18;15:100390. doi: 10.1016/j.jvacx.2023.100390. eCollection 2023 Dec. PMID: 37822891

A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
Kim DG, Kim U, Park IH, Ryu B, Yoo Y, Cha JS, Yoon GY, Kim SH, Oh H, Seo JY, Nam KT, Seong JK, Shin JS, Cho HS, Kim HS. Antiviral Res. 2023 Dec;220:105738. doi: 10.1016/j.antiviral.2023.105738. Epub 2023 Nov 8. PMID: 37944822

A panty rosea-like eruption following the second Pfizer-BioNTech **COVID-19 vaccine** administration dose in a pediatric patient.
Russo A, Benati M, Roncati L, Zengarini C, Neri I. Ital J Dermatol Venerol. 2023 Dec;158(6):497-498. doi: 10.23736/S2784-8671.23.07673-9. Epub 2023 Sep 18. PMID: 37721776

Stability of polymeric cationic niosomes and their plasmid DNA-based complexes as gene delivery carriers.
Mashal M, Attia N, Grijalvo S, Eritja R, Puras G, Pedraz JL. Drug Deliv. 2023 Dec;30(1):2219420. doi: 10.1080/10717544.2023.2219420. PMID: 37322900

Nonarteritic Anterior Ischemic Optic Neuropathy Associated With **COVID-19** Vaccination.
Nachbor KM, Naravane AV, Adams OE, Abel AS. J Neuroophthalmol. 2023 Dec 1;43(4):e111-e113. doi: 10.1097/WNO.0000000000001423. Epub 2021 Dec 16. PMID: 34924538

Reply: Increased risk of fetal loss after **COVID-19** vaccination.
Al Wattar BH, Teh JJ, Mackenzie SC, Rimmer MP. Hum Reprod. 2023 Dec 4;38(12):2536-2537. doi: 10.1093/humrep/dead203. PMID: 37823795

To boost or not to boost: navigating post-pandemic **COVID-19** vaccination.
Goldberg Y, Huppert A. Lancet Respir Med. 2023 Dec;11(12):1039-1041. doi: 10.1016/S2213-2600(23)00350-8. Epub 2023 Oct 25. PMID: 37898149

Lack of influence of social media on **vaccine** decision-making by university students in Ireland.
Moore LE, Vucen S, Moore AC. Hum Vaccin Immunother. 2023 Dec 15;19(3):2287279. doi: 10.1080/21645515.2023.2287279. Epub 2023 Dec 1. PMID: 38038598

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y, Zou J, Kurhade C, Deng X, Chang HC, Kim DK, Shi PY, Ren P, Xie X. Emerg Microbes Infect. 2023 Dec;12(2):2271089. doi: 10.1080/22221751.2023.2271089. Epub 2023 Oct 26. PMID: 37824708

Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021.
Mögling R, Reimerink J, Stanoeva KR, Keramarou M, Guiomar R, Costa I, Haveri A, Holzer B, Korukluoğlu G, Nguyen T, Pakarna G, Pancer K, Trilar KP, Protic J, Stojanović M, De Santis R, Lista F, Vremera T, Leustean M, Pistol A, Zelena H, Reusken C, Broberg EK. J Virol Methods. 2023 Dec;322:114825. doi: 10.1016/j.jviromet.2023.114825. Epub 2023 Sep 29. PMID: 37778539

A single immunization with core-shell structured lipopolyplex mRNA **vaccine** against rabies induces potent humoral immunity in mice and dogs.
Wan J, Yang J, Wang Z, Shen R, Zhang C, Wu Y, Zhou M, Chen H, Fu ZF, Sun H, Yi Y, Shen H, Li H, Zhao L. Emerg Microbes Infect. 2023 Dec;12(2):2270081. doi: 10.1080/22221751.2023.2270081. Epub 2023 Nov 22. PMID: 37819147

Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S **vaccine**.
Schmidt KG, Harrer EG, Schönau V, Simon D, Kleyer A, Steininger P, Korn K, Schett G, Knobloch CS, Nganou-Makamdop K, Harrer T. Infection. 2023 Dec;51(6):1657-1667. doi: 10.1007/s15010-023-02035-6. Epub 2023 Apr 17. PMID: 37067754

A booster of Delta-Omicron RBD-dimer protein subunit **vaccine** augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5.
Duan M, Duan H, An Y, Zheng T, Wan S, Wang H, Zhao X, Dai L, Xu K, Gao GF. Emerg Microbes Infect. 2023 Dec;12(1):e2179357. doi: 10.1080/22221751.2023.2179357. PMID: 36803449

For-Profit Businesses as Public Health Partners to Promote **COVID-19** Vaccination: A Multiple Case Study.

McHugh M, Harris A, Maechling CR, Holl JL. J Occup Environ Med. 2023 Dec 1;65(12):1003-1007. doi: 10.1097/JOM.0000000000002939. Epub 2023 Aug 14. PMID: 37590376

Repurposing antibiotics as potent multi-drug candidates for SARS-CoV-2 delta and omicron variants: molecular docking and dynamics.
Serseg T, Linani A, Benarous K, Goumri-Said S. J Biomol Struct Dyn. 2023 Dec;41(20):10377-10387. doi: 10.1080/07391102.2022.2157876. Epub 2022 Dec 21. PMID: 36541102

Solitary Eruptive Keratoacanthoma Developing at Site of **COVID-19 Vaccine** Injection.
Yumeen S, Robinson-Bostom L, Firoz EF. R I Med J (2013). 2023 Dec 1;106(11):49-51. PMID: 38015786

The booster dose of BNT162b2 mRNA **vaccine** in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors.
Majcherek M, Matkowska-Kocjan A, Szymczak D, Karasek M, Przeorski K, Szeremet A, Kiraga A, Milanowska A, Kuznik E, Kujawa K, Wrobel T, Szenborn L, Czyz A. Acta Oncol. 2023 Dec;62(12):1939-1941. doi: 10.1080/0284186X.2023.2254923. Epub 2023 Sep 5. PMID: 37669166

Effectiveness of BNT162b2 and CoronaVac **vaccines** in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.
Yan VKC, Cheng FWT, Chui CSL, Lai FTT, Wong CKH, Li X, Wan EYF, Wong JSC, Chan EWY, Wong ICK, Kwan MYW, Ip P. Emerg Microbes Infect. 2023 Dec;12(1):2185455. doi: 10.1080/22221751.2023.2185455. PMID: 36852582

Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study.
Lund LC, Rahbek MT, Brown P, Obel N, Hallas J, Frederiksen H. Eur J Haematol. 2023 Dec;111(6):946-950. doi: 10.1111/ejh.14108. Epub 2023 Sep 22. PMID: 37740535

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate **vaccines**.
Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Skull SA, Oguoma VM, Chatfield M, Lehmann D, Binks MJ, Licciardi PV, Andrews R, Snelling T, Krause V, Carapetis J, Chang AB, Morris PS. Int J Pediatr Otorhinolaryngol. 2023 Dec;175:111776. doi: 10.1016/j.ijporl.2023.111776. Epub 2023 Nov 6. PMID: 37951020

Secondary household transmission of SARS-CoV-2: a case-control study on factors associated with reduced transmission risk.
Inaba M, Miyake Y, Yasuda K. Int J Infect Dis. 2023 Dec;137:4-8. doi: 10.1016/j.ijid.2023.09.019. Epub 2023 Oct 1. PMID: 37788740

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L, Grubbs G, Sait S, Yonker LM, Randolph AG, Novak T, Kobayashi T; Overcoming COVID−19 Investigators; Khurana S. Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y. PMID: 38040697

[Vaccination in old age: an overview].
Kwetkat A, Leischker A, Endres AS, Heppner HJ. Z Gerontol Geriatr. 2023 Dec;56(8):679-687. doi: 10.1007/s00391-023-02265-1. Epub 2023 Dec 5. PMID: 38051357

The Potential of Anti-coronavirus Plant Secondary Metabolites in **COVID-19** Drug Discovery as an Alternative to Repurposed Drugs: A Review.
Alipour Z, Zarezadeh S, Ghotbi-Ravandi AA. Planta Med. 2023 Dec 7. doi: 10.1055/a-2209-6357. Online ahead of print. PMID: 37956978

Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates.
Schramm CA, Moon D, Peyton L, Lima NS, Wake C, Boswell KL, Henry AR, Laboune F, Ambrozak D, Darko SW, Teng IT, Foulds KE, Carfi A, Edwards DK, Kwong PD, Koup RA, Seder RA, Douek DC. Nat Commun. 2023 Dec 2;14(1):7961. doi: 10.1038/s41467-023-43420-x. PMID: 38042809

Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.
Shamabadi NS, Bagasra AB, Pawar S, Bagasra O. Libyan J Med. 2023 Dec;18(1):2209949. doi: 10.1080/19932820.2023.2209949. PMID: 37186902

Therapy challenges for NMOSD in a patient with HIV.
Engels D, Havla J, Förderreuther S, Kümpfel T. Mult Scler. 2023 Dec;29(14):1872-1875. doi: 10.1177/13524585231199022. Epub 2023 Sep 15. PMID: 37712413

Online on the frontline: A longitudinal social media analysis of UK healthcare workers' attitudes to **COVID-19 vaccines** using the 5C framework.
Déom N, Vanderslott S, Kingori P, Martin S. Soc Sci Med. 2023 Dec;339:116313. doi: 10.1016/j.socscimed.2023.116313. Epub 2023 Oct 18. PMID: 37984178

Different roles of interpersonal trust and institutional trust in motivating older adults to receive **COVID-19 vaccines** in Singapore.
Yuan Y, Yeo SY, Lee KS. Soc Sci Med. 2023 Dec 2;340:116475. doi: 10.1016/j.socscimed.2023.116475. Online ahead of print. PMID: 38064820

A severe relapse of pemphigus vulgaris after SARS-CoV-2 vaccination.
Ligrone L, Lembo S, Cillo F, Spennato S, Fabbrocini G, Raimondo A. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1369-e1371. doi: 10.1111/jdv.19414. Epub 2023 Aug 19. PMID: 37561928

In silico evidences of Mpro inhibition by a series of organochalcogen-AZT derivatives and their safety in Caenorhabditis elegans.
Viçozzi GP, de Oliveira Pereira FS, da Silva RS, Leal JG, Sarturi JM, Nogara PA, Rodrigues OED, Teixeira da Rocha JB, Ávila DS. J Trace Elem Med Biol. 2023 Dec;80:127297. doi: 10.1016/j.jtemb.2023.127297. Epub 2023 Sep 1. PMID: 37716209

Analysis of participant-reported adverse events following the first dose of inactivated SARS-Cov-2 **vaccine** (TURKOVAC™) through telephone survey in Türkiye.

Kara A, Coskun A, Temel F, Özelci P, Topal S, Ateş I. Ann Med. 2023 Dec;55(1):1070-1079. doi: 10.1080/07853890.2023.2183985. PMID: 36908270

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year **COVID-19** convalescents regardless of vaccination.
Wang M, Zhou B, Fan Q, Zhou X, Liao X, Lin J, Ma Z, Dong J, Wang H, Ge X, Ju B, Zhang Z. Emerg Microbes Infect. 2023 Dec;12(1):2151381. doi: 10.1080/22221751.2022.2151381. PMID: 36444724

Shared health governance, mutual collective accountability, and transparency in COVAX: A qualitative study triangulating data from document sampling and key informant interviews.
Gorodensky A, Grundy Q, Persaud N, Kohler JC. J Glob Health. 2023 Dec 8;13:04165. doi: 10.7189/jogh.13.04165. PMID: 38063440

Relative age and persistence of ADHD diagnosis in young children.
Wong ICK. Lancet Psychiatry. 2023 Dec;10(12):910-911. doi: 10.1016/S2215-0366(23)00334-6. Epub 2023 Oct 25. PMID: 37898141

Designing Cell Delivery Peptides and SARS-CoV-2-Targeting Small Interfering RNAs: A Comprehensive Bioinformatics Study with Generative Adversarial Network-Based Peptide Design and *In Vitro* Assays.
González RD, Simões S, Ferreira L, Carvalho ATP. Mol Pharm. 2023 Dec 4;20(12):6079-6089. doi: 10.1021/acs.molpharmaceut.3c00444. Epub 2023 Nov 8. PMID: 37941379

Operational strategies to deal with the **COVID-19** emergency: recommendations from the Italian national society SIAGASCOT following the introduction of **vaccines** against the SARS-CoV-2 infection.
Compagnoni R, Cucchi D, Klumpp R, Ronga M, Berruto M, Di Giacomo G, Randelli PS; SIAGASCOT "Guidelines" Work-group. Musculoskelet Surg. 2023 Dec;107(4):471-479. doi: 10.1007/s12306-023-00796-9. Epub 2023 Sep 2. PMID: 37658981

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 **vaccine** by single-cell RNA sequencing.
Tong R, Luo L, Zhao Y, Sun M, Li R, Zhong J, Chen Y, Hu L, Li Z, Shi J, Lyu Y, Hu L, Guo X, Liu Q, Shuang T, Zhang C, Yuan A, Sun L, Zhang Z, Qian K, Chen L, Lin W, Chen AF, Wang F, Pu J. Emerg Microbes Infect. 2023 Dec;12(1):e2187245. doi: 10.1080/22221751.2023.2187245. PMID: 36987861

IgA Vasculitis following AstraZeneca/Oxford **COVID-19**, case report.
Alzoabi N, Alqahtani J, Algamdi B, Alghamdi N, Ahmad A, Alkaltham G, Beidas T, Alakloby O. Acta Biomed. 2023 Dec 5;94(6):e2023074. doi: 10.23750/abm.v94i6.12959. PMID: 38054690

Psychopharmacology in children and adolescents: unmet needs and opportunities.
Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Correll CU, Grünblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Roessner V, Santosh P, Simonoff E, Stevanovic D, Stringaris A, Vitiello B, Walitza S, Weizman A, Wong ICK, Zalsman G, Zuddas A, Carucci S, Butlen-Ducuing F, Tome M, Bea M, Getin C, Hovén N, Konradsson-Geuken A, Lamirell D, Olisa N, Nafria Escalera B, Moreno C. Lancet Psychiatry. 2023 Dec 7:S2215-0366(23)00345-0. doi: 10.1016/S2215-0366(23)00345-0. Online ahead of print. PMID: 38071998

Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
Hsieh HC, Chen CC, Chou PH, Liu WC, Wu SC. Antiviral Res. 2023 Dec;220:105752. doi: 10.1016/j.antiviral.2023.105752. Epub 2023 Nov 8. PMID: 37949318

Bridging upstream and downstream for improved adenovirus 5 bioprocess.
Petrović Koshmak I, Jug H, Vrabec K, Mavri A, Novak V, Dekleva P, Fujs V, Leskovec M, Štrancar A. Electrophoresis. 2023 Dec 7. doi: 10.1002/elps.202300131. Online ahead of print. PMID: 38059740

Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
Quan J, Markovinović A, Hracs L, Ma C, Panaccione R, Kaplan GG; STOP COVID-19 in IBD Research Group. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1074-1075. doi: 10.1016/S2468-1253(23)00310-2. Epub 2023 Oct 6. PMID: 37813111

Impact of household decision makers' hesitancy to vaccinate children against **COVID-19** on other household members: A family-based study in Taizhou, China.
Deng JS, Ying CQ, Lin XQ, Huang CL, Zhang MX, Tung TH, Zhu JS. SSM Popul Health. 2023 Sep 21;24:101517. doi: 10.1016/j.ssmph.2023.101517. eCollection 2023 Dec. PMID: 37767519

Case Series: Atypical Optic Neuritis After **COVID-19** Vaccination.
Tugizova M, Siegel DT, Huang S, Su E, Subramanian PS, Beres S, Vora N. J Neuroophthalmol. 2023 Dec 1;43(4):e120-e122. doi: 10.1097/WNO.0000000000001519. Epub 2022 Jan 10. PMID: 35020705

Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR.
Lu S, Luo S, Liu C, Li M, An X, Li M, Hou J, Fan H, Mao P, Tong Y, Song L. Emerg Microbes Infect. 2023 Dec;12(1):2151383. doi: 10.1080/22221751.2022.2151383. PMID: 36453209

A real-world study on the effectiveness of BBIBP-CorV and CoronaVac in Nanjing area.
Huang M, Jia L, Ye S, Pang R, Ma C, Zhang J, Dai S, Zhang K, Dai Y, Fu Q, Zhang L. Sci Rep. 2023 Dec 6;13(1):21533. doi: 10.1038/s41598-023-48989-3. PMID: 38057587

Comparison of the Serial Humoral Immune Response according to the Immunosuppressive Treatment after SARS-CoV-2 mRNA Vaccination.
Menjo H, Hasegawa M, Fujigaki H, Ishihara T, Minatoguchi S, Koide S, Hayashi H, Saito M, Takahashi K, Ito H, Yuzawa Y, Saito K, Tsuboi N. Intern Med. 2023 Dec 1;62(23):3445-3454. doi: 10.2169/internalmedicine.1949-23. Epub 2023 Sep 29. PMID: 37779074

Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects.
Chen J, Xu Y, Zhou M, Xu S, Varley AJ, Golubovic A, Lu RXZ, Wang KC, Yeganeh M, Vosoughi D, Li B. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2309472120. doi: 10.1073/pnas.2309472120. Epub 2023 Dec 7. PMID: 38060560

If Long-Term Suppression is not Possible, how do we Minimize Mortality for Infectious Disease Outbreaks?
Handel A, Miller JC, Ge Y, Fung IC. Disaster Med Public Health Prep. 2023 Dec 1;17:e547. doi: 10.1017/dmp.2023.203. PMID: 38037811

Identification of a novel inhibitor of SARS-CoV-2 main protease: an in silico, biochemical, and cell-based approach.
Trivedi A, Kardam V, Inampudi KK, Vrati S, Gupta D, Singh A, Kayampeta SR, Appaiahgari MB, Sehgal D. FEBS J. 2023 Dec;290(23):5496-5513. doi: 10.1111/febs.16947. Epub 2023 Sep 10. PMID: 37657928

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection.
Bingula R, Chabrolles H, Bonnet B, Archimbaud C, Brebion A, Cosme J, Ollier A, Dutheil F, Junda M, Mirand A, Regagnon C, Vidal M, Henquell C, Evrard B. Emerg Microbes Infect. 2023 Dec;12(1):2184176. doi: 10.1080/22221751.2023.2184176. PMID: 36848040

Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey.
Hussein I, Vänskä S, Sivelä J, Leino T, Nohynek H. Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2200828. PMID: 38062946

Correspondence on Bell's palsy as an adverse event following **COVID-19** vaccination.
Kleebayoon A, Wiwanitkit V. Acta Neurol Belg. 2023 Dec;123(6):2405. doi: 10.1007/s13760-023-02217-x. Epub 2023 Mar 3. PMID: 36867347

Effective measures to improve influenza vaccination coverage among healthcare workers during and after **COVID-19**.
Jia W, Zhang X, Sun R, Li P, Wang D, Song C. Hum Vaccin Immunother. 2023 Dec 15;19(3):2289243. doi: 10.1080/21645515.2023.2289243. Epub 2023 Dec 6. PMID: 38053367

Immunodominant conserved moieties on spike protein of SARS-CoV-2 renders virulence factor for the design of epitope-based peptide **vaccines**.
Mohapatra S, Kumar S, Kumar S, Singh AK, Nayak B. Virusdisease. 2023 Dec;34(4):456-482. doi: 10.1007/s13337-023-00852-9. Epub 2023 Nov 23. PMID: 38046066

Association of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Coronavirus Disease 2019 Vaccination and Infection: A Case Report of Cortical Encephalitis and Transverse Myelitis Relapse.
Himeno Y, Tateishi T, Irie KI, Ueno S, Morimitsu M, Mizoguchi S, Koga T, Taniwaki T. Intern Med. 2023 Dec 1;62(23):3549-3554. doi: 10.2169/internalmedicine.2471-23. Epub 2023 Sep 22. PMID: 37743511

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination[1].
Wang H, Xue Q, Zhang H, Yuan G, Wang X, Sheng K, Li C, Cai J, Sun Y, Zhao J, Lu J, Fang S, Yang Y, Zhang Y, Huang Y, Wang J, Xu JH, Jiang MX, Wang X, Shen L, Liu Y, Liu Q, Zhang Q, Wang S, Wang P, Qiu C, Ai J, Zhang W. Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5. PMID: 37668156

Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study.
Hormazábal J, Nuñez-Franz L, Rubilar P, Apablaza M, Vial C, Cortés LJ, González N, Vial P, Said M, González C, Olivares K, Aguilera X, Ramírez-Santana M. Vaccine X. 2023 Aug 26;15:100372. doi: 10.1016/j.jvacx.2023.100372. eCollection 2023 Dec. PMID: 37693843

SARS-CoV-2 mucosal **vaccine** protects against clinical disease with sex bias in efficacy.
Sui Y, Andersen H, Li J, Hoang T, Minai M, Nagata BM, Bock KW, Alves DA, Lewis MG, Berzofsky JA. Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.11.059. Online ahead of print. PMID: 38071106

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants.
de La Vega MA, Polychronopoulou E, Xiii A, Ding Z, Chen T, Liu Q, Lan J, Nepveu-Traversy ME, Fausther-Bovendo H, Zaidan MF, Wong G, Sharma G, Kobinger GP. Emerg Microbes Infect. 2023 Dec;12(1):e2169198. doi: 10.1080/22221751.2023.2169198. PMID: 36655944

[Vaccinations as a key to pandemic management - Lessons learned from the **COVID-19** pandemic].
Le NH, Hillus D, Tober-Lau P, Sander LE. Dtsch Med Wochenschr. 2023 Dec;148(24-25):1557-1563. doi: 10.1055/a-2124-2366. Epub 2023 Dec 5. PMID: 38052219

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
Proschmann U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, Haase R, Dillenseger A, Dunsche M, Atta Y, Ziemssen T, Akgün K. Mult Scler. 2023 Dec;29(14):1849-1859. doi: 10.1177/13524585231200719. Epub 2023 Sep 30. PMID: 37776101

Immune thrombocytopenic purpura in an elderly patient with cerebral hemorrhage after the fourth mRNA-1273 **COVID-19** vaccination.
Kobayashi M, Kobayashi S, Hayashi T, Tachibana M, Saito T, Ogura K, Miyakoshi S. Geriatr Gerontol Int. 2023 Dec;23(12):969-970. doi: 10.1111/ggi.14737. Epub 2023 Nov 15. PMID: 37967853

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.
Zhang C, Liu J, Sui Y, Liu S, Yang M. Sci Rep. 2023 Dec 4;13(1):21404. doi: 10.1038/s41598-023-48398-6. PMID: 38049492

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or **vaccine** antigen.
Wang X, Sun L, Liu Z, Xing L, Zhu Y, Xu W, Xia S, Lu L, Jiang S. Emerg Microbes Infect. 2023 Dec;12(2):2244084. doi: 10.1080/22221751.2023.2244084. PMID: 37534910

A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect *vs.* **COVID-19** related immunization complications.
Esechie A, Fang X, Banerjee P, Rai P, Thottempudi N. Int J Neurosci. 2023 Dec;133(10):1120-1123. doi: 10.1080/00207454.2022.2050907. Epub 2022 Apr 3. PMID: 35369847

Axillary lymph nodes enlargement after Sars-CoV-2 **vaccine** in patients undergoing breast examination: comment.
Kleebayoon A, Wiwanitkit V. Radiol Med. 2023 Dec;128(12):1593-1594. doi: 10.1007/s11547-023-01737-z. Epub 2023 Nov 14. PMID: 37962776

T-cell lymphopenia in frequent volunteer platelet donors.
Kaufman RM. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):305-310. doi: 10.1182/hematology.2023000484. PMID: 38066852

Effectiveness of VSV vectored SARS-CoV-2 spike when administered through intranasal, intramuscular or a combination of both.
Beitari S, Agbayani G, Hewitt M, Duque D, Bavananthasivam J, Sandhu JK, Akache B, Hadžisejdić I, Tran A. Sci Rep. 2023 Dec 4;13(1):21390. doi: 10.1038/s41598-023-48397-7. PMID: 38049498

The Health Justice Policy Tracker: **COVID-19** Policies To Advance Health Justice For Vulnerable Populations.
Manoj M, Truong PP, Shiffman J, Shawar YR. Health Aff (Millwood). 2023 Dec;42(12):1689-1696. doi: 10.1377/hlthaff.2023.00704. PMID: 38048505

Response to: Correspondence on Bell's palsy as an adverse event following **COVID-19** vaccination.
Kim S, Kang M, Park JS, Seok HY. Acta Neurol Belg. 2023 Dec;123(6):2417-2418. doi: 10.1007/s13760-023-02245-7. Epub 2023 Mar 20. PMID: 36940060

Immunization of children with inflammatory bowel disease against SARS-CoV-**19** infection: A prospective single centre cohort study.
Dohos D, Karoliny A, Gombos E, Rimanóczy É, Müller KE. Vaccine X. 2023 Aug 19;15:100374. doi: 10.1016/j.jvacx.2023.100374. eCollection 2023 Dec. PMID: 37822890

Are bivalent **vaccines** better than ancestral-virus monovalent **vaccines** in protecting against severe omicron **COVID-19**?
Madhi SA, Feikin DR. Lancet Infect Dis. 2023 Dec;23(12):1325-1327. doi: 10.1016/S1473-3099(23)00425-5. Epub 2023 Jul 18. PMID: 37478878

Equity Work Among Accredited Health Departments in the United States, 2015-2021.
Lang B, Kronstadt J, Rich N. Public Health Rep. 2023 Dec 3:333549231210033. doi: 10.1177/00333549231210033. Online ahead of print. PMID: 38044683

Myelin Oligodendrocyte Glycoprotein Antibody-Mediated Optic Neuritis Following **COVID-19** Vaccination.
Donaldson LC, Margolin EA. J Neuroophthalmol. 2023 Dec 1;43(4):e123-e125. doi: 10.1097/WNO.0000000000001482. Epub 2022 Feb 28. PMID: 35234675

A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study.
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Collaro AJ, Chalmers JD, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, Grimwood K. Lancet Respir Med. 2023 Dec 6:S2213-2600(23)00233-3. doi: 10.1016/S2213-2600(23)00233-3. Online ahead of print. PMID: 38070531

Inferring mechanical properties of the SARS-CoV-2 virus particle with nano-indentation tests and numerical simulations.
Nonn A, Kiss B, Pezeshkian W, Tancogne-Dejean T, Cerrone A, Kellermayer M, Bai Y, Li W, Wierzbicki T. J Mech Behav Biomed Mater. 2023 Dec;148:106153. doi: 10.1016/j.jmbbm.2023.106153. Epub 2023 Oct 8. PMID: 37865016

Optimized Biomimetic Minerals Maintain Activity of mRNA Complexes after Long Term Storage.
Choe JA, Brinkman HM, Lee JS, Murphy WL. Acta Biomater. 2023 Dec 5:S1742-7061(23)00703-1. doi: 10.1016/j.actbio.2023.11.044. Online ahead of print. PMID: 38061679

Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus **Vaccine** (COVAX) physician-reported registry" by Machado *et al*.
Bourguiba R, Delplanque M, Savey L, Hentgen V, Grateau G, Georgin-Lavialle S; French national reference Center for autoinflammatory diseases and AA amyloidosis (CEREMAIA). Ann Rheum Dis. 2023 Dec;82(12):e228. doi: 10.1136/annrheumdis-2022-222118. Epub 2022 Jul 11. PMID: 35817471

The valley of death: why Australia failed to develop clinically effective drugs in **COVID-19**.
Martin JH. Intern Med J. 2023 Dec 5. doi: 10.1111/imj.16260. Online ahead of print. PMID: 38050949

An *in vitro* experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody.
Atanasoff KE, Brambilla L, Adelsberg DC, Kowdle S, Stevens CS, Slamanig S, Hung C-T, Fu Y, Lim R, Tran L, Allen R, Sun W, Duty JA, Bajic G, Lee B, Tortorella D. mBio. 2023 Dec 6:e0247723. doi: 10.1128/mbio.02477-23. Online ahead of print. PMID: 38054729

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Suryawanshi RK, Taha TY, McCavitt-Malvido M, Silva I, Khalid MM, Syed AM, Chen IP, Saldhi P, Sreekumar B, Montano M, Foresythe K, Tabata T, Kumar GR, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Kojima N, Arellanor T, Bussanich A, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Wang Y, Ghazarian S, Davis G, Rodriguez D, Doudna J, Spraggon L, Chiu CY, Ott M. Emerg Microbes Infect. 2023 Dec;12(2):2270071. doi: 10.1080/22221751.2023.2270071. Epub 2023 Oct 31. PMID: 37869789

Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian **covid** pandemic.
Galli E, Di Rocco A, Pansini I, Frondizi F, Di Palma M, Metafuni E, Piccirillo N, Bianchi M, Cingolani A, Torelli GF, Hohaus S, Chiusolo P, Iori AP, Sica S, Martelli M, Sorà F. Bone Marrow Transplant. 2023 Dec;58(12):1394-1396. doi: 10.1038/s41409-023-02093-2. Epub 2023 Sep 4. PMID: 37666956

SARS-CoV-2 Vaccination can Only Be Held Responsible for Small Fiber Neuropathy if all Differential Diagnoses Are Excluded.
Finsterer J. J Clin Neuromuscul Dis. 2023 Dec 1;25(2):63-64. doi: 10.1097/CND.0000000000000447. PMID: 37962192

Application of "B+1" heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus **vaccines**.

Liu Z, Lu L, Jiang S. Emerg Microbes Infect. 2023 Dec;12(1):2192817. doi: 10.1080/22221751.2023.2192817. PMID: 36927258

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 **vaccine** trial.
Hejazi NS, Shen X, Carpp LN, Benkeser D, Follmann D, Janes HE, Baden LR, El Sahly HM, Deng W, Zhou H, Leav B, Montefiori DC, Gilbert PB. Int J Infect Dis. 2023 Dec;137:28-39. doi: 10.1016/j.ijid.2023.09.012. Epub 2023 Oct 25. PMID: 37820782

Phenotypic Features of Pediatric Bronchiectasis Exacerbations Associated With Symptom Resolution After 14 Days of Oral Antibiotic Treatment.
Goyal V, Yerkovich ST, Grimwood K, Marchant JM, Byrnes CA, Masters IB, Chang AB. Chest. 2023 Dec;164(6):1378-1386. doi: 10.1016/j.chest.2023.07.002. Epub 2023 Jul 10. PMID: 37437879

Bilateral Ischemic Optic Neuropathy From Giant Cell Arteritis Following **COVID-19** Vaccination.
Che SA, Lee KY, Yoo YJ. J Neuroophthalmol. 2023 Dec 1;43(4):e107-e108. doi: 10.1097/WNO.0000000000001570. Epub 2022 Jun 14. PMID: 36166772

Does the homologous booster with the inactivated coronavirus disease 2019 **vaccine** work for the omicron variant? Real-world evidence from Jilin, China.
Guo J, Zha L, Zeng K, Shao M, Chen D, Wang B, Zhou Y, Yang G, Zhang X, Zou X, Zhang Y, Kang Y. Chin Med J (Engl). 2023 Dec 5;136(23):2892-2894. doi: 10.1097/CM9.0000000000002575. PMID: 37106536

Risk Communication Principles for **COVID-19** Vaccination: Application in China.
Du H, Mao A, Fan J, Du S, Wang X, Qiu W. Disaster Med Public Health Prep. 2023 Dec 5;17:e544. doi: 10.1017/dmp.2023.185. PMID: 38050383

Synbiotics in post-acute **COVID-19** syndrome-a potential new treatment framework?
Raman B, Ramasamy MN. Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735-1. doi: 10.1016/S1473-3099(23)00735-1. Online ahead of print. PMID: 38071991

Reply to comment to "axillary lymph nodes enlargement after Sars-CoV-2 **vaccine** in patients undergoing breast examination: a single-centre experience in 285 women".
Marcon M, Catanese C, Scarano AL, Del Grande F, Manganiello M, Palermo M, Rizzo S. Radiol Med. 2023 Dec;128(12):1595-1596. doi: 10.1007/s11547-023-01738-y. Epub 2023 Oct 31. PMID: 37907674

A case of anti-MDA5 antibody-positive dermatomyositis with severe necrosis on limbs after **COVID-19** vaccination.
Nakanishi M, Mizutani K, Sugioka K, Nishimura M, Habe K, Yamanaka K. J Dermatol. 2023 Dec;50(12):e402-e403. doi: 10.1111/1346-8138.16906. Epub 2023 Jul 24. PMID: 37485592

A case of generalized pustular psoriasis complicated by acute respiratory distress syndrome after **COVID-19** vaccination.
Itami A, Miyagaki T, Mitsuishi S, Horie A, Okano T, Takeuchi S, Ando T, Kadono T. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1366-e1368. doi: 10.1111/jdv.19401. Epub 2023 Aug 19. PMID: 37561536

Dual Effects of 3-*epi*-betulin from *Daphniphyllum glaucescens* in Suppressing SARS-CoV-2-Induced Inflammation and Inhibiting Virus Entry.
Yeh YJ, Chao TL, Chang YJ, Chang SY, Lu CH, Chao CH, Su WC, Tseng CP, Lai MMC, Cheng JC. Int J Mol Sci. 2023 Dec 1;24(23):17040. doi: 10.3390/ijms242317040. PMID: 38069363

Development of Pilomatrixoma at the Vaccination Site: A Rare Complication of **COVID-19** Vaccination - A Case Report.
Yang Z, Song F, Winters L, Zhong J. Am J Case Rep. 2023 Dec 6;24:e942280. doi: 10.12659/AJCR.942280. PMID: 38055654

SARS-CoV-2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently **COVID-19** vaccinations.
Singh K, Misra DP. Int J Rheum Dis. 2023 Dec;26(12):2609-2611. doi: 10.1111/1756-185X.14727. Epub 2023 May 16. PMID: 38041652

Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8$^+$ T cells in persons with previous **COVID-19**.
Ford ES, Mayer-Blackwell K, Jing L, Laing KJ, Sholukh AM, St Germain R, Bossard EL, Xie H, Pulliam TH, Jani S, Selke S, Burrow CJ, McClurkan CL, Wald A, Greninger AL, Holbrook MR, Eaton B, Eudy E, Murphy M, Postnikova E, Robins HS, Elyanow R, Gittelman RM, Ecsedi M, Wilcox E, Chapuis AG, Fiore-Gartland A, Koelle DM. Nat Immunol. 2023 Dec 6. doi: 10.1038/s41590-023-01692-x. Online ahead of print. PMID: 38057617

Genome-based prediction of cross-protective, HLA-DR-presented epitopes as putative **vaccine** antigens for multiple *Bordetella* species.
Natrajan MS, Hall JM, Weigand MR, Peng Y, Williams MM, Momin M, Damron FH, Dubey P, Tondella ML, Pawloski LC. Microbiol Spectr. 2023 Dec 6:e0352723. doi: 10.1128/spectrum.03527-23. Online ahead of print. PMID: 38054724

[Potential Impact of Public Communication on Emergency Presentations due to Headache during the **Covid-19** Pandemic].
Wittayer M, Sandikci V, Ebert A, Koehler C, Szabo K, Hoyer C. Gesundheitswesen. 2023 Dec 8. doi: 10.1055/a-2146-6286. Online ahead of print. PMID: 38065548

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20231201:20231210 as the publication date 43 records*

1.20230390384RECOMBINANT COVID-19 VACCINE COMPOSITION COMPRISING LIPOPEPTIDE AND POLY (I:C) ADJUVANT, AND USE THEREOF
US - 07.12.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18035884 Solicitante CHA VACCINE RESEARCH INSTITUTE CO., LTD Inventor/a Jung Sun Yum
The present invention relates to a recombinant COVID-19 vaccine composition comprising a lipopeptide and a poly(I:C) adjuvant. The vaccine composition for preventing or treating COVID-19, provided in one aspect of the present invention, can greatly induce both a humoral immune response and a cellular

immune response to a recombinant COVID-19 antigen, and thus can be developed as a COVID-19 vaccine so as to be commercially and effectively usable.

2.WO/2023/234407ORAL VACCINE COMPOSITION
WO - 07.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/JP2023/020590 Solicitante KAICO LTD. Inventor/a YAMATO Kenta
An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant baculovirus into which a DNA encoding a porcine circovirus type 2 protein has been introduced and subjected to a freeze-drying treatment.

3.20230390376VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS
US - 07.12.2023
Clasificación Internacional A61K 39/09 Nº de solicitud 18453684 Solicitante Intervet Inc. Inventor/a Antonius Arnoldus Christiaan Jacobs
The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of *Streptococcus suis*, for use in a method for protecting pigs against a pathogenic infection with *Streptococcus suis* by administering the vaccine only once, wherein the vaccine comprises at most 120 µg per dose of the antigen.

4.4284830IMPFSTOFFZUSAMMENSETZUNG ZUM BRECHEN VON SELBSTTOLERANZ
EP - 06.12.2023
Clasificación Internacional C07K 16/24 Nº de solicitud 22703598 Solicitante BAYER ANIMAL HEALTH GMBH Inventor/a ILG THOMAS
The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments. The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

5.4284831IMPFSTOFFZUSAMMENSETZUNG ZUM BRECHEN VON SELBSTTOLERANZ
EP - 06.12.2023
Clasificación Internacional C07K 16/24 Nº de solicitud 22703599 Solicitante BAYER ANIMAL HEALTH GMBH Inventor/a ILG THOMAS
The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines, in particular against the endogenous IL-4, IL-5, IL-13, IL-31 and IL-33 proteins in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments. The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention

provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

6.4286510ORALER IMPFSTOFF GEGEN CORONAVIRUS-INFEKTION
EP - 06.12.2023
Clasificación Internacional C12N 1/21 Nº de solicitud 22745867 Solicitante UNIV KOBE NAT UNIV CORP Inventor/a SHIRAKAWA TOSHIRO
Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.

7.4284424IMPFSTOFFZUSAMMENSETZUNGEN
EP - 06.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 22702778 Solicitante UNIV OXFORD INNOVATION LTD Inventor/a CARLISLE ROBERT
The invention describes vaccine compositions containing particles having a polypeptide shell and a water-immiscible core. The polypeptide shell may comprise one or more pathogenic antigen proteins and/or one or more adjuvant polypeptides. Administration of the composition generates an immune response to the polypeptide contained in the shell. Adjuvant may be comprised in the water-immiscible core of the particle. The particles are therefore useful in methods of vaccination.

8.WO/2023/232901CLOSTRIDIUM DIFFICILE VACCINE
WO - 07.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/EP2023/064602 Solicitante VALNEVA AUSTRIA GMBH Inventor/a LUNDBERG, Urban
The present invention relates to a lipidated immunogenic Clostridium difficile toxin A and toxin B polypeptide, a pharmaceutical composition comprising the immunogenic Clostridium difficile toxin A and/or toxin B polypeptide for use as a medicament, particularly a vaccine and/or for use in a method for the prevention or treatment of C. difficile infection and/or C. difficile-associated disease.

9.WO/2023/235303VACCINE COMPOSITIONS AND USES THEREOF
WO - 07.12.2023
Clasificación Internacional A61K 47/69 Nº de solicitud PCT/US2023/023846 Solicitante THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor/a CHENG, Wei
Provided herein are vaccine compositions and uses thereof. In particular, provided herein are synthetic viral-like structures (sVLSs) based vaccines and the use of such vaccines to prevent infection by a pathogen (e.g., viral pathogen).

10.WO/2023/231250BOVINE PASTEURELLA MULTOCIDA CAPSULAR TYPE A CAPSULAR POLYSACCHARIDE VACCINE AND PREPARATION METHOD THEREFOR
WO - 07.12.2023
Clasificación Internacional A61K 39/102 Nº de solicitud PCT/CN2022/121942 Solicitante JINYUBAOLING BIO-PHARMACEUTICAL CO., LTD. Inventor/a JIN, Yilan
Disclosed are a bovine Pasteurella multocida capsular type A capsular polysaccharide vaccine and a preparation method therefor, and belongs to the technical field of veterinary vaccines. The capsular polysaccharide vaccine provided is prepared from bovine Pasteurella multocida capsular type A capsular

polysaccharide and a vaccine adjuvant made from raw materials including refined Span-80 and refined Tween-80. The capsular polysaccharide vaccine can effectively prevent and control bovine cellulose suppurative pneumonia caused by A-type Pm, has good safety, and can be used for providing a safe and effective protection effect for healthy and susceptible calves, healthy pregnant cows and healthy milk cows.

11.WO/2023/234300MODIFIED VACCINE DESIGN DEVELOPMENTS
WO - 07.12.2023
Clasificación Internacional C12N 15/44 Nº de solicitud PCT/JP2023/020111 Solicitante VLP THERAPEUTICS JAPAN, INC. Inventor/a AKAHATA, Wataru
Provided herein is an isolated polynucleotide, which encodes a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. Also provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. The antigen may be influenza. The polynucleotide such as RNA is useful as a vaccine against influenza infection.

12.20230391833MODIFIED VACCINE DESIGN DEVELOPMENTS
US - 07.12.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 18325281 Solicitante VLP Therapeutics Japan, INC. Inventor/a Wataru AKAHATA
Provided herein is an isolated polynucleotide, which encodes a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. Also provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. The antigen may be influenza. The polynucleotide such as RNA is useful as a vaccine against influenza infection.

13.4284832ANTIGENE POLYPEPTIDE AUS CHLAMYDIA TRACHOMATIS UND DEREN VERWENDUNG FÜR IMPFSTOFFE
EP - 06.12.2023
Clasificación Internacional C07K 16/28 Nº de solicitud 22703597 Solicitante INST NAT SANTE RECH MED Inventor/a LEVY YVES
Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against *Chlamydia trachomatis*. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to *in silico* analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to *Chlamydia trachomatis (Ct)* antigenic polypeptides and uses thereof for vaccine purposes.

14.20230390389Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines
US - 07.12.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18235432 Solicitante The Government of the United States, as Represented by the Secretary of the Army Inventor/a Jay W. HOOPER
A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a

method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and/or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle/syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3β-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically. It was unexpectedly discovered that the level of immunogen, or immune response molecules, produced in vivo is increased (versus administering merely the vaccine or immunotherapy) and, in the case of a vaccine immunogen, the immune response is enhanced.

15.WO/2023/231333WATER-IN-OIL ADJUVANT FOR POULTRY ANIMAL VACCINE, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 07.12.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/134909 Solicitante JINYUBAOLING BIO-PHARMACEUTICAL CO., LTD. Inventor/a LI, Xiaoyan
Provided are a water-in-oil adjuvant for a poultry animal vaccine, a preparation method therefor and use thereof, which belong to the technical field of animal vaccines in the category of biological products. Raw materials of the water-in-oil adjuvant provided herein comprise, by weight in percentage: 85 wt%-90 wt% of oil for injection, 5 wt%-10 wt% of refined Span 80 and 1 wt%-5 wt% of refined Tween 80, and can further comprise 0.1 wt%-1 wt % of an immunostimulatory complex. A vaccine prepared by using the water-in-oil adjuvant provided herein is stable in quality and high in safety, and can induce a body to generate a longer-duration and more efficient immunoreaction, so that the water-in-oil adjuvant can be used as a safe and effective adjuvant for a poultry animal vaccine and the like.

16.4284827ANTIVIRALES THERAPEUTIKUM
EP - 06.12.2023
Clasificación Internacional C07K 16/08 Nº de solicitud 22703040 Solicitante UNIV COLLEGE CARDIFF CONSULTANTS LTD Inventor/a STANTON RICHARD
The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

17.4284423IMPFSTOFF
EP - 06.12.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 21885518 Solicitante YAHALOMI EREZ Inventor/a YAHALOMI EREZ
Methods and systems and architecture for producing cells, virus and bacteria of different sizes and structures by parameters control of temperature or humidity. While these parameters can be constant or time dependent. Said systems may comprising heating elements such as electric heaters and steam generated in boilers, incubating chambers and cooling elements such as cooling towers or ammonia refrigerants.

18.WO/2023/232807IMMUNOGENIC COMPOSITION

WO - 07.12.2023
Clasificación Internacional A61K 39/095 Nº de solicitud PCT/EP2023/064439 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a MARCELLI, Agnese
The present invention relates to an immunogenic composition against *N. meningitidis* serogroup B in liquid form, and to a reconstituted vaccine against *N. meningitidis* serogroups A, B, C, W135, and Y comprising the liquid composition. Kits and methods for the prevention and treatment of meningococcal infection and disease with the immunogenic composition or the reconstituted vaccine are also provided.

19.WO/2023/232815IMMUNOGENIC COMPOSITION
WO - 07.12.2023
Clasificación Internacional A61K 39/095 Nº de solicitud PCT/EP2023/064448 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a MARCELLI, Agnese
The present invention relates to an improved immunogenic composition against N. meningitidis serogroups A, C, W135 and Y in solid form, and to a reconstituted vaccine against N. meningitidis serogroups A, B, C, W135, Y obtained by reconstitution with a liquid immunogenic composition of Men B antigens. Kits and methods for the prevention and treatment of meningococcal infection and disease with the immunogenic composition or the reconstituted vaccine are also provided.

20.WO/2023/235749RNA ADJUVANTS, METHODS AND USES THEREOF
WO - 07.12.2023
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/US2023/067691 Solicitante FLAG BIO, INC. Inventor/a ANDRIANOVA, Ekaterina L.
Provided herein are adjuvants, compositions, and methods for the prevention and treatment of infectious diseases and cancer. Various toll-like receptor (TLR) agonists and RNA encoding TLR agonists are provided herein. The adjuvants provided herein can be complexed with a carrier or formulated with a delivery vehicle for administration to a subject. Further provided are adjuvants that can be delivered with vaccine compositions or as part of a vaccine composition to enhance the innate immune response in a subject.

21.4284421TRANSDERMALER IMPFSTOFF
EP - 06.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 22702777 Solicitante UNIV OXFORD INNOVATION LTD Inventor/a HETTINGA JOHANNA
The invention describes transdermal vaccines which contain ultrasound responsive particles comprising a polypeptide shell. The surface of the particle has one or more indentations which are generally able to entrap a gas bubble. The particles are capable of generating inertial cavitation on exposure to ultrasound. The particles can be delivered transdermally, and can comprise antigen protein and/or adjuvant within the particle structure. The particles are therefore useful in methods of vaccination using transdermal delivery routes.

22.4286002CANINE PARVOVIRUS (CPV)-ÄHNLICHE PARTIKELIMPFSTOFFE UND VERWENDUNGEN DAVON
EP - 06.12.2023
Clasificación Internacional A61P 31/20 Nº de solicitud 23190361 Solicitante BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC Inventor/a DAVID FREDERIC
The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP_2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

23.20230390414PARTICLE BASED FORMULATION OF SARS-COV-2 RECEPTOR BINDING DOMAIN
US - 07.12.2023
Clasificación Internacional A61K 47/69 Nº de solicitud 18247235 Solicitante The Research Foundation for The State University of New York Inventor/a Jonathan Lovell
Provided are vaccine compositions and methods for generation of immune response (including neutralizing antibodies) against SARS-CoV-2 virus. The vaccine compositions comprise a poly-histidine tagged receptor binding domain (RBD) of the SARS-CoV-2 virus incorporated into a liposome comprising cobalt-porphyrin-phospholipid conjugates, such that one or more histidines of the polyhistidine tag are coordinated to the cobalt of the cobalt-porphyrin and at least a portion of the RBD is exposed to the outside of the liposome.

24.20230390379RESPIRATORY SYNCYTIAL VIRUS VACCINE
US - 07.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18314980 Solicitante ModernaTX, Inc. Inventor/a Giuseppe Ciaramella
The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

25.20230391834WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES TARGETING CORONAVIRUSES
US - 07.12.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 18032134 Solicitante President and Fellows of Harvard College Inventor/a Quan Lu
Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles, or WAEVs for presenting SARS-CoV-2 antigen domains, for example the SARS-CoV-2 M protein, the SARS-CoV-2 E protein, or the SARS-CoV-2 S protein. These WAEVs can be harnessed to deliver and present SARS-CoV-2 antigens useful for vaccine development.

26.20230390370NEOANTIGEN VACCINES FOR PANCREATIC CANCER
US - 07.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18328209 Solicitante William Gillanders Inventor/a William Gillanders
The present disclosure is directed to compositions and methods for treating pancreatic cancer. A method of treating pancreatic cancer includes administering a therapeutically effective amount of a composition including a neoantigen vaccine including at least one pancreatic cancer-associated neoantigen and at least one immune checkpoint inhibitor. The methods and compositions of the present disclosure are particularly useful for inducing a neoantigen-specific CD4 or CD8 T cell response against a tumor.

27.20230390373A LIVE STRAIN OF STAPHYLOCOCCUS AUREUS AND USES THEREOF
US - 07.12.2023
Clasificación Internacional A61K 39/085 Nº de solicitud 17927139 Solicitante Versitech Limited Inventor/a Jiandong HUANG
The invention relates to the field of biomedicine. In particular, the invention relates to a live strain of *Staphylococcus aureus* and uses thereof. More particularly, the invention relates to a live strain of *Staphylococcus aureus* which lacks adenosine synthase A (AdsA) activity, to a vaccine against *Staphylococcus aureus* infection comprising said live strain, and a method for preventing and/or treating *Staphylococcus aureus* infection in a subject by administering said live strain.

28.4284418FALTUNGSPROMOTOREN UND IHRE VERWENDUNG ZUR HERSTELLUNG UND STABILISIERUNG VON POLYPEPTIDEN

EP - 06.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 22701406 Solicitante MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WSS Inventor/a GÖRLICH DIRK
The present invention relates to the recombinant production of a protein of interest in a prokaryotic host cell or eukaryotic host cell wherein the protein of interest is obtained in a correctly folded and stable form. The protein of interest may be a difficult-to-make polypeptide for use as a vaccine or a pharmaceutical. The protein of interest is co- expressed with or fused to a 'fold promoter', which may be a VHH antibody recognizing the said protein.

29.20230390378IMMUNOGENIC FORMULATION CONTAINING A MODIFIED BCG STRAIN EXPRESSING AN ANDESVIRUS PROTEIN (ANDV) USEFUL FOR PREVENTING AND TREATING HANTA-ANDV VIRUS INFECTIONS
US - 07.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18247824 Solicitante PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE Inventor/a Alexis KALERGIS PARRA
The invention relates to an immunogenic formulation containing the *bacillus* Calmette-Guerin (BCG) strain in a concentration between 10^4-10^9 bacteria, expressing at least one protein or immunogenic fragment of Andesvirus (ANDV), in a pharmaceutically acceptable saline buffer solution, which serves to prepare a vaccine useful for preventing, treating or attenuating ANDV infections. ANDV belongs to the Hantavirus family and is a highly virulent human pathogen, which annually affects dozens of people in Chile generating in some infected a Hantavirus Cardiopulmonary Syndrome (HCPS).

30.4286009KOMBINATIONSTHERAPIE AUS ONKOLYTISCHEM VACCINIAVIRUS UND CHECKPOINT-INHIBITOR
EP - 06.12.2023
Clasificación Internacional A61P 35/00 Nº de solicitud 23205199 Solicitante SILLAJEN INC Inventor/a KIM CHAN
A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer.

31.WO/2023/235863LIVE-ATTENUATED SARS-COV-2 VACCINE
WO - 07.12.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2023/067862 Solicitante THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor/a WANG, Tony T.
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.

32.20230390382WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES TARGETING HIV
US - 07.12.2023

Clasificación Internacional A61K 39/21 Nº de solicitud 18032140 Solicitante President and Fellows of Harvard College Inventor/a Quan Lu
Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles (WAEVs) for presenting HIV antigen domains. These WAEVs can be harnessed to deliver and present HIV antigens useful for vaccine development. Specifically, the disclosure provides a fusion protein comprising: (a) a WW-containing domain; (b) a transmembrane domain; and (c) an extracellular domain, wherein the extracellular domain is an HIV antigen domain. Further provided are sequences of each domain as well as methods of producing and using the fusion protein.

33.20230390380BACULOVIRUS EXPRESSION VECTOR
US - 07.12.2023
Clasificación Internacional A61K 39/135 Nº de solicitud 18249431 Solicitante Intervet Inc. Inventor/a Erwin VAN DEN BORN
The invention concerns a baculovirus expression vector for recombinantly expressing a Foot-and-mouth disease virus (FMDV) capsid precursor protein under control of a promoter, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein, wherein the ATG start codon of an open reading frame encoding the FMDV capsid precursor protein © is preceded at position −4 to −1 by the nucleic acid sequence 5'-AAAT-3'. The invention further relates to a host cell comprising the baculovirus expression vector, a method of producing FMDV virus-like particles (VLPs), and a method of producing a vaccine.

34.3430027PEPTID TIL ANVENDELSE VED IMMUNTERAPI MOD IKKE-SMÅCELLET LUNGECANCER OG SMÅCELLET LUNGECANCER
DK - 04.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17710904 Solicitante Immatics Biotechnologies GmbH Inventor/a SCHOOR, Oliver
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

35.WO/2023/235771CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS
WO - 07.12.2023
Clasificación Internacional A61K 41/00 Nº de solicitud PCT/US2023/067719 Solicitante THE UNIVERSITY OF CHICAGO Inventor/a ESSER-KAHN, Aaron
The disclosure provides for methods and compositions that can be used for modulating an immune response. Described are methods comprising administering an effective amount of (a) an adjuvant; and (b) one or more of bafetinib (INNO-406), LY3009120, MK-8353 (SCH900353), amodiaquine, zanubrutinib (BGB-3111), Ku55933, Tucidinostat, PD318088, WNK463, and TRx0237 (LMTX) mesylate to a subject. The methods may be for the vaccination of subjects, or for the treatment or prevention of cancer, graft rejection, graft versus host disease, a bacterial infection, or a viral infection in a subject. The method may be for modulating an immune response in vivo, in vitro, or ex vivo. The methods also include immune activation of a population of immune cells in vitro or ex vivo. Also described is a method for identifying the efficacy of an adjuvant, the method comprising: (a) administering the adjuvant to a population of cells; (b) administering a PRR agonist to the population of cells; and (c) measuring expression of one or more

cytokines from the cells. Also described are pharmaceutical composition comprising: (a) an adjuvant; and (b) one or more of bafetinib (INNO-406), LY3009120, MK-8353 (SCH900353), amodiaquine, zanubrutinib (BGB-3111), Ku55933, Tucidinostat, PD318088, WNK463, and TRx0237 (LMTX) mesylate.

36.20230390369CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1
US - 07.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18033035 Solicitante CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA Inventor/a Yanelys MORERA DIAZ
Chimeric antigen comprising multimeric aggregates of the extracellular domain of the programmed death ligand 1 (PD-L1) with a reduced binding capacity to the PD-1 and CD80 receptors as compared to the native PD-L1 molecule. The invention further discloses pharmaceutical compositions including said chimeric antigen and at least a pharmaceutically acceptable vaccine adjuvant. The chimeric antigen is used for the manufacturing of a drug to treat cancer or its metastases. The invention also discloses a method of treating cancer or its metastases in a subject in need thereof, characterized by the administration of a therapeutically effective amount of the pharmaceutical composition comprising the chimeric antigen described herein.

37.4284419IMMUNOGEN
EP - 06.12.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 22702310 Solicitante UNIV PRETORIA Inventor/a MILLAR ROBERT PETER
This invention relates to an immunogen comprising a gonadotropin releasing hormone (GnRH) peptide sequence, a kisspeptin peptide sequence and a stimulant of raising an immune response, such an immunogen for use in a method to regulate the release of hormones in a vertebrate including modulation of reproductive hormones, to reduce fertility in a vertebrate and to treat hormone-dependent diseases including hormone-dependent tumours including prostate tumours, breast, ovary and endometrial tumours, benign hyperplasia including benign prostatic hyperplasia and uterine fibroids, endometriosis, polycystic ovarian disease, infertility, sexual dysfunction and any disorder that would benefit from an increased or decreased GnRH-dependent activity and a vaccine formulation comprising the immunogen. The invention also relates to the use of the immunogen in the preparation of a medicament for use in a method to regulate the release of hormones in a vertebrate.

38.20230390383REPLICATION INCOMPETENT INFLUENZA VACCINE PLATFORM FOR FOREIGN PROTEIN DELIVERY
US - 07.12.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18033039 Solicitante Duke University Inventor/a Nicholas S. HEATON
The present invention provides replication incompetent influenza viral particles comprising a modified hemagglutinin (HA) protein. Also provided are methods for making and using the viral particles, and cell lines for making the viral particles.

39.20230393122STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF
US - 07.12.2023
Clasificación Internacional G01N 33/50 Nº de solicitud 18345934 Solicitante Centre for Translational Stem Cell Biology Limited Inventor/a Degong Ruan
Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-nucleated or mature cells. The methods can also include assessing the eSTBs for coronavirus susceptible markers. Also disclosed are compositions and methods (i) for inducing the differentiation of eSTBs and

mature STBs from trophoblast stem cells (TSCs), (ii) for inducing the differentiation of TSCs from EPSCs, primed and naïve stem cells, pre-implantation embryos, placental stem cells, and iPSCs, and (ii) for producing TSCs by reprogramming non-trophoblast cells. The disclosed compositions and methods can be used for producing large quantities of coronavirus particles, including human, non-human, and variant coronavirus particles for virus production, the vaccine inductry, disease modeling studies, screening and evaluation of antiviral reagents, compound candidates, testing kits, and evaluation of clinical therapies.

40.20230392169NUCLEIC ACID NANOSTRUCTURES FOR DELIVERY OF NUCLEIC ACID SEQUENCES TO CELLS
US - 07.12.2023
Clasificación Internacional C12N 15/88 Nº de solicitud 18246447 Solicitante UCL BUSINESS LTD Inventor/a Stefan HOWORKA
Improved nucleic acid nanostructures provide a platform for stable and effective intra-cellular delivery of nucleic acids, suitably coding nucleic acids such as mRNA or ssDNA. A nucleic acid nanostructure is provided that comprises a first single stranded nucleic acid sequence that defines a scaffold sequence, wherein the scaffold sequence comprises at least one open reading frame that encodes a first gene product; and a plurality of single stranded nucleic acid sequences that define a plurality of staple sequences, wherein the plurality of staple sequences are capable of hybridising with one or more regions of the scaffold sequence in order to induce the formation of a geometrically defined higher order structure. The nanostructure may further comprise at least one membrane binding moiety, wherein the membrane binding moiety is configured to associate with a cell membrane. The nanostructures may be used in pharmaceutical compositions, such as vaccine compositions, and in methods of treating subjects in need thereof.

41.WO/2023/235592TLR AGONISTS COMPRISING SAPONIN NANOPARTICLE VACCINE ADJUVANTS TO IMPROVE IMMUNOMODULATION
WO - 07.12.2023
Clasificación Internacional A61K 9/14 Nº de solicitud PCT/US2023/024332 Solicitante THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor/a APPEL, Eric A.
Provided herein are nanoparticles including a TLR agonist, a saponin, a phospholipid, and a sterol. The composition of the nanoparticles is modularly tunable and can be configured such that the nanoparticles are particularly useful as adjuvants for enhancing a variety of potent and durable immunogenic responses. Also provided are adjuvant compositions and immunogenic compositions including the nanoparticles, and methods for using these compositions to induce an immunogenic response and treat or prevent a disease.

42.WO/2023/235660FLAVIVIRUS IMMUNOGENS AND VACCINE COMPOSITIONS AND METHODS OF USING THE SAME
WO - 07.12.2023
Clasificación Internacional Nº de solicitud PCT/US2023/067128 Solicitante THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Inventor/a DUSSUPT, Vincent
This application relates generally to flavivirus immunogens and to methods and compositions related thereto. More particularly, the disclosure relates to compositions and methods for the preparation, production, and administration of flavivirus immunogens comprising modified E proteins, including, for example, compositions for use as vaccines against flavivirus and for capturing antibodies against flavivirus.

43.20230390345COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE, A PROBIOTIC, AND SEMAPHORIN

US - 07.12.2023
Clasificación Internacional A61K 35/741 Nº de solicitud 18021847 Solicitante H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. Inventor/a Krithika N. KODUMUDI
Disclosed are anti-cancer therapies comprising i) at least one dendritic cell pulsed with an oncodriver and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor and methods of the use of said therapies to treat cancer.

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES